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A B S T R A C T
Background
An overwhelming body of evidence stating that the completeness of reporting of randomised controlled trials (RCTs) is not optimal
has accrued over time. In the mid-1990s, in response to these concerns, an international group of clinical trialists, statisticians,
epidemiologists, and biomedical journal editors developed the CONsolidated Standards Of Reporting Trials (CONSORT) Statement.
The CONSORT Statement, most recently updated in March 2010, is an evidence-based minimum set of recommendations including
a checklist and flow diagram for reporting RCTs and is intended to facilitate the complete and transparent reporting of trials and aid
their critical appraisal and interpretation. In 2006, a systematic review of eight studies evaluating the “effectiveness of CONSORT in
improving reporting quality in journals” was published.
Objectives
To update the earlier systematic review assessing whether journal endorsement of the 1996 and 2001 CONSORT checklists influences
the completeness of reporting of RCTs published in medical journals.
Search methods
We conducted electronic searches, known item searching, and reference list scans to identify reports of evaluations assessing the
completeness of reporting of RCTs. The electronic search strategy was developed in MEDLINE and tailored to EMBASE. We searched
the Cochrane Methodology Register and the Cochrane Database of Systematic Reviews using the Wiley interface. We searched the
Science Citation Index, Social Science Citation Index, and Arts and Humanities Citation Index through the ISI Web of Knowledge
interface. We conducted all searches to identify reports published between January 2005 and March 2010, inclusive.
1
Selection criteria
In addition to studies identified in the original systematic review on this topic, comparative studies evaluating the completeness of
reporting of RCTs in any of the following comparison groups were eligible for inclusion in this review: 1) Completeness of reporting
of RCTs published in journals that have and have not endorsed the CONSORT Statement; 2) Completeness of reporting of RCTs
published in CONSORT-endorsing journals before and after endorsement; or 3) Completeness of reporting of RCTs before and after
the publication of the CONSORT Statement (1996 or 2001). We used a broad definition of CONSORT endorsement that includes
any of the following: (a) requirement or recommendation in journal’s ’Instructions to Authors’ to follow CONSORT guidelines; (b)
journal editorial statement endorsing the CONSORT Statement; or (c) editorial requirement for authors to submit a CONSORT
checklist and/or flow diagram with their manuscript. We contacted authors of evaluations reporting data that could be included in
any comparison group(s), but not presented as such in the published report and asked them to provide additional data in order to
determine eligibility of their evaluation. Evaluations were not excluded due to language of publication or validity assessment.
Data collection and analysis
We completed screening and data extraction using standardised electronic forms, where conflicts, reasons for exclusion, and level
of agreement were all automatically and centrally managed in web-based management software, DistillerSR®. One of two authors
extracted general characteristics of included evaluations and all data were verified by a second author. Data describing completeness of
reporting were extracted by one author using a pre-specified form; a 10% random sample of evaluations was verified by a second author.
Any discrepancies were discussed by both authors; we made no modifications to the extracted data. Validity assessments of included
evaluations were conducted by one author and independently verified by one of three authors. We resolved all conflicts by consensus.
For each comparison we collected data on 27 outcomes: 22 items of the CONSORT 2001 checklist, plus four items relating to the
reporting of blinding, and one item of aggregate CONSORT scores. Where reported, we extracted and qualitatively synthesised data
on the methodological quality of RCTs, by scale or score.
Main results
Fifty-three publications reporting 50 evaluations were included. The total number of RCTs assessed within evaluations was 16,604
(median per evaluation 123 (interquartile range (IQR) 77 to 226) published in a median of six (IQR 3 to 26) journals. Characteristics of
the included RCT populations were variable, resulting in heterogeneity between included evaluations. Validity assessments of included
studies resulted in largely unclear judgements. The included evaluations are not RCTs and less than 8% (4/53) of the evaluations
reported adjusting for potential confounding factors.
Twenty-five of 27 outcomes assessing completeness of reporting in RCTs appeared to favour CONSORT-endorsing journals over
non-endorsers, of which five were statistically significant. ’Allocation concealment’ resulted in the largest effect, with risk ratio (RR)
1.81 (99% confidence interval (CI) 1.25 to 2.61), suggesting that 81% more RCTs published in CONSORT-endorsing journals
adequately describe allocation concealment compared to those published in non-endorsing journals. Allocation concealment was
reported adequately in 45% (393/876) of RCTs in CONSORT-endorsing journals and in 22% (329/1520) of RCTs in non-endorsing
journals. Other outcomes with results that were significant include: scientific rationale and background in the ’Introduction’ (RR 1.07,
99% CI 1.01 to 1.14); ’sample size’ (RR 1.61, 99% CI 1.13 to 2.29); method used for ’sequence generation’ (RR 1.59, 99% CI 1.38
to 1.84); and an aggregate score over reported CONSORT items, ’total sum score’ (standardised mean difference (SMD) 0.68 (99%
CI 0.38 to 0.98)).
Authors’ conclusions
Evidence has accumulated to suggest that the reporting of RCTs remains sub-optimal. This review updates a previous systematic review
of eight evaluations. The findings of this review are similar to those from the original review and demonstrate that, despite the general
inadequacies of reporting of RCTs, journal endorsement of the CONSORT Statement may beneficially influence the completeness
of reporting of trials published in medical journals. Future prospective studies are needed to explore the influence of the CONSORT
Statement dependent on the extent of editorial policies to ensure adherence to CONSORT guidance.
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A group of experts has developed a checklist and flow diagram called the CONSORT Statement. The checklist is designed to help
authors in the reporting of randomised controlled trials (RCTs). This systematic review aims to determine whether the CONSORT
Statement has made a difference to the completeness of reporting of RCTs. Reporting of RCTs published in journals that encourage
authors to use the CONSORT Statement with those that do not is compared. We found that some items in the CONSORT Statement
were fully reported more often when journals encouraged the use of CONSORT. While the majority of items are reported more often
when journals endorse CONSORT, the data only showed a statistically significant improvement in reporting for five of 27 items. No
items suggest that CONSORT decreases the completeness of reporting of RCTs published in medical journals.
None of the evaluations included in this review used experimental designs, and their methodological approaches were mostly poorly
described and variable when they were described. Furthermore, evaluations assessed the completeness of reporting of RCTs within a
wide range of medical fields and in journals with a wide variation in the enforcement of CONSORT endorsement. Our results do have
some limitations, but given the number of included evaluations and the number of assessed RCTs, we conclude that while most RCTs
are incompletely reported, the CONSORT Statement beneficially influences their reporting quality.
B A C K G R O U N D
An overwhelming body of evidence demonstrating that the com-
pleteness of reporting of randomised controlled trials (RCTs) is
sub-optimal has accrued over time (Chan 2005; Glasziou 2008;
Hopewell 2008; Moher 2010). In the mid-1990s, in response to
concerns about this issue, an international group of clinical tri-
alists, statisticians, epidemiologists, and biomedical editors devel-
oped the CONsolidated Standards Of Reporting Trials (CON-
SORT) Statement (Begg 1996), which has been twice revised and
updated (Moher 2001a; Schulz 2010). The CONSORT State-
ment is an evidence-based set of recommendations for reporting
two-arm, parallel-group RCTs, including a minimum set of items
to be reported pertaining to the rationale, design, analysis, and in-
terpretation of the trial (i.e. CONSORT checklist) and a diagram
describing flow of participants through a trial (i.e. flow diagram).
It is intended to facilitate the complete and transparent reporting
of RCTs and in turn aid in their critical appraisal and interpreta-
tion.
The CONSORT Statement was first published in 1996 (Begg
1996). It included 21 checklist items pertaining to the rationale,
design, analysis, and interpretation of a trial (i.e. CONSORT
checklist) and a flow diagram outlining the progress of participants
through a trial. In 2001, the CONSORT checklist, updated to 22
items, and flow diagram were revised to reflect emerging evidence
indicating that lack of, or poor reporting of particular elements
of RCTs is associated with biased estimates of treatment effect
(Moher 2001a). Some new items were also added because report-
ing them was found to increase the ability to judge the validity or
relevance of trial findings (Moher 2001a). Evidence and examples
for each checklist item are found in an accompanying Explana-
tion and Elaboration (E&E) document (Altman 2001). The sec-
ond revision, and current version, of the CONSORT Statement
(CONSORT 2010) was published in March 2010 (Schulz 2010).
It contains an updated 25-item checklist and flow diagram, also ac-
companied by an E&E document (Moher 2010). All CONSORT
materials are available on the CONSORT website (www.consort-
statement.org; CONSORT Group 2009). For ease, henceforth,
’CONSORT’ will refer to this collective body of literature, unless
otherwise stated.
To date, the CONSORT Statement has received positive atten-
tion, in part, by way of endorsement by biomedical journals. To
date, over 600 journals have endorsed the CONSORT Statement.
Such endorsement is typically evidenced by a statement in a jour-
nal’s ’Instructions to Authors’ regarding the use (suggested or re-
quired) of CONSORT while preparing trial reports for publica-
tion. Some journals publish editorials indicating their support,
while others institute mandatory submission of a guideline check-
list and/or flow diagram along with manuscript submission. As
such, while the CONSORT Statement is widely endorsed, there
is huge variation in terms of how CONSORT policies are imple-
mented.
Description of the problem or issue
Concurrent with the publication of the 2001 CONSORT State-
ment, Moher and colleagues reported the first evaluation of en-
dorsement of the CONSORT checklist. The authors reported
that the completeness of reports of RCTs in CONSORT-endors-
ing journals was higher than one non-endorsing journal (Moher
2001). Since then, other evaluations have been published which
assess the influence of CONSORT either directly or indirectly on
the completeness of reporting of RCTs. In 2006, Plint and col-
leagues (Plint 2006) published a systematic review synthesising
data from all such evaluations to gauge their combined findings
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about the influence of CONSORT endorsement on the complete-
ness of reporting of RCTs. Despite methodological weaknesses of
the eight included evaluations, the review found that endorsement
of CONSORT may influence the completeness of reporting in
some checklist items. For example, reporting of the method of
sequence generation, allocation concealment, and overall number
of CONSORT items (i.e. ’total sum score’) was more common
in RCTs published in CONSORT-endorsing compared to non-
endorsing journals, but CONSORT endorsement seemed to have
less effect on the reporting of participant flow and blinding (Plint
2006).
In the six years since this systematic review was published, a num-
ber of additional evaluations of the effects of CONSORT on the
completeness of reporting have been published. Some of these
evaluations directly assess the effect of CONSORT on complete
reporting (e.g. Hopewell 2010), others assess complete reporting
based on CONSORT criteria in a specific medical field or research
area, for example RCTs investigating weight loss (e.g. Thabane
2007), glaucoma (Llorca 2005), and surgery (Agha 2007). For
these latter evaluations, the effect of CONSORT can be assessed
through a post hoc comparison of completeness of reporting of
RCTs published in CONSORT-endorsing versus non-endorsing
journals.
This systematic review updates Plint et al’s review to include and
synthesise results that have been published in the time since the
first review was conducted.
Why it is important to do this review
The Plint et al systematic review included evaluations published
between January 1996 and July 2005 (Plint 2006). Over six years
have passed since the search for literature in that review was car-
ried out and a considerable number of additional evaluations have
been published that are relevant to include in this update. For
readers looking to know whether CONSORT endorsement influ-
ences the completeness of reporting, it is necessary to update Plint
et al’s review and to incorporate the most comprehensive corpus of
literature on this topic. This updated review provides a more com-
plete perspective regarding the possible influence of CONSORT
on the completeness of reporting of RCTs and, subsequently, will
allow journal editors, methodologists, and trialists to understand
the potential benefits of using CONSORT when reporting the
design, analysis, and interpretation of RCTs.
O B J E C T I V E S
To assess whether journal endorsement of CONSORT is associ-
ated with more complete reporting of RCTs, by examining the
following comparisons:
• comparison 1: completeness of reporting of RCTs
published in journals that have and have not endorsed the
CONSORT Statement; and/or
• comparison 2: completeness of reporting of RCTs
published in CONSORT-endorsing journals before and after
endorsement; or
• comparison 3: completeness of reporting of RCTs before
and after the publication of CONSORT (i.e. 1996 and 2001).
During the review process, two additional comparisons were iden-
tified and reported in already included evaluations, namely com-
pleteness of reporting of RCTs published before endorsement in
endorsing and non-endorsing journals and completeness of re-
porting of RCTs published in non-endorsing journals before and
after endorsement (where after endorsement was determined by
their endorsing counterparts). These comparisons were formed in
evaluations to assess, by proxy, potential confounding. We col-
lected data for these comparisons as encountered as they provided
information on potential confounders (i.e. the effect of non-en-
dorsement over time and the effect of potential pre-existing differ-
ences in completeness of reporting between endorsing and non-
endorsing journals). Data for these comparisons were sparse and
we carried out no meta-analyses; these data are available upon re-
quest.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Any report evaluating the completeness of reporting of RCTs,
potentially eligible for any of the three main comparisons, was
included; such studies are termed ’evaluations’ for the remainder
of this report.
We identified evaluations for potential inclusion using the follow-
ing pre-specified screening questions:
• Does the evaluation involve a relevant comparison (e.g. pre
CONSORT publication versus post CONSORT publication or
otherwise)?
• Does the evaluation examine the influence of the
CONSORT checklist on the completeness of reporting of RCTs?
• Does the evaluation report any of the following: a) 22 items
on the CONSORT checklist?, b) any type of overall quality
indicators/score? c) adherence to CONSORT checklist?
We approached authors of evaluations that were not comparative,
or did not report data in a format coinciding with our needs, for
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supplementary information. Subsequently any additional evalua-
tions for which a comparison could be drawn, were included (e.g.
Dias 2006).
Types of data
We included studies published in biomedical journals, pertaining
to any general or medical subspecialty that enabled comparison of
the completeness of reporting of RCTs in any of our three main
comparison groups.
In addition, this review only includes evaluations of the 1996 and
2001 CONSORT Statements, since publication of the CON-
SORT 2010 statement coincides with the search dates for this
review and so no evaluations could have been conducted and re-
ported in time for inclusion.
Types of methods
Evaluations using any method to identify and evaluate the report-
ing of RCTs were included in this review. Evaluations may or may
not have considered endorsement of CONSORT as the primary
’exposure’ of interest. For instance, evaluations that did not specif-
ically assess CONSORT checklist items, but evaluated the report-
ing of items relating to existing CONSORT items, were included.
Types of outcome measures
Primary outcomes
The primary outcome is the completeness of reporting of RCTs,
as measured by adequate or inadequate reporting of any of the
following 27 outcomes: 22 items on the 2001 CONSORT check-
list, four additional items relating to the reporting of blinding (i.e.
blinding of participants, data analyst, outcome assessor, or inter-
vention), or a sum score across aggregate checklist items, as re-
ported in evaluations. The 2001 CONSORT checklist is repro-
duced in Table 1. We considered the 22 checklist items in the
2001 Statement as the ’core’ items and the four additional items
on blinding are simply referred to en masse as pertaining to the
CONSORT item on ’blinding’. All analyses presented are ordered
in line with the CONSORT checklist (i.e. allocation concealment
is checklist item number 9 and, hence, results are presented as 1.9,
2.9, and 3.9 for the three comparison groups).
Secondary outcomes
1. Methodological quality of RCTs included in evaluations, as
reported
In addition to primary and secondary outcomes, we have included
and described evaluations which met the inclusion criteria, but
were not eligible for inclusion in meta-analyses.
Search methods for identification of studies
We conducted electronic searches of bibliographic databases,
known item searching, and reference list scans to identify records
published from January 2005 to March 2010, to capture studies
reported in the period after the search of the original systematic
review (Plint 2006).
It should be noted that the search was purposefully limited to
exclude records published after the publication of the CONSORT
2010 Statement (on 25 March 2010), as there was insufficient
time for evaluations of CONSORT 2010 to have been carried out.
A future update of this systematic review will include evaluations
of the 2010 Statement.
Electronic searches
To ensure all possibly relevant evaluations were obtained, we de-
signed the main search strategy to retrieve reports published since
the date of the last search of the original review, carried out in
July 2005. Specifically, the dates of the search for this review cover
publications from January 2005 in order to ensure that articles
which may have been published in the first half of 2005, but not
indexed at the time of searching during the original review, were
identified.
We conducted literature searches in Ovid MEDLINE (January
2005 to 19 March 2010); OVID EMBASE (January 2005 to
2010 Week 10); ISI Web of Knowledge (including citing ref-
erence searches) 2005 to 19 March 2010; Cochrane Methodol-
ogy Register; and the Cochrane Database of Systematic Reviews
(The Cochrane Library 2010, Issue 1). We searched the Cochrane
Methodology Register and the Cochrane Database of Systematic
Reviews using the Wiley interface. We searched the Science Cita-
tion Index, Social Science Citation Index, and Arts and Humani-
ties Citation Index through the ISI Web of Knowledge interface.
Please see Appendix 1 for the full search strategy, which was de-
veloped in MEDLINE and tailored to EMBASE.
Searching other resources
Evaluations were also identified by members of the research team
when attending conferences, or from discussions with experts in
the field.
Data collection and analysis
Selection of evaluations
We conducted all screening using an online data management
software, DistillerSR®, a program capable of tracking and man-
aging the progress of records (i.e. abstracts and full-text reports)
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through a review. Title and abstract screening were completed in-
dependently, in duplicate by two of three authors (LS, LT, LW) us-
ing broad screening criteria. All possibly relevant evaluations and
those with all conflicting assessments of reports were included for
further review.
The full text of all records identified as potentially eligible were
retrieved and independently reviewed for eligibility by two au-
thors (LS and LT) using standardised inclusion criteria developed
a priori. Full-text screening disagreements were resolved by con-
sensus or by an independent third author (DM). Six non-English
language articles were assessed by colleagues fluent in the relevant
language, who completed the same standardised inclusion forms
as the other assessors.
Potentially eligible studies were either categorised into one of the
three main comparisons of this review or needed further infor-
mation from authors to determine eligibility, such as whether in-
cluded trials were published in endorsing or non-endorsing jour-
nals or, if that information was unavailable, a list of included jour-
nals for review authors to follow up with and determine date and
status of endorsement. We contacted authors for this information
during data extraction so that both eligibility and potentially nec-
essary data could be obtained in one effort.
For the purpose of this review, endorsement is defined as any of the
following situations, implying that, in principle, the CONSORT
Statement is incorporated into the editorial process for a particu-
lar journal: (a) requirement or recommendation in journal’s ’In-
structions to Authors’ to follow CONSORT when preparing their
manuscript; (b) journal editorial statement endorsing the CON-
SORT Statement: either the flow diagram, the checklist or both;
or (c) editorial requirement for authors to submit a CONSORT
checklist and/or flow diagram with their manuscript. We deter-
mined endorsement status by first cross-checking with the CON-
SORT group’s endorser database. If the journal was not listed, we
then reviewed the journals’ ’Instructions to Authors’ for related text
and, if unavailable, lastly by searching for an editorial statement or
through previous journal issues for such a statement. Finally, we
assumed journals determined not to have endorsed CONSORT
at the time we checked for this information never to have been
endorsers.
For journals identified as CONSORT endorsers at the time of
checking, we sought dates of endorsement by contacting their
managing editors or other editorial staff. This information was
collected to determine whether RCTs were published after a rea-
sonable amount of time following endorsement, such that its ef-
fect had sufficient time to be realised in a journal’s output. For this
review, we considered six months an adequate amount of time.
Determining dates of endorsement was a resource-intense process;
for evaluations assessing large numbers of RCTs or large numbers
of journals it was not feasible to collect this information. For eval-
uations where endorsement status has not been verified, this has
been noted in the Characteristics of included studies. Evaluations
were not excluded on this basis; we used this information to con-
duct sensitivity analyses, as described below.
We did not exclude evaluations based on publication status, lan-
guage of publication, or validity assessment. When multiple re-
ports of a single evaluation were identified and outcomes were
overlapping, only outcome data from the main publication were
included. Data on additional outcomes presented in secondary
publications were included under their corresponding secondary
publications.
Data extraction and management
We completed data extraction using standardised electronic forms,
where conflicts, reasons for exclusion, and level of agreement were
all automatically and centrally managed in web-based manage-
ment software, DistillerSR®. One of two authors extracted general
characteristics of included evaluations and all data were verified by
a second author. Data describing completeness of reporting were
extracted by one author using a pre-specified form; a 10% ran-
dom sample of evaluations was verified by a second author. Any
discrepancies were discussed by both authors.
We extracted the following data from included evaluations:
We extracted general characteristics of evaluations including its
journal of publication, number of included RCTs, number of jour-
nals, country of publication, source of funding, and CONSORT
checklist version used and information pertaining to journal ’qual-
ity’ (i.e. enforcement of the checklist, editorial policy, size of edi-
torial team, volume of publications, impact factor, and other po-
tential determinants) included in the evaluation.
We collected completeness of reporting of RCTs in included eval-
uations across 27 a priori outcome measures (Primary outcomes).
These included adequacy of reporting any of the 22 2001 core
CONSORT checklist items, four additional items pertaining to
the 2001 CONSORT checklist item on blinding, and/or a ’sum
score’ of aggregate checklist items.
For simplicity, we used items on the 2001 CONSORT as data
extraction items since they were all encompassing of both CON-
SORT checklist versions; they include all items contained within
the 1996 checklist (some with rewording for improved report-
ing) as well as some additional items. When completeness of re-
porting using the 1996 CONSORT checklist was reported in an
evaluation, we included items from that checklist that were the
same as those in the 2001 checklist. However, for those items of
the 2001 version which differed from the 1996 version, we con-
ducted subgroup analyses as described below (Subgroup analysis
and investigation of heterogeneity).
Again, for simplicity, we refer to core checklist items with abbre-
viated descriptions according to their ’Paper section and topic’
as found on the CONSORT 2001 checklist. For example, when
we refer to reporting of ’title and abstract’ and/or ’item one’, we
are addressing whether reports of RCTs in evaluations contained
“randomised” in the title or abstract. For full details of associated
recommendations for these items (or more appropriately, method-
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ological guidance) please see Table 1.
The four items reporting blinding stem from the 2001 CON-
SORT checklist item recommending that adequate reporting of
blinding should detail “whether or not participants, those admin-
istering the interventions, and those assessing the outcomes were
blinded to the assessment group”. Reflective of the original sys-
tematic review (Plint 2006), included evaluations, and subsequent
changes made to the CONSORT 2010 checklist, we collected
reporting of blinding in four distinct items, in addition to the
’composite’ item (i.e. blinding by any description) contained in
the 2001 CONSORT checklist. These include: blinding of par-
ticipants, blinding of the intervention, blinding of outcome as-
sessment, and blinding of the data analyst. We sub-categorised
analyses for this item, as described in the subgroup analysis section
below.
While calculation of a total sum score based on several CONSORT
items is potentially misleading as items are of unequal importance,
we collected this information if reported in included evaluations.
We abstracted data on assessment of methodological quality of
RCTs included within evaluations, if reported. Although a recent
study (Dechartres 2011) identified 74 different items and 26 dif-
ferent scales used for assessing quality of RCTs, measurement of
methodological quality using any of these means (e.g. Jadad score,
Olivo 2008, Schulz allocation concealment, MINCIR, MINCIR
Score) was considered and was not pre-specified for this review.
Validity assessment in included evaluations
The validity of included evaluations was assessed by one author
(LS) and all assessments were independently verified by one of
three authors (LT, AP, LW); we resolved all conflicts by consensus.
We assessed validity using an a priori checklist developed by the
research team for the purpose of this review. As no formal checklist
for assessing validity of quasi-experimental evaluations of RCTs
currently exists, our research team developed a checklist based on
principles of internal and external validity (Campbell 1966). We
used the Data Collection Checklist developed by the Cochrane
Effective Practice and Organisation of Care Review Group and
the ’Risk of bias’ tool as guides (Cochrane EPOC 2009; Higgins
2008). The resulting criteria used to gauge validity of evaluations
in this review were as follows:
1. The RCTs included in the study represented a large cohort
(i.e. at least an entire year), or were randomly chosen from a large
cohort.
2. The reviewer(s) who assessed CONSORT criteria were
blinded to study authors, institutions, sponsorship, and/or
journal name.
3. Consideration of potential clustering by journal was
reported (if potential for clustering did not exist, the study was
deemed ’low risk’).
4. There was no evidence of selective outcome reporting.
5. More than one reviewer assessed adherence to CONSORT
criteria.
6. If more than one reviewer assessed CONSORT criteria,
whether inter-reviewer agreement was greater than or equal to
90% agreement or a kappa statistic of 0.8.
7. If quality of included RCTs was assessed, the reviewer(s)
conducted a blinded assessment.
We assigned each criterion a judgement of yes (i.e. low risk of bias/
high validity), no (i.e. high risk of bias/low validity), or can’t tell
(unclear risk of bias). For some criteria, we allowed an additional
rating of ’not applicable’ if it was irrelevant to a given comparison,
or was dependent on the rating of a previous criterion. For instance,
there was no potential for clustering by journal (criterion 3) in
comparisons 2 and 3. Criterion 6 was dependent on the rating
for criterion ’5’ being ’yes’ and therefore was not applicable when
the rating was ’no’. Likewise, criterion 7 is dependent on whether
assessment of methodological quality was carried out. For these
three criteria (3, 6, and 7) we chose not to penalise evaluations
with ’not applicable’ ratings, nor to rate them as ’unclear’, since
this is taken to mean ’not reported’, which is also incorrect. As
such, the only remaining option which would not connote any
negative judgement is a rating of ’yes’ (i.e. low risk of bias/high
validity).
Note, with regards to item three above, we report here the terms
used when validity assessment was conducted. For clarification,
from here on we refrain from using the term ’clustering’ as this
potential bias, more aptly, refers to confounding by journal.
Measures of the effect of the methods
Comparison 1 examines the completeness of reporting of RCTs
published in endorsing and non-endorsing journals, comparison
2 examines the completeness of reporting of RCTs published in
journals before and after endorsement, and comparison 3 exam-
ines completeness of reporting of RCTs before and after publi-
cation of CONSORT. Where data from a single evaluation were
applicable to more than one comparison, the evaluation was in-
cluded for each comparison. For instance, where data from an
evaluation comparing endorsing and non-endorsing journals were
available, it was sometimes possible to use data from only the en-
dorsing journals to also compare the reporting before and after
endorsement.
For the primary outcome, where data on completeness of report-
ing were represented by one or more of the 22 CONSORT 2001
checklist items or of the four additional blinding items, we col-
lected dichotomised adherence to each item. Where evaluations
used more than two categories to judge adherence to a given check-
list item, we collapsed these to create a dichotomy between ’ad-
equately’ and ’inadequately’ reported RCTs. For instance, where
an item was judged as ’partially’ reported, it was considered ’inad-
equate’. As such, within each comparison, for each dichotomous
outcome, the proportion of RCTs within each evaluation ade-
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quately reporting one or more checklist items in each comparison
group was calculated. Using these proportions we compared com-
pleteness of reporting between comparison groups (i.e. endorsers
versus non-endorsers, before versus after endorsement, pre versus
post publication) in each evaluation using a risk ratio (RR) with a
99% confidence interval for each outcome. A RR greater than 1
was taken to indicate relatively increased reporting of any CON-
SORT item following CONSORT endorsement. Where com-
pleteness of reporting of RCTs was represented by a sum score
of aggregate checklist items, we collected the mean sum score for
each comparison group within an evaluation. We then calculated
the standardised mean difference (SMD) with 99% confidence
interval to estimate the difference in completeness of reporting
between comparison groups in each evaluation. An SMD greater
than 0 indicates better overall reporting of items following CON-
SORT endorsement.
Due to the design of included evaluations and poor availability
of data to make necessary adjustments to estimates of effect at
the evaluation level, we were unable to adjust for potential con-
founders (i.e. improvements in completeness of reporting over
time and/or by discrepancies in journal editorial ’quality’) and we
introduced the use of 99% confidence intervals post hoc to ensure
conservative estimates of effect are presented throughout this re-
view.
Data collected on the methodological quality of RCTs within eval-
uations were reported as collected in evaluations. As these were
expected to be variable and inconsistently reported across evalua-
tions, we planned no measures of effect to estimate whether groups
within each comparison differed on methodological quality.
Issues of potential confounding
There are two potential factors by which the estimates of effect ob-
tained for each evaluation could be confounded. The first is when
there may have been an uneven distribution of journal quality
(defined in Data extraction and management) between endorsing
and non-endorsing journals in comparison 1. Time is considered a
second potential confounder of effect estimates for individual eval-
uations, since the completeness of reporting may have naturally
changed over time with or without endorsement or publication
of CONSORT. Time potentially affects effect estimates across all
three comparisons of this review, however it is not considered a
true confounder for comparison 1, since it may only play a role
where comparison groups were sampled at different times. Please
see Assessment of risk of bias in included studies.
Dealing with missing data
We experienced two types of missing data: endorsement status of
journals included in evaluations and date of endorsement of jour-
nals determined to be endorsers by either authors of the evaluation
or review authors.
Endorsement status of journals publishing RCTs included in each
evaluation was needed to determine whether evaluations were eli-
gible for inclusion in comparisons 1 or 2 or not at all. As described
in the Selection of studies and Data extraction and management
sections, we contacted corresponding authors a maximum of three
times via email over an eight-month period to provide us with
these data. If data would have been needed to complete the com-
parative analysis (i.e. adequacy of reporting data for each checklist
item for each included RCT), these were requested at the same
time.
Where date of endorsement of CONSORT by journals was not
explicit, data for RCTs that subsequently could not be identified
as published in either an endorsing or non-endorsing journal were
not included in the analyses in order to prevent misclassification.
In some circumstances, where this would result in a high propor-
tion of data for a given evaluation being excluded, we categorised
these reports as published in an endorsing journal, a conserva-
tive classification that underestimates the effect of CONSORT
endorsement. Similarly, for before and after comparisons, when
a number of evaluations were published in 2001 (or 1996, more
infrequently), these evaluations would be classified as pre-CON-
SORT to ensure that any estimate of the effect of CONSORT
endorsement would be conservative.
Assessment of heterogeneity
We explored consistency across the included evaluations quantita-
tively using the I² statistic, and by visual inspection (Deeks 2008).
Variation in journal policy regarding how CONSORT is imple-
mented, for example whether submission of a completed check-
list is ’required’ versus ’recommended’, will likely contribute to
methodological heterogeneity of results across included evalua-
tions. However, ongoing research by the CONSORT group sug-
gests that the means of implementing CONSORT in the editorial
process is difficult to determine without speaking to journal edi-
torial staff directly. As our experience with this review has shown,
even when in contact, this information is vague and generally no
standardised processes are in place. As it was beyond the scope and
feasibility of the current review, we were unable to explore this
factor meaningfully.
Assessment of reporting biases
Selective reporting of outcomes has been assessed for each included
evaluation as a component of validity assessment (Appendix 2). We
conducted assessment by searching for a review protocol and, in
the absence of a protocol, compared methods and results sections
of included evaluations. An advantage to the design of this review
is that unpublished data are provided and included by evaluation
authors, which would contribute to mitigating the potential issue
of selective reporting of CONSORT items.
Although it is possible to generate funnel plots to assess the po-
tential of publication bias for each meta-analysis in each evalua-
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tion within included evaluations, the suitability of this method of
assessment is unexplored (although the number of included stud-
ies may be insufficient). We know of no alternative methods for
assessing publication bias in this review of evaluations of RCTs.
Moreover, the number of included studies would frequently not
allow for this; as such we are unable to determine any failure to
report within the literature.
Data synthesis
We used a pooled RR with 99% confidence intervals to estimate
the overall difference between groups within each comparison. We
used a random-effects model for all analyses. All available data
contributed to our main analyses.
Some evaluations totaled adherence to all or a subset of CON-
SORT checklist items, and reported averages over assessed RCTs.
Because these continuous data are on differing scales, we calculated
SMDs for this outcome, with 99% confidence intervals. When
medians and ranges were reported instead of means and stan-
dard deviations, we used suitable approximations (Higgins 2008).
When necessary, we imputed standard deviations.
Data from evaluations reporting on, and comparing, CONSORT-
endorsing journals’ adherence to items of methodological quality,
using means not otherwise evaluated in this review, were qualita-
tively described and not included in meta-analysis.
In addition to our main analyses, we conducted a descriptive anal-
ysis of the included evaluations based on general characteristics
of the evaluations. For example, we documented the number of
RCTs and journals assessed in those evaluations and the validity
of those evaluations.
Subgroup analysis and investigation of heterogeneity
We did not pre-specify any subgroups for analysis. However, post
hoc, we decided that for five items of the 1996 checklist that
underwent substantial modifications (i.e. re-arranging and word-
ing modifications) in the 2001 checklist, analyses would be sub-
grouped by CONSORT checklist version (i.e. 1996 or 2001).
These items are ’title and abstract’, ’outcomes’, ’sample size’, ’par-
ticipant flow’, and ’numbers analysed’.
In addition, because data on adequacy of reporting of blinding
were collected in five different outcomes in this review (as described
in Data extraction and management), we sub-categorised meta-
analyses for this item (blinding) by each of the five outcomes for
which we collected data and carried out pooled estimates of effect
within each subcategory.
Sensitivity analysis
As previously stated, when CONSORT endorsement status for a
subset of journals in an evaluation was not available, we conducted
a sensitivity analysis to compare the pooled risk ratios with jour-
nals that were and were not strictly compliant with our definition
of a CONSORT endorser (i.e. endorsement occurred at least six
months prior to publication of RCT). We also conducted sensi-
tivity analysis for effects which we considered to result in outlying
effect estimates when the forest plots were inspected.
Other methodological considerations
Review updating
Given the substantial number of new evaluations included in this
update, we treated this update as if it were an original review fol-
lowing the original protocol. A full literature search was conducted
from six months prior to the end search date of the original re-
view (Plint 2006) to as recent a date as possible. We then screened
all retrieved evaluations, at which point inclusion of the original
eight evaluations was confirmed. We conducted data extraction
for general characteristics, full data extraction, and validity assess-
ment for all included evaluations in the same manner. We then
compared data extracted for the original eight evaluations with the
original published results as a means of validation. Data provided
by authors and modified for inclusion in the original review were
not sought again.
R E S U L T S
Description of studies
Results of the search
Our electronic search strategy identified a total of 4777 records.
Two additional evaluations (Dickinson 2002; Kidwell 2001) were
presented as posters at Cochrane Colloquia and identified by mem-
bers of the research team. We removed duplicates and left the re-
maining 2888 records as potentially relevant articles. Details about
the flow of evaluation records through this review are provided in
the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) flow diagram (Moher 2009; Figure 1).
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Figure 1. Flow of evaluations through this review
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Content experts identified four evaluations before the search was
conducted (Agha 2007; Peckitt 2007; Smith 2008; Wang 2007),
all of which were also identified through the electronic search. No
additional evaluations were identified by screening reference lists
of eligible evaluations.
Included studies
After title and abstract screening, we retrieved and reviewed 624
full-text articles. Fifty evaluations, reported in 53 publications,
were deemed eligible for inclusion (Figure 1).
We considered three pairs of evaluations to be potential multiple
reports of each other as they reported outcomes from the same
data set (Hopewell 2010 and Yu 2010; Balasubramanian 2006 and
Tiruvoipati 2005; Spring 2007 and Thoma 2006). For 35 evalu-
ations, additional data were needed to determine eligibility or to
define the comparative analysis. Of 21 authors who responded,
20 were able to provide additional information to supplement the
published data. Some of the information received from authors
was not in the necessary format to allow inclusion in meta-anal-
yses. In these cases, only data provided in the evaluation report
were included in meta-analyses. One included evaluation was an
abstract (Peckitt 2007), for which all necessary data were fully re-
ported; a full-text article for this evaluation was not available at
the time of data extraction. One evaluation (Dickinson 2002) was
presented as a poster and was not published as a full article. For this
evaluation, supplementary details were supplied by the evaluation
author. All other included evaluations were journal publications.
An additional author (Ellis 2005) provided data that confirmed
that their evaluation was ineligible for inclusion.
The total number of included RCTs was 16,604 (median per eval-
uation (interquartile range, IQR) 123 (77 to 226)). Included eval-
uations reviewed RCTs published in a median of six (IQR 3 to 26)
journals. Two evaluations reported on especially large numbers of
RCTs (Hopewell 2010; Wang 2007), with 1135 and 7496 RCTs
respectively.
Thirty-five included evaluations used CONSORT checklist items
as a means of assessing completeness of reporting of RCTs within
a given medical area, from which we could obtain information
to form suitable comparisons. Seven evaluations did not list the
influence of CONSORT or RCT adherence to the CONSORT
checklist as primary or secondary outcomes, but assessed reporting
on the basis of self determined methodological outcomes, consis-
tent with the CONSORT checklist, which in turn allowed for a
suitable comparison applicable to our review.
All included evaluations were published in English. Seventeen eval-
uations considered the influence of the 1996 CONSORT check-
list, 25 reported data for the 2001 checklist, and the remaining
eight evaluations considered outcomes from some form of modi-
fied CONSORT checklist. For example, Bian 2006 modified the
CONSORT checklist suitable to their field of study or objectives.
Forty-one evaluations addressed reporting quality by focusing on
trials published within a specific medical field; these fields were
broad and diverse, including, for example, behavioural health,
urology, drug abuse, and anaesthesiology.
Some evaluations were eligible for more than one of our three com-
parisons and across the these comparisons, 29 evaluations were
included in comparison 1 (CONSORT endorsers versus CON-
SORT non-endorsers), 11 evaluations were included in compari-
son 2 (CONSORT-endorsing journals, before and after endorse-
ment), and 21 evaluations were included in comparison 3 (before
and after CONSORT publication). Overall, 69 outcomes were
quantitatively reported, across the three comparison groups (mean
of eight outcomes reported per evaluation).
Evaluations used varying definitions for endorsement. Of the to-
tal number of included RCTs, 84% (13,955/16,604) across 85%
(45/53) of evaluations were published in journals which endorsed
CONSORT at least six months prior to RCT publication (as de-
fined in Selection of studies).
Eight evaluations also assessed RCT quality by proxy, using means
of assessing methodological quality; eight assessed quality using
the Jadad Score (Jadad 1996); three assessed the completeness of
reporting of allocation concealment; two used Schulz allocation
concealment (Schulz 1995); and four used other scores or means
of quality assessment (Effects of methods).
Excluded studies
We screened 2888 evaluations by title and abstract; we excluded
2264 evaluations as they did not assess completeness of reporting
of RCTs. Of the remaining 56 included evaluations, we excluded
a further 11 from the review at the data extraction phase due to
unavailability of data (Excluded studies).
Risk of bias in included studies
Validity assessment of included studies
Overall, the rated validity of included evaluations was high or
unclear (Figure 2; Figure 3). The majority of included evaluations
had a large cohort, did not demonstrate selective reporting of
outcomes, had more than one rater assessing CONSORT criteria
and, if methodological quality was assessed using another tool,
blinded assessments were performed. We note, however, that for
this latter domain, as well as those pertaining to criteria 3 and 6
(as described in Assessment of risk of bias in included studies), a
rating of high validity may appear as a potential overestimate of
validity for a given evaluation.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Across domains, we were uniformly unable to assess validity due to
poor reporting of included evaluations, contributing to the large
number of ’unclear’ ratings. This ’unclear’ rating also reflects the
need for improvement in the validity assessment tool used in this
review. For instance, whether or not confounding by journal oc-
curred was difficult to assess since, for some evaluations, we used
data provided by authors to create our own comparisons, thereby
nullifying any adjustments for confounding that may have been
carried out by authors. Moreover, as frequently discussed with re-
gard to assessing quality of the RCT, the reporting of included
evaluations may not reflect their actual conduct; however, infor-
mation on many of our items was unobtainable from the text,
which we thus rated ’unclear’.
It is important to note that these evaluations were not randomised
trials; less than 8% (4/53) of the evaluations reported adjusting for
potential confounding factors, for evaluations that did not adjust
for confounding (criterion 3), their estimates of effect may poten-
tially be confounded by the natural improvement in completeness
of reporting of RCTs over time, or by journal ’quality’, as discussed
above (’Issues of potential confounding’).
Effect of methods
Comparison 1: Completeness of reporting of
randomised controlled trials (RCTs) in CONSORT-
endorsing journals versus non-endorsing journals
Twenty-nine evaluations were included in this comparison, with
RCT level data for at least one of the 2001 CONSORT check-
list items, blinding subcategories, or total sum score. Across 27
potential outcomes, the number of evaluations per meta-analysis
varied (median (interquartile range, IQR) 6 (5 to 8)). ’Allocation
concealment’ and ’participant flow’ were reported in the largest
number of included evaluations: 16 each, with 2396 and 2140 as-
sessed RCTs respectively. ’Ancillary analysis’ and ’overall evidence’
were reported in the fewest evaluations included in meta-analy-
ses, with four evaluations each, that assessed 378 and 317 RCTs
respectively. Results for all outcomes in this comparison are pre-
sented in Figure 4.
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Figure 4. Pooled risk ratios across assessed 2001 CONSORT checklist items with 99% confidence intervals
for primary comparison, adherence of RCTs published in CONSORT-endorsing journals versus RCTs published
in CONSORT non-endorsing journalsPlot generated in Comprehensive Meta-analysis Version 2.0 (CMA).
For the 27 outcomes evaluated, five items resulted in statistically
significantly more complete reporting in CONSORT-endorsing
journals than non-endorsing journals, including complete report-
ing of: allocation concealment, description of scientific explana-
tion and rationale in the ’Introduction’, how ’sample size’ was de-
termined, and total sum score. Reporting details of adequate ’al-
location concealment’ had the largest estimate of effect(risk ratio
(RR) 1.81, 99% confidence interval (CI) 1.25 to 2.61) (16 eval-
uations, 2396 RCTs, I2 = 75%, Figure 5). For interpretation, this
suggests an increase in adequate reporting of allocation conceal-
ment of between 25% and 161% in RCTs published in CON-
SORT-endorsing journals. Allocation concealment was reported
adequately in 45% (393/876) of RCTs in CONSORT-endors-
ing journals and in 22% (329/1520) of RCTs in non-endorsing
journals. For all other significant outcomes, which can be inter-
preted in a similar manner, results are as follows. Description of
scientific explanation and rationale in the ’Introduction’ was re-
ported 7% more in CONSORT-endorsing journals than non-en-
dorsing journals (RR 1.07, 99% CI 1.01 to 1.14) (five evalua-
tions, 513 RCTs, I2 = 0%, Figure 6). How ’sample size’ was de-
termined was reported between 13% and 129% more in RCTs of
CONSORT-endorsing journals (RR 1.61, 99% CI 1.13 to 2.29)
(11 evaluations, 1843 RCTs, I2 = 76%, Figure 7). Description of
the method used for ’sequence generation’ was reported between
38% and 84% more in CONSORT-endorsing RCTs (RR 1.59,
99% CI 1.38 to 1.84) (14 evaluations, 2231 RCTs, I2 = 24%,
Figure 8). The ’total sum score’ item resulted in a significant dif-
ference between endorsers and non-endorsers(standardised mean
difference (SMD) 0.68, 99% CI 0.38 to 0.98) (seven evaluations,
560 RCTs, I2 = 0%, Figure 9). This effect estimate suggests that
the average reporting of items in RCTs in CONSORT-endorsing
journals was more complete than for RCTs in CONSORT non-
endorsing journals. For one evaluation (Kidwell 2001), standard
deviations were not reported and were imputed from the values
reported in other evaluations, using a weighted average.
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Figure 5. Forest plot of comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing
journals, outcome: 1.9 Allocation concealment.
Figure 6. Forest plot of comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing
journals, outcome: 1.2 Introduction.
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Figure 7. Forest plot of comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing
journals, outcome: 1.7 Sample size.
Figure 8. Forest plot of comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing
journals, outcome: 1.8 Sequence generation.
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Figure 9. Forest plot of comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing
journals, outcome: 1.23 Total sum score.
For 20 of the 22 remaining outcomes, pooled estimates of ef-
fect showed reporting was more complete in a higher proportion
of RCT reports for CONSORT-endorsing journals compared to
non-endorsing journals (RR > 1.0), but these were not statisti-
cally significant. Precise details of ’interventions’, item four, were
equally well reported in endorsing and non-endorsing journals(RR
1.0, 99% CI 0.95 to 1.05) (six evaluations, 638 RCTs, I2 = 0%),
and eligibility criteria for ’participants’, item three, produced a
non-significant negative effect (RR 0.95, 99% CI 0.56 to 1.62)
(six evaluations, 683 RCTs, I2 = 91%).
Subgroups for CONSORT 1996 and 2001 checklists
All items resulted in estimates of effect larger in those evaluations
assessing reporting using the 2001 checklist than those using the
1996 checklist. Determination of ’sample size’ was reported sig-
nificantly more in CONSORT-endorsing journals in evaluations
assessing both the 1996 and 2001 CONSORT checklist versions.
The completeness of reporting of ’participant flow’ differs be-
tween 1996 and 2001 checklist versions. For ’title and abstract’,
’outcomes’, and ’numbers analysed’ comparisons between endors-
ing and non-endorsing journals were all non-significant for both
1996 and 2001 subgroups. Complete reporting of how ’sample
size’ was determined yields significant results for CONSORT en-
dorsers for evaluations adhering to either checklist version. This
effect is greater in magnitude across evaluations assessing the 2001
checklist version, with RR 1.25 (99% CI 1.08 to 1.46) and RR
1.81 (99% CI 1.25 to 2.61) for 1996 evaluations and 2001 evalu-
ations respectively, but these subgroups did not differ significantly
(P = 0.07) (Figure 7). Complete reporting of ’participant flow’
also increases in effect, with evaluations assessing the 1996 version,
RR 1.01 (99% CI 0.99 to 1.02) and the 2001 evaluations, RR
1.35 (995 CI 1.00 to 1.82). Six evaluations were included in the
1996 subgroup and 10 evaluations in the 2001 subgroup; the lat-
ter considered inclusion of a flow diagram or otherwise to describe
patient flow in 548 RCTs in CONSORT-endorsing journals and
1088 RCTs in CONSORT non-endorsing journals; testing for
differences between subgroups demonstrates a statically significant
difference between 1996 and 2001 checklist version groups (P =
0.01).
Complete reporting of randomisation in the ’title and abstract’ was
reviewed in one evaluation subject to the 1996 checklist, and six
evaluations according to the 2001 checklist. Across all evaluations
for this outcome, the pooled effect suggests an increase in reporting
of 13% (RR 1.13, 99% CI 0.96 to 1.33). Estimates of effect did
not differ greatly between checklist versions (P = 0.14), with effect
estimates, RR 0.93 (99% CI 0.65 to 1.32) and RR 1.16 (99% CI
0.97 to 1.39) for 1996 and 2001 checklist versions respectively.
Overall, complete reporting of ’outcomes’ is not significantly dif-
ferent in CONSORT-endorsing journals compared to non-en-
dorsing(RR 1.17, 99% CI 0.95 to 1.43). The test for subgroup
differences did not result in a difference between groups (P = 0.52),
where one evaluation saw an effect of RR 1.02 (99% CI 0.58 to
1.78) in 1996 and seven evaluations saw an effect of RR1.18 (99%
CI 0.94 to 1.48) in 2001.
Complete reporting of ’numbers analysed’ did not differ between
the 1996 and the 2001 checklist versions. Across all 13 evaluations
in this outcome assessing 2145 RCTs, the estimate of effect was
not significant(RR 1.23, 99% CI 0.98 to 1.55). The 1996 version
evaluations did not yield more complete reporting in endorsers
when pooled(RR 0.99, 99% CI 0.83 to 1.19). The magnitude
of effect increases according to the 2001 checklist definition (RR
1.23, 99% CI 0.98to 1.55); testing for differences between sub-
groups suggests that assessments subject to the two versions differ
(P = 0.03) (Figure 10; Figure 11; Figure 12; Figure 13).
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Figure 10. Forest plot of comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing
journals, outcome: 1.13 Participant flow.
Figure 11. Forest plot of comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing
journals, outcome: 1.1 Title and abstract.
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Figure 12. Forest plot of comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing
journals, outcome: 1.6 Outcomes.
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Figure 13. Forest plot of comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing
journals, outcome: 1.16 Numbers analysed.
Sensitivity analysis
Eight included evaluations (Ethgen 2009; Hopewell 2010;
Kidwell 2001; Tharyan 2008; Tiruvoipati 2005; Uetani 2009; Wei
2009; Yu 2010) were not strictly compliant with our definition of
CONSORT-endorsing journal (Objectives). Of these eight eval-
uations, three did not report how a CONSORT endorser was de-
fined, one evaluation categorised endorsing journals as those listed
on the CONSORT website, and the remaining four referred to
the online journal ’Instructions to authors’ to determine if RCTs
in a given journal were associated with a journal that endorsed the
CONSORT checklist. Although this met our definition for how
journal endorsement information is obtained, it does not confirm
the date of publication of each assessed RCT as six months prior
to the publishing journal endorsing CONSORT; therefore it has
not been confirmed that the journal was endorsing CONSORT at
the time of manuscript writing. It is important to note that, for all
known definitions, such misclassification would lead to underesti-
mates of the relative effect of adherence to the CONSORT items
by RCTs in journals which endorse the CONSORT Statement.
We conducted sensitivity analysis across outcomes, excluding the
above mentioned evaluations that did not strictly meet our defini-
tion of CONSORT endorsement. Only 1/27 outcomes, although
only minimally different, differed substantially when evaluations
that did not directly meet our definition of endorsement were ex-
cluded. Completeness of reporting of the ’Introduction’ changed
from RR 1.07 (99% CI 1.01 to 1.14) to 1.05 (99% CI 0.87 to
1.27). This suggests that relaxing our criteria for CONSORT en-
dorsement did not alter substantially the estimates for reporting of
RCTs published in non-endorsing journals versus those published
in journals endorsing CONSORT.
In addition, we considered several point estimates large outliers
and we examined these in sensitivity analyses. These include: ’sta-
tistical methods’, item 12, reported in the Areia 2010 evaluation;
’blinding of data analyst’ in the Devereaux 2002 evaluation; ’par-
ticipants’, item three in the Faunce 2003 evaluation; ’blinding of
outcome assessor’ in Haahr 2006; and ’sample size and allocation
concealment’ in Wei 2009. Sensitivity analyses excluding these
evaluations did not change the significance of completeness of re-
porting items in RCTs in CONSORT-endorsing journals com-
pared with RCTs published in CONSORT non-endorsing jour-
nals.
Comparison 2: Completeness of reporting of RCTs in
CONSORT-endorsing journals before and after
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endorsement
Eleven evaluations assessed only journals that endorse the CON-
SORT Statement, but presented RCT completeness of reporting
of at least one CONSORT item before and after the journal’s date
of endorsement of CONSORT. The number of RCTs assessed per
outcome had a median (IQR) of 532 (512 to 919). The number
of reported CONSORT checklist items varied over evaluations,
with a median of 3 (IQR 2 to 5). ’Sequence generation’ and ’par-
ticipant flow’ were both reported in eight evaluations. For 15 of
27 outcomes data were reported in fewer than five evaluations.
The results across all outcomes in this comparison are presented
in Figure 14.
Figure 14. Pooled risk ratios across assessed 2001 CONSORT checklist items with 99% confidence intervals
for comparison 2, adherence of RCTs published in CONSORT-endorsing journals before and after
endorsement.Plot generated in Comprehensive Meta-analysis Version 2.0 (CMA).
Seven outcomes resulted in statistically significantly more com-
plete reporting in journals after CONSORT endorsement. These
include: complete reporting of the scientific rationale and back-
ground in the ’Introduction’ (RR 1.04, 99% CI 1.00 to 1.08) (two
evaluations, 457 RCTs, I2 = 0%); ’baseline data’ (RR 1.42, 99%
CI 1.24 to 1.62) (two evaluations, 529 RCTs, I2 = 0%); ’numbers
analysed’ (RR 1.72, 99% CI 1.18 to 2.49) (six evaluations, 1005
RCTs, I2 =76%); ’ancillary analyses’ (RR 3.46, 99% CI 2.47 to
4.84) (one evaluation, 442 RCTs); ’adverse events’ (RR 1.39, 99%
CI 1.12 to 1.73) (three evaluations, 507 RCTs, I2 = 0%); and
’generalisability’ (RR 1.77, 99% CI 1.47 to 2.11) (one evaluation,
442 RCTs). Aggregate scores of items were also significant for this
comparison: the total sum score was SMD 0.74 (99% CI 0.30 to
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1.18) (one evaluation, 148 RCTs).
Of the remaining outcomes, 13/20 resulted in pooled estimates of
effect showing that reporting was more complete in a higher pro-
portion of trial reports for CONSORT-endorsing journals com-
pared to non-endorsing (RR > 1.0), but these were not statisti-
cally significant. Overall, completeness of reporting was not op-
timal either before or after endorsement, even when results have
demonstrated a difference when journals have endorsed the state-
ment. For example, only 76% (428/560) of RCTs published af-
ter journal endorsement of CONSORT and 38% (171/445) of
RCTs published before completely reported ’numbers analysed’
as per the CONSORT consolidated standards of reporting trials
(CONSORT) and the completeness of reporting guidance.
For seven items, estimates of effect showed less complete report-
ing in RCTs published in journals after endorsement of CON-
SORT, but none of the differences were statistically significant.
These outcomes include complete reporting of eligibility criteria
for participants (RR 0.98, 99% CI 0.88 to 1.09) (four evalua-
tions, 622 RCTs, I2 = 28%) and complete reporting of statistical
methods used (RR 0.86, 99% CI 0.62 to 1.19) (five evaluations,
1111 RCTs, I2 = 90%). Across all possible blinding subgroups, the
relative reporting of blinding decreased in RCTs in CONSORT-
endorsing journals after endorsement. Blinding of interventions
was reported in one evaluation of 75 RCTs, indicating that report-
ing is significantly reduced post endorsement (RR 0.26, 99% CI
0.09 to 0.73) (one evaluation, 75 RCTs). All subgroups reflected
larger reductions in reporting than the blinding (any description)
item, which is considered to be most consistent with the 2001
checklist(RR 0.96, 99% CI 0.61 to 1.50) (four evaluations, 926
RCTs, I2 = 95%). All blinding subgroups were evaluated by one
evaluation assessing 75 RCTs. For all blinding outcomes, RCTs
in CONSORT-endorsing journals post endorsement were found
to report blinding less completely than in RCTs of CONSORT
non-endorsing journals.
Subgroup analyses for 1996 and 2001 checklist version
There were no statistically significant tests for differences in sub-
groups for the five identified outcomes. Three items saw effects of
greater magnitude in the 2001 checklist version group, and two
outcomes saw greater effects in the 1996 groups. Three items, the
’title and abstract’, ’sample size’, and ’numbers analysed’ check-
list items, were completely reported significantly more in CON-
SORT-endorsing journals than non-endorsing journals in both
subgroups. Despite an increase in effect estimates from 1996 to
2001 checklist versions, ’title and abstract’ subgroups did not differ
significantly (P = 0.42). There was no statistically significant dif-
ference between ’sample size’ subgroups, despite the 2001 check-
list increasing the magnitude of the effect estimate (P = 0.67). Nor
was there a difference between subgroups when assessing ’numbers
analysed’ (P = 0.26). Two items, ’participant flow’ and ’outcomes’
had larger effect estimates across evaluations assessing the 1996
checklist version, but neither of these groups differed significantly
when subgroups were tested.
Sensitivity analysis
Two evaluations over three outcomes were considered for sensi-
tivity analyses due to relatively large effects. The Sanchez-Thorin
2001 evaluation reported relatively large effects in favour of CON-
SORT endorsement for reporting the CONSORT items ’out-
comes’ and ’participant flow’, however, the comparisons remained
non-significant at the 1% level when this evaluation was excluded.
The Han 2008 evaluation is one of two evaluations reporting on
generated and assigned sequence allocation, namely ’implementa-
tion’. This evaluation reported a relatively large effect; excluding
this evaluation did not change the overall significance of effect for
this item.
Comparison 3: Completeness of reporting of RCTs
before and after CONSORT publication
This comparison was developed due to the large body of evidence
that did not comply fully with our definition of endorsement. Al-
though these data were abundant and consistent with the find-
ings of the other comparisons, evaluations in this comparison did
not comply with our prespecified definition of within-journal en-
dorsement (see Objectives). As such the findings may not be as
robust and should be interpreted cautiously. The results across all
outcomes for this comparison are presented in Figure 15.
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Figure 15. Cross-sectional sample of RCTs before and after the publication of CONSORT.
Twenty-one evaluations provided comparisons of completeness of
reporting compliant with the CONSORT checklist items, before
and after either the 1996 or 2001 publication of CONSORT.
Methods for assessing the pre-post intervention were inconsistent
across evaluations. Over all outcomes, there were on average 7
(5 to 8) (median, (IQR)) evaluations per checklist item, with an
average of 8224 (8017 to 8676) (median (IQR) RCTs per outcome
(CONSORT item). ’Allocation concealment’ was reported in the
largest number of included evaluations: 12 evaluations assessed
reporting adherence in 9772 trials.
Six outcomes saw statistically significant results, suggesting that
these items were statistically significantly more completely re-
ported after the publication of the CONSORT Statement. These
include complete reporting of ’sample size’ (RR 2.45, 99% CI 1.37
to 4.39) (10 evaluations, 9568 RCTs, I2 = 91%), ’sequence gen-
erations (RR 1.67, 99% CI 1.14 to 2.45) (11 evaluations, 9934
RCTs, I2 = 79%), ’allocation concealment’ (RR 1.61, 99% CI
1.23 to 2.10) (11 evaluations, 9772 RCTs, I2 = 13%), ’statisti-
cal methods’ (RR 1.13, 99% CI 1.01 to 1.25) (seven evaluations,
8223 RCTs, I2 = 67%), ’participant flow’ (RR 1.36, 99% CI 1.01
to 1.83) (eight evaluations, 8373 RCTs, I2 = 72%), and ’baseline
data’ (RR 1.20, 99% CI 1.01 to 1.43) (six evaluations, 8114 RCTs,
I2 = 47%).
Of the 21 remaining outcomes, 18 showed completeness of re-
porting was higher in RCTs published after CONSORT, but the
differences were not significantly significant. Complete reporting
of the ’intervention’ resulted in a neutral effect(RR 1.00, 99% CI
0.97 to 1.04) (seven evaluations, 8224 RCTs, I2 = 7%) and ’inter-
pretation of the results’ had a pooled effect which did not favour
the impact of CONSORT on the completeness of reporting(RR
0.99, 99% CI 0.98 to 1.01) (four evaluations, 7989 RCTs, I2 =
0%).
All subcategories of blinding descriptions resulted in higher pro-
portions of RCTs completely reporting, but the difference before
and after publication of CONSORT was not significant. Evalu-
ations providing analyses of any description of blinding showed
that fewer RCTs reported a complete description of blinding after
the publication of CONSORT (RR 0.95, 99% CI 0.76 to 1.19)
(three evaluations, 1660 RCTs, I2 = 0%). Complete reporting was
infrequent for both groups, for example, in total less than 18%
(1041/5891) post CONSORT publication RCTs, and less than
9% (345/4043) of pre-CONSORT RCTs, completely report their
method of ’sequence generation’ as per the CONSORT guidance.
Subgroup analyses for 1996 and 2001 checklist versions
There were no differences between subgroup analyses for the five
outcomes specified. Subgroup analyses effect estimates for com-
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plete reporting of randomisation in the ’title and abstract’ were
consistent: the 1996 version saw a relative increase in adequate
reporting of 13% (RR 1.13, 99% CI 0.96 to 1.33), while the 2001
version saw a relative increase of 18%(RR 1.18, 99% CI 0.88 to
1.59); the difference between these two groups was not signifi-
cant (P = 0.73). Complete reporting of derivation of ’sample size’
was reported more frequently in assessed RCTs post CONSORT
publication, with significant results for both checklist versions as-
sessed. Evaluations considering the 2001 version of the checklist
produced a larger pooled effect, suggesting that the percentage of
RCTs published after publication of the 2001 CONSORT State-
ment reporting ’sample size’ was greater than those RCTs pub-
lished before 2001 (RR 2.68, 99% CI 1.00 to 7.16). There was no
statistical difference between these groups (P = 0.90). Adequate
reporting of ’participant flow’ in RCTs published after the pub-
lication of the CONSORT Statement saw a larger improvement
in evaluations considering the 2001 version of the checklist as the
intervention, with 2.14 times more RCTs adequately reporting
the flow of participants through the trial (RR 2.14, 99% CI 0.90
to 5.09) than those considering the 1996 evaluation where only
1.16 times more RCTs adequately reported ’participant flow’ (RR
1.16, 99% CI 0.87 to 1.53); these differences were not statistically
significant (P = 0.08).
Reporting of primary and secondary ’outcomes’ saw a greater mag-
nitude of effect across those evaluations assessing the 1996 ver-
sion(RR 1.47, 99% CI 0.87 to 2.48 and RR 1.15, 99% CI 0.85
to 1.54 for the 1996 and 2001 versions respectively); this differ-
ence between subgroups was not significant (P = 0.29). Adequate
description of the ’numbers analysed’ was non-significantly rel-
atively more frequent in RCTs published after the CONSORT
Statement, for both subgroups of evaluations considering the 2001
version and the 1996 version(RR 1.37, 99% CI 0.80 to 2.36 and
RR 2.32, 99% CI 0.50 to 10.87 respectively). Over all evaluations,
there was a non-significant 57% increase in adequate reporting of
denominators for the number of participants analysed in RCTs
published after than before the publication of the CONSORT
Statement (RR 1.57, 99% CI 0.91 to 2.70); subgroup differences
between checklist versions were not significant (P = 0.41).
Sensitivity analysis
The third comparison group was developed to synthesise results
of cross-sectional samples of RCTs before and after CONSORT
publication, as well as evaluations for which timing of endorsement
of CONSORT could not be confirmed as the intervention within
journals. As a result, all included evaluations in this comparison
have been confirmed to have RCTs pre- and post CONSORT
publication of the CONSORT Statement. No sensitivity analysis
could be conducted in relation confirmation of endorsement.
Five evaluations (Parés 2008; Partsinevelou 2009; Peckitt 2007;
Scales 2007; Wang 2007) report effects that were relatively large.
As such we performed sensitivity analyses to assess the difference
in pooled effects when these evaluations were not included.
Across all outcomes, evaluations with large effects were not in-
cluded in pooled effect estimates and discrepancies were observed.
Peckitt 2007 and Wang 2007 were simultaneously excluded from
the ’sample size’ outcome, with a reduction in effect from RR
2.45 (99% CI 1.37 to 4.39) to RR 1.80 (99% CI 1.10 to 2.93).
Parés 2008 and Scales 2007 were simultaneously removed from
the ’participant flow’ outcome, with a reduction from RR 1.36
(99% CI 1.01 to 1.83) to RR 1.20 (99% CI 0.95 to 1.50). When
the Partsinevelou 2009 results were removed from the reporting
of dates for the ’recruitment’ outcome, the effect remained non-
significant; and from the adequacy of reporting of which ’numbers
[were] analysed’ (RR 1.57, 99% CI 0.91 to 2.70 to RR 1.52, 99%
CI 0.88 to 2.61).
Qualitative reports on the influence of reporting
Four evaluations that met inclusion criteria were not included in
the three quantitative comparisons for this review (Al-Namankany
2009; Chauhan 2009; Montané 2010; Sinha 2009). Relatively
few trials were assessed in these reports (n = 305 RCTs). Each
provided qualitative descriptions of the influence of endorsement
of CONSORT on the completeness of reporting, as detailed below.
Three of the four evaluations reported that there was no difference
in reporting subject to CONSORT endorsement.
Al-Namankany 2009 aimed to assess the reporting of published
RCTs in paediatric dental journals between 1985 and 2006, and to
assess whether completeness of reporting had improved since the
introduction of CONSORT as a secondary outcome. Although
data for inclusion in meta-analysis in this review were not available,
the evaluation reported that “overall quality of reporting has not
substantially improved since the publication of CONSORT”.
The Chauhan 2009 evaluation modified the CONSORT check-
list to 50 outcomes to assess the quality of obstetric practice bul-
letins after the publication of the 1996 CONSORT Statement.
The results were not reported or provided upon request, leaving
insufficient information for quantitative inclusion in our review.
An interesting finding of the evaluation was that regressions con-
ducted to determine if a number of variables could predict re-
porting based on CONSORT criteria resulted in only multicentre
trials proving to be significant, suggesting that for this sample of
RCTs completeness of reporting was ’better’ in trials conducted
in multiple centres. Another result of the evaluation is that even
for the RCTs published after the CONSORT Statement, the ad-
herence is variable and lacking at times. This evaluation reported
finding no difference before and after publication of the 1996
Statement.
Montané 2010 assessed reports of RCTs assessing analgesics in
postoperative pain after traumatic or orthopaedic surgery. The
quality of reports was assessed using the CONSORT checklist
(scoring range from 0 to 22). The publication year and the impact
factor of journals were recorded, but we were unable to obtain
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additional information for quantitative inclusion in this review.
The authors reported a comparison over time: “The mean (SD)
CONSORT scores for RCTs published after 2001 was higher than
the mean CONSORT scores for those published previously (14.4
and 10.3 respectively; p<0.0001).”
Sinha 2009 used the Jadad score and eight other methodological
items (sequence generation, allocation concealment, implementa-
tion of randomisation, blinding status of outcomes, blinding of
data analysts, sample size, numbers analysed, and participant flow
diagram) to assess quality of reporting in high impact factor surgi-
cal journal RCTs, and compared the quality of RCTs from CON-
SORT-endorsing journals with non-endorsers. In a sample of 42
RCTs, they observed: “There was no significant difference in the
number of high-quality RCTs published in CONSORT-endors-
ing journals compared with non endorsers. This difference did not
reach statistical significance suggesting that CONSORT endorse-
ment by surgical journals does not appear to increase quality of
reporting, although our study might not be adequately powered
to detect such a difference because only one of the three journals
studied did not endorse CONSORT”.
Other means used to assess the influence of
CONSORT on the quality of trials
Seven evaluations assessed the completeness of reporting using
CONSORT checklist items in conjunction with another means of
assessment. An additional evaluation considered the influence of
endorsement of the CONSORT Statement by comparing Jadad
scores only. All eight evaluations assessed quality by Jadad score;
three evaluations also assessed quality by clear or unclear reporting
of allocation concealment (attributed to Schulz); four evaluations
also assessed quality by another means, namely, using the MIN-
CIR score, ’quality score’, modified Chalmers Score or ’Analytic
Quality Elements’ score. Four evaluations were of pre-post design
with the publication of the CONSORT Statement as the inter-
vention, three evaluations compared CONSORT endorsers and
CONSORT non-endorsers, and the final evaluation considered
both pre-post and post intervention designs.
Four evaluations compared quality of reporting between CON-
SORT endorsers and non-endorsers, or listed sufficient data to
draw this comparison. Two of the four evaluations (Sinha 2009;
Tiruvoipati 2005) found no significant difference between Jadad
scores for RCTs in endorsing and non-endorsing journals, where
the median for both groups of both evaluations was reported to
be 2.0. Aggregate assessments were made in a total of 76 trials in
non-endorsing journals and 25 trials in endorsing journals. Two
evaluations (Balasubramanian 2006; Tharyan 2008), with a total
of 220 RCTs, reported differences in Jadad score means of 0.27
and 0.20 respectively, between RCTs published in endorsing and
non-endorsing journals. The mean scores were higher in endors-
ing journal publications, but these results were not significant.
Four evaluations assessed the pre-post influence on RCT quality
according to CONSORT items, as well as the Jadad score. One
evaluation did not provide sufficient data or description for com-
parison of RCT quality according to the Jadad score, before and
after publication of CONSORT. The remaining three evaluations
reported that there was a difference in quality, assessed by the
Jadad score, of RCTs published before and after the publication
of CONSORT. Moher 2001 detailed that “Over time, 3 of the
4 journals improved the quality of reports of RCTs as assessed
by the Jadad scale, which was statistically significant for 1 jour-
nal (Lancet) and across the adopter journals pre-CONSORT, 2.7;
mean change, 0.4; 95% CI, 0.1-0.8).” In a total of 2380 trials,
Wang 2007 reported the mean (SD) Jadad score was 0.85 (0.53)
in 1999 (746 RCTs) and 1.20 (0.62) in 2004 (1634 RCTs); and
Parés 2008 reported a median (range) of 3 (0 to 5) in 2001 and
after and 2 (0 to 4) before 2001, P = 0.046.
Sufficient reporting of allocation concealment was considered
in three evaluations (Balasubramanian 2006; Moher 2001;
Tiruvoipati 2005), the first of which did not provide enough in-
formation to abstract this data. The two evaluations that could
be compared quantitatively suggest the difference in the Jadad
scores of RCTs published before and after the endorsement of
CONSORT was significant. Tiruvoipati 2005 reported 21% of
RCTs with adequate reporting of allocation concealment pre-
CONSORT and 50% in RCTs published after the Statement.
Similarly, Moher 2001 describes “the proportion of RCTs with
unclear reporting of allocation concealment decreased over time in
all 4 journals and was statistically significant for adopter journals
(pre-CONSORT, 61%; mean change, −22%; 95% CI, −38% to
−6%).”
Four evaluations assessed quality of the included RCTs using an au-
thor-developed tool or assessment scale. Two evaluations assessed
quality, but did not categorise this in relation to RCTs published in
CONSORT-endorsing and non-endorsing journals. These eval-
uations reported RCT quality to a modified Chalmers score and
an ’analytic quality elements score’ developed for the paper. MIN-
CIR is a methodological scaling tool consisting of three domains
with subcategories, where a sum across the three outcomes can
total between six and 36 ’points’. The Parés 2008 evaluation re-
ported significant differences in the quality of 40 RCTs subject to
a MINCIR score assessment, between pre- and post CONSORT-
endorsing journals, pre and post respectively, mean (range), 19
(13 to 25), 23 (13 to 36) P = 0.016. Llorca 2004 assessing 37
RCTs, also developed a ’quality score’ to assess RCT quality, with
a maximum score of 21. No significant differences in scores were
found between RCTs published before and after the publication
of the CONSORT Statement. For both groups mean scores were
< 5/21.
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Summary of main results
A substantial number of new evaluations have been published and
were eligible for inclusion in this review since the last search in
July 2005 and the publication of the original systematic review
(Plint 2006). We included 50 quasi-experimental evaluations in
53 evaluation reports, examining 16,604 reports of randomised
controlled trials (RCTs) in this update; eight evaluations were in-
cluded in the original CONSORT systematic review. Across the
50 evaluations, a mean of eight CONSORT items were reported.
Across the three comparisons, 29 evaluations were included in
comparison 1 (CONSORT endorsers versus non-endorsers), 11
evaluations were included in comparison 2 (CONSORT-endors-
ing journals, before and after endorsement), and 21 evaluations
were included in comparison 3 (before and after CONSORT pub-
lication).
The number of evaluations per meta-analysis (median (interquar-
tile range, IQR)) were: comparison 1, 6 (5 to 8), comparison 2,
3 (2 to 5), and comparison 3, 7 (5 to 8). Overall, the results
demonstrate an improvement in the completeness of reporting
when journals endorse the CONSORT Statement. These results
are consistent across the three comparison groups, with the ex-
ception of outcomes related to blinding, which are inconsistent
(Figure 4; Figure 14; Figure 15).
For comparison 1, five of 27 outcomes pertaining to CONSORT
items were found to be significantly more completely reported
in studies published in CONSORT-endorsing journals than in
non-endorsing journals: ’allocation concealment’, ’introduction’,
’sample size’, ’sequence generation’, and ’total sum score’. While
not statistically significant, completeness of reporting for 18 items
favoured CONSORT endorsement. Endorsement was not found
to be beneficial for two outcomes (non statistically significantly less
complete reporting): ’participants’ and ’interventions’. We con-
sider comparison 1 to be the most robust comparison in this re-
view, because it is closest to the RCT design since it compares
an intervention (endorsement) to a control (non-endorsement)
in a cross-section of time. Within comparison 2, six of 27 out-
comes evaluated had estimates of effect demonstrating significant
improvement in reporting following CONSORT endorsement:
’introduction’, ’baseline data’, ’numbers analysed’, ’ancillary anal-
yses’, ’adverse events’, ’generalisability’, and ’total sum score’. In
contrast to comparison 1, comparison 2 included few evaluations
per meta-analysis.
For comparison 3, six of 27 outcomes pertaining to CONSORT
items demonstrate statistically significant improvement in re-
porting following the publication of CONSORT in both 1996
and 2001: ’sample size’, ’sequence generation’, ’allocation con-
cealment’, ’statistical methods’, ’participant flow’, and ’baseline
data’. Completeness of reporting for all other items demonstrated
non-significant improvements following publication of the CON-
SORT Statement.
Quality of the evidence
Like the first review on this topic in 2006 (Plint 2006), assess-
ment of validity of included evaluations indicates that weaknesses
regarding the design of evaluations still exist and there remains
considerable room for improvement in the quality of the evidence
base. Across evaluations, we were uniformly unable to appraise
validity due to unclear reporting of methods and findings by eval-
uation authors; this resulted in largely unclear ratings across all
pre-specified domains (Figure 2). This ’unclear’ rating may also
reflect the need for improvement, validation, and standardisation
in a tool to assess aspects of quality (i.e. validity) in future method-
ological reviews. For instance, whether or not included evaluations
determined whether RCTs were clustered within journals of better
or worse ’quality’ in each comparison arm was assessed in item 3 of
our validity assessment, but because we sometimes artificially cre-
ated comparison arms where none existed, for the purpose of this
review, this item can not be interpreted as an informative measure
of validity of included evaluations.
None of the eight evaluations included in the original review or the
45 additional included evaluations were prospective in nature. An
experimental design such as an RCT, arguably the strongest design
that could be used, would help to control for many confounding
variables, such as improvement due to the passage of time and
variable editorial policies across journals. Such an RCT might
target non-endorsing journals with an endorsement ’intervention’
that might include a request to endorse CONSORT, evidence of its
impact (i.e. the results of this review) and offer explicit wording to
insert in a journal’s ’Instructions to Authors’; with a control group
not receiving any intervention. Future evaluations of the impact
of endorsement of CONSORT (or other reporting guidelines) on
completeness of reporting should utilise methodologically stronger
designs than have been used to date, such as rigorous experimental
designs.
Agreements and disagreements with other
studies or reviews
Five of 22 items of the 2001 CONSORT checklist were signifi-
cantly better when endorsement was present and similar positive
effects are exhibited for another 15 items. However, there is no
evidence to suggest that use of the CONSORT checklist is asso-
ciated with reduced completeness of reporting of RCTs for some
checklist items (i.e. reporting eligibility criteria for ’participants’,
risk ratio (RR) 0.95, 99% CI 0.56 to 1.62). The findings of this
review are consistent with several other evaluations including the
original review (Plint 2006) and the two largest evaluations in-
cluded in this review (Hopewell 2010; Wang 2007).
This update extends the results reported by Plint and colleagues,
which is the only previous systematic review of evaluations of
the CONSORT checklist. The Plint 2006 review included eight
evaluations. The main results demonstrated that CONSORT en-
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dorsers had significantly better reporting of the method of se-
quence generation (RR 1.67, 95% CI 1.19 to 2.33), allocation
concealment (RR 1.66, 95% CI 1.37 to 2.00), and overall number
of CONSORT items (standardised mean difference 0.83, 95% CI
0.46 to 1.19) than non-endorsers. CONSORT endorsement had
a weaker association with participant flow and blinding of par-
ticipants. For before and after endorsement evaluations, good re-
porting of sequence generation, participant flow, and total CON-
SORT items were all associated with the endorsement of CON-
SORT.
Although our review uses confidence intervals at the 1% signifi-
cance level (compared to the original review, which used 5%), all
but one of the significant results in the original review remained
statistically significant in this review; sequence generation was no
longer significant for the before and after endorsement evaluations
(RR 1.46, 99% CI 0.99 to 2.16). In addition to all other outcomes
remaining significant, where there were sparse data per outcome
in the original review, the inclusion of results of additional evalu-
ations has seen that additional outcomes (title and abstract, intro-
duction, sample size, participant flow, numbers analysed for en-
dorsing versus non-endorsing journals, and introduction, baseline
data, numbers analysed, ancillary analyses, adverse events, gen-
eralisability, and overall evidence) have all been influenced when
comparing endorsing journals before and after endorsement.
Wang 2007 aimed to assess the quality of Traditional Chinese
Medicine (TCM) RCTs published in 13 journals in mainland
China, and assessed 20/22 items of the CONSORT checklist in
7422 trials. This evaluation was included as a non-strict compar-
ison before and after the publication of the 2001 version of the
CONSORT Statement as we were unable to verify whether all
journals were endorsing, with corresponding dates of endorsement
to classify each of the 7422 RCTs. Of the 20 items, 13 outcomes
resulted in statistically significant effects for higher completeness
of reporting after CONSORT publication. These were consistent
with the six results deemed significant over all evaluations in this
review, and with the findings of the original review.
Hopewell 2010 assessed quality of reporting of trials and also di-
rectly compared trials before and after the publication of CON-
SORT in 2001. This evaluation, assessing 1135 RCTs, was eligible
for inclusion in both CONSORT-endorsing versus CONSORT
non-endorsing, and pre-post publication of CONSORT compar-
ison groups. Significant increases between 2000 and 2006 in the
proportion of trial reports that included details of the primary
outcome, sample size calculation, and the methods of random se-
quence generation and allocation concealment were reported. All
of these were found to be significant in this review, for the com-
parison of completeness of reporting before and after the publica-
tion of the CONSORT Statement. Moreover, comparing RCTs of
endorsing and non-endorsing journals, reporting of “randomised”
in the title and abstract, reporting of the primary outcome, sam-
ple size calculation, sequence generation, allocation concealment,
blinding, participant flow, and loss to follow-up all yielded signif-
icant increases in reporting for CONSORT-endorsing journals.
All of these were also found to be significant results when com-
paring endorsing and non-endorsing journals in this review.
This review assessed the impact of endorsement of CONSORT
by biomedical journals, however, evaluations assessing adherence
to CONSORT (i.e. not just endorsement) may provide more
meaningful insight into its impact on completeness of report-
ing when used at different stages of the editorial process. One
such evaluation, carried out recently (Cobo 2011), incorporated
these concepts by comparing use and non-use of reporting guide-
lines (including CONSORT) during peer review on author-re-
vised manuscript quality. Findings indicate that manuscript qual-
ity was higher following peer review using reporting guidelines,
including CONSORT.
This review is, itself, reported following the recommendations of
the Preferred Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) Statement (Moher 2009).
Limitations
While the CONSORT checklist aims to provide guidance on a
minimum set of items to be reported in trials, during the review
process we noted that what constitutes ’complete’ reporting for
each checklist item appeared to be variable between evaluations,
depending on author interpretation. While it is the intention of
the CONSORT group that complete reporting of a single check-
list item means that all concepts contained within an individual
checklist item be reported in order to be considered adequately
(or completely) reported, some authors may have considered re-
porting as complete when at least one concept was reported in
a given RCT; whether or not this was done is not identifiable
or quantifiable in this review. For some evaluations, authors were
more explicit in their interpretation of what constituted complete
reporting by including ratings of ’partially reported’; for the pur-
poses of this review, we took ’partial’ ratings as ’incomplete’. We
recommend that future evaluations assess the completeness of re-
porting of each checklist item in a dichotomous fashion (i.e. ’com-
plete’ versus ’incomplete’) and moreover generally suggest to trial
authors that items are only ’complete’ when adhered to in their
entirety.
This review does not assess the most current version of the CON-
SORT checklist (Moher 2010). To address problems with inter-
pretation of checklist items, when the CONSORT Statement was
revised in 2010, some items of the 2001 checklist that covered
multiple concepts were purposefully split out into two or more
sub-items. For instance, item 3 of the 2001 checklist, which ad-
dresses both the reporting of participant eligibility criteria and
setting and location where data were collected, became two sub-
items in the 2010 checklist (items 4a and 4b). When comparing
RCTs published in endorsing and non-endorsing journals, two
items ’participants’ and ’interventions’, although not statistically
significant, resulted in effects which did not favour the endorse-
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ment of CONSORT. These items have since been divided into
two sub-items in the 2010 CONSORT Statement.
The objectives and methods of included evaluations varied con-
siderably. Specification of items assessed pertaining to methods
differed from evaluation to evaluation, some of which did not
coincide specifically with CONSORT items. For example, some
checklists used in evaluations to assess completeness of reporting
contained modifications to the native wording of the CONSORT
checklist(s) and/or sub-categorised items (and these modifications
differed across evaluations); some evaluations assessed additional
methodological items. Although we consider these aspects to have
had little impact on the overall results, they were, nevertheless, a
limitation. Moreover, data that were excluded to prevent poten-
tial misclassification as described in the Dealing with missing data
section, or RCTs published in 2001 for which endorsement status
could not be confirmed and thus were classified as non-endorsers,
should be noted. All such classifications were made to ensure that
any effect was underestimated rather than inflated.
Within the included evaluations, only four reported data regarding
potential confounders. Some evaluations considered broad time
intervals over which completeness of reporting was assessed, be-
fore and after CONSORT publication, or within endorsing jour-
nals before and after endorsement. Unfortunately, as there is in-
sufficient information to adjust for confounding by improvement
in reporting quality over time, and as this potential confounding
factor impacts results at the evaluation level, we were unable to
adjust for it. Similarly, confounding by journal quality, addressing
whether those journals that endorse the CONSORT Statement
are perhaps of higher ’quality’ than those that do not, should also
be considered when assessing our findings. This aspect was assessed
for each evaluation, with results detailed in the validity assessment
tables. Validity assessment was conducted based on pre-specified
criteria developed specifically for this review. In particular, some
items of the tool are more rigorous than others and quality assess-
ment results should be interpreted cautiously, in particular, there
is no evidence to suggest that blinding of assessors to trialists and
institutions would improve the validity of the evaluations in this
study.
One practical and important implication that could not be as-
sessed when designing or carrying out this review, was the level at
which the endorsement of CONSORT was implemented. This
review assessed endorsement of the CONSORT Statement at the
journal level, but not all journals may enforce CONSORT en-
dorsement in the same manner, which could lead to a different
impact of CONSORT on completeness of reporting. As suggested
by Cobo et al (Cobo 2011), when and how CONSORT is imple-
mented within the editorial process and who takes responsibility
for ensuring adherence to CONSORT policies could impact on
RCT reporting. It is reasonable to expect that a recommendation
in a journal’s ’Instructions to Authors’ without any further edito-
rial checks might have less of an impact on completeness of re-
porting as compared to a requirement to complete a CONSORT
checklist and/or flow diagram before a manuscript is considered
for peer review. These issues require further prospective study to
understand better the impact of CONSORT on completeness of
reporting. In the absence of such understanding, however, we be-
lieve our handling of reporting data in this review has resulted
in an underestimate of the impact of the CONSORT Statement
on the completeness of reporting. When authors do not adhere
to a journal’s recommendations to use CONSORT, endorsement
does not achieve its full potential. Alternatively, some journals may
not endorse the CONSORT Statement, but authors may use the
checklist under their own volition. Again, this would result in an
underestimate of the impact of the CONSORT Statement on the
completeness of reporting.
It should be noted that comparisons 1 and 3 yield results in favour
of CONSORT endorsement for the ’total sum score’ item. This
result is inclusive of evaluations that reported mean data for RCT
adherence over all checklist items. Such scores give equal weight-
ing to all checklist items, which may not be appropriate, although
there is no sound basis on which to use unequal weights. Addi-
tionally, some evaluations scored an aggregate over CONSORT
Statement modifications and included more or fewer than the 22
recommended items. In addition, one evaluation did not report
all necessary data for inclusion in meta-analyses (e.g. median and
range rather than mean, or not reporting standard deviations). For
one evaluation the standard deviation was imputed. These dif-
ferences between evaluations present some challenges when inter-
preting the significance of results for total sum scores.
A U T H O R S ’ C O N C L U S I O N S
Implication for methodological research
While it is gratifying that approximately 600 health journals en-
dorse CONSORT, this is still only a small proportion of all
journals in existence. Even among those journals that mention
CONSORT, the data suggest that there is considerable room for
improvement in how it is endorsed. Hopewell and colleagues
(Hopewell 2008) examined the ’Instructions to Authors’ in 165
journals for any mention of CONSORT. These researchers ob-
served that 38% mentioned CONSORT, although the language
used varied across journals. This figure is an improvement on the
22% reported by Altman a few years earlier (Altman 2005).
We need to better understand barriers and facilitators to introduc-
ing CONSORT to the editorial process, and to develop and eval-
uate different implementation strategies that will increase CON-
SORT endorsement and adherence. The CONSORT group is
currently undertaking further explorations in this area.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Agha 2007
Methods Evaluates the degree to which RCTs involving urological surgical techniques (as the inter-
vention) published in the years 2000-2003 complied with the CONSORT Statement, and
assesses trends and patterns of compliance
The study was then extended to a number of other specialties to assess whether our findings
in urology could be generalised to other surgical disciplines
Data 90 RCTs from 35 journals, 22 items unweighted CONSORT score recorded, unable to obtain
dates of endorsement for all journals, included what was readily available
Comparisons CONSORT-endorsing and non-endorsing journals, quality of RCTs before and after CON-
SORT publication
Outcomes Total sum score
Included number of RCTs, Journals 88, 33
Checklist version used 2001
Field of Study Surgical medicine
Notes Author was contacted, additional item data no longer available
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Yes 2 electronic databases were searched over 3
years
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Yes No difference between planned and reported
outcomes/analyses
Multiple raters? Unclear Not reported
Rater agreement? Yes Not applicable
Blinding, quality assessment? Yes Not applicable
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Al-Namankany 2009
Methods This evaluation assesses completeness of reporting in published RCTs in paediatric dental
journals, as a secondary outcome to see whether quality of reporting has improved since the
introduction of the CONSORT guidelines
Trials published from 1985 to 1997, and from 1998 to 2006 were compared
Data 173 RCTs from 8 journals, 22 CONSORT items converted into 34 questions
Comparisons Qualitatively synthesised based on data in the text considering quality of RCTs before and
after the publication of CONSORT
Outcomes Sequence generation, allocation concealment, blinding of participants, blinding of administer
of interventions, outcome assessor blinding
Included number of RCTs, Journals 173, 8
Checklist version used 1996
Field of Study Pediatric dentistry
Notes Data sent by author, but was not consistent with our needs for inclusion, so used as readily
available in the text; as the denominator for comparison groups is not included this study is
included for qualitative synthesis
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Yes Searched PubMed over 2 decades
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Yes No evidence of selective reporting
Multiple raters? Yes Quote: “...all items were considered together
for each paper and a good agreement between
the two reviewers...”
Rater agreement? Yes Quote: “...was found with κ = 0.92 (0.88-0.
96)”
Blinding, quality assessment? Yes Not applicable
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Alvarez 2009
Methods Assesses the effect of the adoption of CONSORT on the reporting quality of RCTs by sys-
tematic evaluation of RCTs published in 2 dermatology journals pre- and post CONSORT
adoption; RCTs were published in 1997 and 2006
6 CONSORT checklist items were evaluated by equal weight
Data 98 RCTs from 2 journals
Comparisons CONSORT-endorsing journals before and after CONSORT endorsement
Outcomes Interventions, methods, blinding, outcomes, sample size and sequence generation
Included number of RCTs, Journals 98, 2
Checklist version used 2001
Field of Study Dermatology
Notes Author provided all raw data and gave permission to be adapted for inclusion in our study. As
such, the endorsement definition holds
Risk of bias
Item Authors’ judgement Description
Large Cohort ? No From 2 years in 2 journals
Blinding? Unclear Not reported
Confounding by journal quality? Yes Not applicable
Outcome Reporting? Yes No evidence of selective reporting of outcomes
Multiple raters? Unclear Not reported
Rater agreement? Unclear Not reported
Blinding, quality assessment? Yes Not applicable
Anttila 2006
Methods Evaluates trial reporting by using the CONSORT Statement recommendations for trials pub-
lished in or after 1990; the checklist was modified to include 33 items
Trials published between 1990-1997 and 1998-2002 were compared to see if CONSORT had
an influence on the quality of reporting
Data 15 trials from 9 journals, only 1 journal deemed to be an endorsing journal
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Anttila 2006 (Continued)
Comparisons Before and after CONSORT publication
Outcomes Title and abstract, background, participants, interventions, objectives, outcomes, sample size,
sequence generation, allocation concealment, implementation, blinding of: participants, data
analyst and outcome assessor, statistical methods, participant flow, recruitment, baseline data,
numbers analysed, outcomes and estimation, ancillary analyses, adverse events
Included number of RCTs, Journals 14, 9
Checklist version used 1996
Field of Study Cerebral palsy
Notes Data needed provided in the appendix; recategorised data to be compliant with our comparison
Risk of bias
Item Authors’ judgement Description
Large Cohort ? No 15 included RCTs
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Yes No difference between planned and reported
outcomes/analyses
Multiple raters? Yes Quote: “Two researchers (R.K. and H.A.) in-
dependently evaluated the quality of reporting
in the identified trials by using this modified
checklist.”
Rater agreement? No Quote: “The evaluators disagreed in 23% of
the evaluations.”
Blinding, quality assessment? Yes Not applicable
Areia 2010
Methods This study evaluated quality in recently published endoscopic articles in articles published
from 1998 to 2008 by assessing STARD and CONSORT
Data 10 RCTs of 120 articles, 2 endorsing journals
Comparisons CONSORT-endorsing journals versus CONSORT non-endorsing journals
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Areia 2010 (Continued)
Outcomes Title and abstract, background, participants, interventions, objectives, outcomes, sample size,
sequence generation, allocation concealment, implementation, blinding of: participants, data
analyst and outcome assessor, statistical methods, participant flow, recruitment, baseline data,
numbers analysed, outcomes and estimation, ancillary analyses, adverse events, interpretation,
generalisability, overall evidence
Included number of RCTs, Journals 10, 5
Checklist version used 2001
Field of Study Endoscopy
Notes Author provided full data set; endorsement was confirmed and meets our definition
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Yes Sampled over a decade, large number of trials
in study
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Yes No evidence of selective outcome reporting
Multiple raters? Yes 2 reviewers independently reviewed
Rater agreement? Yes Interobserver agreement was 97.3%
Blinding, quality assessment? Yes Not applicable
Balasubramanian 2006
Methods Evaluates the quality of reporting of surgical randomised controlled trials published in surgical
and general medical journals in 2003 using Jadad score, allocation concealment, and adherence
to CONSORT guidelines and to identify factors associated with good quality
Data CONSORT score is reported as a median across all 30 items scored from 1 to 3 where 1 was
no description and 3 corresponded to adequate description
Comparisons CONSORT endorsers versus non-endorsers
Outcomes Total sum score
Included number of RCTs, Journals 69, 10
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Balasubramanian 2006 (Continued)
Checklist version used 2001 (modified to 30 items)
Field of Study General surgery
Notes To be an endorser of the journal had to have such guidance in their ’instructions to authors’
which meets the definition in this review
Unable to obtain scores for each RCT which would have allowed inclusion across all items
This study also assessed quality using the Jadad score and Schulz allocation concealment
Risk of bias
Item Authors’ judgement Description
Large Cohort ? No RCTs published in 10 top journals over 1-year
period
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Yes No difference between planned and reported
outcomes/analyses
Multiple raters? Yes Quote: “Each article was then assessed for ev-
ery item on the checklist and scored indepen-
dently by 2 observers (S.P.B. and R.T.)”
Rater agreement? No Quote: “The agreement between the pair
of observers who independently assessed the
RCTs using the CONSORT checklist was
good (ICC 0.85; 95% CI 0.77-0.91; P 0.001)
”
Blinding, quality assessment? Unclear Not reported
Bausch 2009
Methods Assessed trial quality in COPD RCTs by key items; quality of reporting was compared over
several comparisons, of which CONSORT endorsement was one
RCTs published in 1957-2000 versus after 2000
Data As individual RCT data were available, data were extracted to compare 239 RCTs pre-2001
versus 105 RCTs from 2001 onwards
Comparisons Before and after CONSORT publication
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Bausch 2009 (Continued)
Outcomes Allocation concealment, sequence generation, participants, blinding: participants, interven-
tion, outcome assessor, outcomes and estimation, numbers analysed
Included number of RCTs, Journals 344, 110
Checklist version used Used pre-specified criteria which coincide with 8 CONSORT 2001 checklist items
Field of Study Chronic obstructive pulmonary disease
Notes Author provided RCT level data ensuring this study could be included in our analysis
With more resources, this study could potentially be included in the CONSORT endorsers
versus non-endorsers comparison
90 RCTs were published before 1990; it is of importance to note potential confounding by
improvement in reporting quality over time
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Yes Multiple databases, large number of trials as-
sessed
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Unclear Unsure, no explicit evidence of selective re-
porting
Multiple raters? Unclear Multiple raters, but not specified for CON-
SORT items assessment
Rater agreement? Unclear Not reported
Blinding, quality assessment? Unclear Not applicable
Bian 2006
Methods Evaluated the quality of Chinese herbal medicine RCTs using a modified CONSORT checklist
before and after 2000, the 4th of a 4-part series considering the quality of Chinese herbal
medicine RCTs
Data Percentage reported by year, data extracted to form comparison before 2001 and 2001 onwards
Comparisons Before and after CONSORT publication
Outcomes Total sum score of 63 items
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Bian 2006 (Continued)
Included number of RCTs, Journals 167, 35
Checklist version used 63-item modification of the 2001 checklist
Field of Study Chinese herbal medicine
Notes Author provided additional information, but this was not all that was necessary to include in
a more robust comparison
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Unclear RCTs from 11 systematic reviews on Chinese
herbal medicine
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Yes No difference between planned and reported
outcomes
Multiple raters? Yes Independent assessment by 2 reviewers
Rater agreement? Unclear Not reported
Blinding, quality assessment? Yes Not applicable
Chauhan 2009
Methods Appraised the compliance of randomised clinical trials (RCTs) cited for level A recommenda-
tions in obstetric practice bulletins (OPBs) and published after the CONSORT (Consolidated
Standards of Reporting Trials, published 1996) statement
Data 50-item checklist
Unweighted median score reported before and after 1997
Compares 58 RCTs before 1997 and 32 RCTs after 1997, described as before and after
CONSORT
Post
Comparisons Median 50-item score before and after CONSORT publication
Outcomes Included as ’primary evidence’, synthesised qualitatively
Median total sum score
Included number of RCTs, Journals 90, 5
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Chauhan 2009 (Continued)
Checklist version used 1996
Field of Study Obstetric practice
Notes RCT level data unavailable to include with comparison data
Desciptive comparison only
Risk of bias
Item Authors’ judgement Description
Large Cohort ? No RCTs from single journal over 8-year period
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Yes No difference between planned and reported
outcomes/analyses
Multiple raters? Unclear Not reported
Rater agreement? Yes Not applicable
Blinding, quality assessment? Yes Not applicable
Devereaux 2002
Methods Observational study to determine the quality of reporting key methodological factors in RCTs
since the publication of the CONSORT Statement and if CONSORT endorsement by jour-
nals of the checklist was associated with superior reporting. 11 key methodological factors
Examined the quality of reporting in relation to whether a journal was a ’CONSORT promoter’
as defined by inclusion of the CONSORT checklist in a journal’s ’information to authors’
section or a requirement that authors, manuscript reviewers, or copy editors complete the
CONSORT checklist
Data 7 journals were confirmed to meet our definition of CONSORT endorser, versus 19 non-
endorsing journals
Comparisons CONSORT endorsers versus non-endorsers
Outcomes Allocation concealment, sequence generation, statistical methods, participant flow, baseline
data, blinding: outcome assessor, intervention, data analyst, participants
Included number of RCTs, Journals 105, 26
Checklist version used 1996
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Devereaux 2002 (Continued)
Field of Study Internal medicine
Notes This study was included in the original review
Risk of bias
Item Authors’ judgement Description
Large Cohort ? No 3 journals, shorter time period
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Quote: “We conducted a multivariable analy-
sis (i.e., least squares regression) in which the
dependent variable was the number of factors
included in each article and the independent
variables were the impact factor of the jour-
nal”
Outcome Reporting? Yes No evidence of selective reporting
Multiple raters? Yes Quote: “Two of us (W.G. and G.G.) indepen-
dently evaluated all summaries”
Rater agreement? Yes > 0.8
Blinding, quality assessment? Yes Not applicable
Dias 2006
Methods Aim was to assess whether quality has improved over time, particularly since the publication
of CONSORT, and to assess what proportion of trials could be included in the meta-analyses
of pregnancy outcomes such as those included in Cochrane Reviews
Trials selected were published in 1990, 1996, and 2002; only trials published in English as
full journal articles, claiming to be randomised and reporting on pregnancy outcomes, were
included
Data Journal endorsement was verified for compliance with our definition, as such a total of 60
and 53 RCTs were included for the endorsers versus non-endorsers, and before and after
endorsement comparisons respectively
Comparisons CONSORT endorsers versus non-endorsers, CONSORT-endorsing journals before and after
CONSORT endorsement




Included number of RCTs, Journals 164, 29
Checklist version used 1996
Field of Study Subfertility
Notes Author provided necessary data for our review
This study also included data for control comparisons including, pre-CONSORT endorsers
versus pre-CONSORT non-endorsers: allocation concealment, sequence generation and ad-
verse events. pre-post consort non-endorsers: sequence generation, allocation concealment,
participant flow, adverse events
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Yes RCTs from Cochrane review group register
from which 3455 references were available
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not clearly reported
Outcome Reporting? Yes No difference between planned and reported
outcomes/analyses
Multiple raters? Unclear Not reported
Rater agreement? Yes Not applicable
Blinding, quality assessment? Yes Not applicable
Dickinson 2002
Methods Assessed the quality of reporting in RCTs of lifestyle interventions
Data From the provided data, items were sorted into before and after 1996 publication, 10 RCTs
were published after 1996 and 72 RCTs were published before, from 1977
Comparisons Cross-sectional sample before and after CONSORT publication
Outcomes Allocation concealment, blinding of participants
Included number of RCTs, Journals 166, not reported
Checklist version used 1996
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Dickinson 2002 (Continued)
Field of Study Lifestyle interventions
Notes Author presented poster at Cochrane Colloquium. Author provided data
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Unclear Over long time period, journals unknown
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Unclear Not reported
Multiple raters? Unclear Not reported
Rater agreement? Unclear Not reported
Blinding, quality assessment? Unclear Not reported
Ethgen 2009
Methods Objective of study was to evaluate the quality of reporting internal and external validity data
in published reports of RCTs assessing the stents for percutaneous coronary interventions
Quality attributed to CONSORT-endorsing journals was also reported in the abstract
Data Quality was assessed using the CLEAR NPT checklist
Comparisons CONSORT-endorsing journals versus non-endorsing journals
Outcomes Interventions, sequence generation, allocation concealment, numbers analysed, blinding: out-
come assessor, intervention, participants
Included number of RCTs, Journals 123, 29 (unknown for 9 RCTs)
Checklist version used 2001
Field of Study Stents for percutaneous coronary interventions
Notes Author provided data




Item Authors’ judgement Description
Large Cohort ? Yes Over 5 years, MEDLINE and Cochrane
searched, large number of RCTs
Blinding? Unclear Not reported
Confounding by journal quality? No Quote: “The quality of reporting was better in
journals with high impact factors and in jour-
nals endorsing the CONSORT statement.”
Outcome Reporting? Yes No evidence of selective reporting
Multiple raters? Unclear Verification of sample conducted
Rater agreement? Unclear Not reported
Blinding, quality assessment? Yes Not applicable
Faunce 2003
Methods Reviewed RCTs before and after 1996 publication of CONSORT based on key methodological
items
Data Endorsement of journals was verified, 2 of which endorse the CONSORT checklist
Comparisons CONSORT endorsers verus non-endorsers, CONSORT-endorsing journals before and after
CONSORT endorsement
Outcomes Participants, sample size, and participant flow for endorsers versus non-endorsers and partici-
pants and participant flow before and after endorsement
Included number of RCTs, Journals 13, 7
Checklist version used 1996
Field of Study Overdoses in health volunteers
Notes This study was included in the original review
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Yes 2-year, multiple journal sample
Blinding? Unclear Not reported
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Faunce 2003 (Continued)
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Yes No evidence of selective reporting
Multiple raters? Unclear Not reported
Rater agreement? Unclear Not reported
Blinding, quality assessment? Yes Not applicable
Folkes 2008
Methods Assesses the extent of completeness of reporting to pre-randomisation data reporting in 4
leading general medicine journals, as recommended by CONSORT
Data Study reports the improvement in reporting from 2004 and 2006, 3 endorsing journals and
one journal endorsing in 2005
Data reported for 2004 included only
Comparisons CONSORT endorsers versus non-endorsers
Outcomes Participants
Included number of RCTs, Journals 480, 4
Checklist version used 2001
Field of Study None specified
Notes Author unable to provide data for RCTs included published by NEJM to confirm non-endorser
comparison group for 2006 data
Including only 2004 data endorsers meets definition for our review
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Yes Cross-sections of 2 calendar years at 4 top jour-
nals; 480 included studies
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not reported




Multiple raters? Yes Quote: “...two reviewers (AF, RU) indepen-
dently evaluated the trials’ reporting of pre-
randomization information (the ’Enrollment’
stage), as outlined in the CONSORT state-
ment”
Rater agreement? Unclear Not reported
Blinding, quality assessment? Yes Not applicable
Greenfield 2005
Methods To assess the quality of reporting in anesthesiology journals with RCTs published in 2000
Data A modified version of the Chalmers tool was used to assess quality
Comparisons CONSORT endorsers versus non-endorser
Outcomes Allocation concealment, blinding, participant flow, adverse events
Included number of RCTs, Journals 279, 4
Checklist version used 2001 (items coincide with)
Field of Study Anesthesiology
Notes Author provided additional data
Journal endorsement was verified and consistent with our definition
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Unclear Large search, 4 journals included over 1 year
Blinding? Yes Quote: “These 279 articles were photocopied,
and all identifiers were removed from all pages
by three investigators (MDN, AS, and MJS)
who were not involved in further evaluation”
Confounding by journal quality? Unclear Quote: “However, it is important to note that
only two of the major general anesthesiology
journals reviewed in this article have adopted
CONSORT guidelines in their instructions to




Outcome Reporting? Yes No evidence of selective reporting of outcomes
Multiple raters? Yes Implied. Quote: “Articles were offered in a
random order using a computer generated
randomization scheme. Both reviewers have
had formal training in research design, epi-
demiology, and biostatistics”
Rater agreement? Unclear Not reported
Blinding, quality assessment? Yes Chalmers score assessed and blinded
Haahr 2006
Methods To assess the reporting of blinding in RCTs, sample of 2001 published trials in the Cochrane
Central Register of Controlled Trials
Data 15 RCTs included from 10 endorsing journals and 185 RCTs from 61 journals
Comparisons CONSORT-endorsing journals versus non-endorsing journals
Outcomes Blinding of: outcome assessor, participants, intervention, data analyst
Included number of RCTs, Journals 200, 171
Checklist version used 2001
Field of Study None specified
Notes Author provided data
Journal endorsement has been verified and complies with our definition
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Yes Sample of 200 trials from Cochrane Trials
Register Issue 1, 2003
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not reported




Multiple raters? Yes 2 raters
Rater agreement? Unclear Not reported
Blinding, quality assessment? Yes Not applicable
Halpern 2004
Methods RCTs pertaining to the practice of obstetric anaesthesia and summarised in Obstetric Anesthesia
Digest between March 2001 and December 2002 were assessed to compare the quality of
reporting to the CONSORT checklist
Data 6 RCTs of one endorsing journal, 77 RCTs from 6 non-endorsing journals
Comparisons CONSORT-endorsing versus non-endorsing journals
Outcomes Title and abstract, participants, interventions, objectives, outcomes, sample size, sequence
generation, allocation concealment, implementation, blinding: participants, outcome assessor
and intervention, statistical methods
Included number of RCTs, Journals 100, 7
Checklist version used 2001
Field of Study Obstetric anaesthesia
Notes Included in the original review
Author provided data
Risk of bias
Item Authors’ judgement Description
Large Cohort ? No Only journal articles published in 1 digest
magazine
Blinding? Unclear Not reported
Confounding by journal quality? Yes Not applicable, only 1 journal
Outcome Reporting? Yes No evidence of selective outcome reporting
Multiple raters? Yes Quote: “Each of the study articles was then
scored by two investigators independently”
Rater agreement? Unclear Not reported
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Halpern 2004 (Continued)
Blinding, quality assessment? Yes Not applicable
Han 2008
Methods Determined whether the CONSORT recommendations influenced the quality of reporting
of randomised controlled trials (RCTs) in the field of psychiatry
Evaluated the quality of clinical trial reports before and after the introduction of CONSORT
Statement
Trials were published from period of 1992-1996 (pre-CONSORT) and 2002-2007 (post
CONSORT)
Data 166 pre-CONSORT RCTs were compared across all CONSORT items with 276 post CON-
SORT items
Comparisons CONSORT-endorsing journals before and after endorsement
Outcomes Title and abstract, background, participants, interventions, objectives, outcomes, sample size,
sequence generation, allocation concealment, implementation, blinding any, statistical meth-
ods, participant flow, recruitment, baseline data, numbers analysed, outcomes and estimation,
ancillary analyses, adverse events, interpretation, generalisability, overall evidence
Included number of RCTs, Journals 442, 7
Checklist version used 2001
Field of Study Psychiatry
Notes
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Yes 7 journals over 9 years search via PubMed
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Yes No evidence of selective outcome reporting
Multiple raters? Yes 2 raters assessed items
Rater agreement? Yes Concordance rate reported of 95%
Blinding, quality assessment? Yes Not applicable
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Hewitt 2005
Methods RCTs in general medical journals in 2002 in 4 medical journals assessed for adequacy of
reporting of allocation concealment
Data 166 endorsing RCTs and 68 non-endorsing RCTs
Comparisons CONSORT endorsers versus non-endorsers
Outcomes Allocation concealment
Included number of RCTs, Journals 234, 4
Checklist version used Modification
Field of Study General medical journals
Notes This study was included in the original review
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Unclear Not a complete year, but large number of in-
cluded studies
Blinding? Unclear Not reported
Confounding by journal quality? Yes Quote: “Our statistical analyses adjusted for
clustering effects by journal.”
Outcome Reporting? Yes No evidence to suggest reported outcomes
were selective
Multiple raters? Unclear Not reported
Rater agreement? Unclear Not reported
Blinding, quality assessment? Yes Not applicable
Hill 2002
Methods RCTs included from 1987-1988 and 1997-1998; quality was assessed by adequate reporting
of a modified Jadad scale
Data 119 pre-CONSORT RCTs versus 121 post CONSORT RCTs




Outcomes CONSORT-endorsing versus non-endorsing: sequence generation, allocation concealment,
statistical methods, participant flow, numbers analysed
CONSORT-endorsing journals before and after endorsement: sequence generation, allocation
concealment, statistical methods, participant flow
Included number of RCTs, Journals 240, 68
Checklist version used 1996
Field of Study Adult rheumatological diseases
Notes This study was included in the original review
Author provided data
Endorsement of journals has been confirmed and is compliant
Used Jadad scaled to assess quality
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Yes Large range of journals over many years
Blinding? Unclear Not reported
Confounding by journal quality? Yes Quote: “Analyses were undertaken... and com-
paring RCTs from “high”- and “low”-impact
journals”
Outcome Reporting? Yes No evidence of selective reporting
Multiple raters? Yes Abstracted in duplicate
Rater agreement? Yes Quote: “Kappa 0.80 for all features combine”
Blinding, quality assessment? Unclear Not reported
Hopewell 2010
Methods Examines the reporting characteristics and methodological details of randomised trials indexed
in PubMed in 2000 and 2006 and assess whether the quality of reporting has improved after
publication of CONSORT in 2001
Data Design: comparison of 2 cross-sectional investigations of indexed trials in PubMed in Decem-
ber 2000 (n = 519) and December 2006 (n = 616)




Outcomes Endorsers versus non-endorsers comparison: blinding any, outcomes, sample size, sequence
generation, allocation concealment
Before and after publication comparison: outcomes, sequence generation, title and abstract,
blinding any, numbers analysed, participant flow, allocation concealment, sample size
Included number of RCTs, Journals 1135, 587
Checklist version used 2001
Field of Study None specified
Notes This study is the primary study of the companion Yu 2010
Does not meet definition of endorser defined for our review
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Yes Cross-section of RCTs in PubMed from De-
cember 2006; 616 primary RCT reports in-
cluded
Blinding? Unclear Not reported
Confounding by journal quality? Yes No potential for clustering by journal
Outcome Reporting? Yes No difference between planned and reported
outcomes/analyses
Multiple raters? Unclear Not reported
Rater agreement? Yes Not applicable
Blinding, quality assessment? Yes Not applicable
Kane 2007
Methods Examines the extent to which CONSORT improved clinical trials reporting and subject
attrition, which may undermine the credibility of published randomised clinical trials (RCTs)
Includes RCTs reported in 2 major medical journals before and after the CONSORT guidelines
were endorsed; one used the CONSORT Statement (JAMA) and one did not acting as control
(NEJM)
Data 308 RCTs pre-CONSORT (1993-1995), 88 RCTs published in JAMA and 220 in NEJM,




Comparisons CONSORT-endorsing versus non-endorsing, CONSORT-endorsing journals before and af-
ter endorsement
Outcomes Endorsers versus non-endorsers: sample size, participant flow, numbers analysed, recruitment,
blinding any, sequence generation
CONSORT endorsers before and after endorsement: participant flow, number analysed, sam-
ple size, blinding any, recruitment
Included number of RCTs, Journals 776, 2
Checklist version used 1996
Field of Study None specified
Notes This study also includes a number of control comparisons. Data available for:
Pre-post CONSORT non-endorsers: sample size, sequence generation, allocation conceal-
ment, blinding any description, participant flow, recruitment, numbers analysed
Pre-CONSORT endorsers versus non-endorsers: sample size, sequence generation, allocation
concealment, blinding any description, participant flow, recruitment, numbers analysed
Risk of bias
Item Authors’ judgement Description
Large Cohort ? No RCTs in 1 endorsing and 1 non-endorsing
journal 3 years prior and post CONSORT
publication
Blinding? Unclear Not reported
Confounding by journal quality? Yes Not applicable
Outcome Reporting? Yes No difference between planned and reported
outcomes
Multiple raters? Yes 2 raters
Rater agreement? Unclear Not reported
Blinding, quality assessment? Yes Not applicable
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Kidwell 2001
Methods Objective of study was to quantitatively characterise developments in clinical trial methodology
over time in the field of acute ischaemic stroke
A formal 100-point scale was used to rate trial quality and unweighted totals for CONSORT
endorsers and non-endorsers was reported in the text
Data 34 RCTs included for our analysis, 9 endorsing journals and 25 non-endorsing journals
Comparisons CONSORT endorsers versus non-endorsers
Outcomes Total sum score on 100-point scale
Included number of RCTs, Journals 178, not reported in text
Checklist version used 1996
Field of Study Stroke
Notes This study was obtained from an external source, Cochrane Colloquium 2010
CONSORT-endorsing journal was not defined and was not confirmed to coincide with our
definition
Please note that the standard deviation for this study was imputed
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Yes 178 articles, 40 years
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Unclear No apparent difference between planned and
reported outcomes
Multiple raters? No Full extraction was not verified
Rater agreement? Yes Validity assessment conducted, kappa > 0.9
Blinding, quality assessment? Yes Not applicable
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Kober 2006
Methods Aims to determine the extent of ambiguity and reporting quality as assessed by completeness
of reporting to the CONSORT Statement in published reports of RCTs involving patients
with Hodgkin lymphoma from 1966 through 2002
Quality of reporting was assessed using a 14-item questionnaire based on the CONSORT
checklist
Reporting was studied in 2 pre-CONSORT periods (1966-1988 and 1989-1995) and one
post CONSORT period (1996-2002)
Data 77 RCTs eligible for inclusion in our study
Comparisons CONSORT endorsers versus non-endorsers, CONSORT endorsers before and after CON-
SORT endorsement
Outcomes Endorsers versus non-endorsers: title and abstract, introduction, interventions, outcomes,
sample size, sequence generation, allocation concealment, statistical methods, participant flow,
numbers analysed, outcomes and estimation, adverse events
CONSORT endorsers before and after: title and abstract, introduction, interventions, out-
comes, sample size, sequence generation, statistical methods, participant flow, numbers anal-
ysed, outcomes and estimation, adverse events
Included number of RCTs, Journals 243, 33
Checklist version used 1996
Field of Study Hodgkin lymphoma
Notes Author provided data in necessary format
Endorsing journals are consistent with our definition
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Yes Multiple databases over 1-month period (May
2003)
Blinding? Unclear Not reported
Confounding by journal quality? Yes Quote: “Clustering of articles in a journal or
by study group was not taken into account in
the analyses.”
Outcome Reporting? Yes No differences between planned and reported
outcomes/analyses
Multiple raters? Unclear Not reported
Rater agreement? Yes Not applicable
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Kober 2006 (Continued)
Blinding, quality assessment? Yes Not applicable
Ladd 2010
Methods Aim of this study was to examine if adopting CONSORT standards of reporting improved
the quality of reporting of alcohol treatment outcome studies
RCTs were identified from 8 journals publishing a substantial number of alcohol treatment
outcome studies (n = 127 RCTs) and coded for the quality of reporting according to the
CONSORT guidelines
Data Pre-CONSORT 70 RCTs, post CONSORT 89 RCTs, 1 endorsing journal of 19 RCTs and
108 RCTs from non-endorsing journals
Comparisons CONSORT endorsers versus non-endorsers, cross-sectional sample before and after CON-
SORT publication
Outcomes CONSORT endorsers before and after endorsement: title and abstract, background, interven-
tions, outcomes, sequence generation, allocation concealment, statistical methods, participant
flow, numbers analysed, outcomes and estimation, adverse events
Endorsers versus non-endorsers: title and abstract, introduction, objectives, outcomes, sample
size, sequence generation, blinding any, statistical methods, participant flow, numbers anal-
ysed, outcomes and estimation, ancillary analyses, interpretation, generalisability and overall
evidence
Included number of RCTs, Journals 127, 8
Checklist version used 2001, 1996 comparison for pre-post
Field of Study Alcohol outcome studies
Notes Author provided data for the review; some dates of journal endorsement provided by MEs
are vague; these have been conservatively categorised as non-endorsers; in turn, definition is
compliant for this study
For before and after, 3 time periods reported; to allow for improvement in quality of reporting
over time, conservatively, we included 1989-1995 and 1996-2002 in our analysis
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Yes Large number of trials from 8 journals over a
long time period
Blinding? Unclear Quote: “It was not feasible to mask year pub-
lished and author due to high rates of self-ci-
tation and dates in reference lists. However,
names of the source journals for each article
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Ladd 2010 (Continued)
were concealed from coders”
Confounding by journal quality? Yes Stratified analysis. Quote: “Studies published
pre-CONSORT (1994-1998) did not differ
significantly on overall CONSORT score be-
tween adopter and nonadopter journals”
Outcome Reporting? Yes No evidence of selective outcome reporting
Multiple raters? Yes Quote: “Four coders (the four authors) coded
the articles for this study. Twenty percent of
studies were randomly selected to be double-
coded throughout the coding process”
Rater agreement? Unclear Not reported
Blinding, quality assessment? Yes Not applicable
Lai 2006
Methods Assesses the reporting quality of randomised controlled trials (RCTs) in the primary treatment
of brain tumours and aimed to identify significant predictors of quality in trials published
between 1990 and 2004 using items from the CONSORT checklist
Data 23 RCTs pre-CONSORT (1990-1994) and 32 RCTs post CONSORT (2000-2004)
Score out of 15
Comparisons Cross-sectional sample of before and after CONSORT publication
Outcomes Total sum score
Included number of RCTs, Journals 74, 26
Checklist version used 2001 (1996 intervention)
Field of Study Brain tumours
Notes Author provided study data
Median overall score
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Yes Reasonable number of assessed trials, from 4
journals, over 15 years
Blinding? Unclear Not reported
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Lai 2006 (Continued)
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Yes No evidence of selective outcome reporting
Multiple raters? Yes Quote: “Two trained investigators (R.L. and
R.C.) who were blinded to each other’s rat-
ings abstracted data independently into a stan-
dardized data abstraction form, which was pi-
lot tested on 15 studies and subsequently was
revised”
Rater agreement? Yes Quote: “The overall inter-rater agreement was
0.83”
Blinding, quality assessment? Yes Not applicable
Lai 2007
Methods Evaluates the reporting quality of key methodological items in randomised controlled trials
(RCTs) in 4 general clinical ophthalmology journals
The reporting of 11 key methodological items in RCTs published in American Journal of
Ophthalmology, Archives of Ophthalmology, British Journal of Ophthalmology and Ophthalmology
in the year 2005 was assessed
Data 51 CONSORT-endorsing RCTs from 3 journals and 16 non-endorsing RCTs from 1 journal
Comparisons CONSORT endorsers versus non-endorsers
Outcomes Sample size, sequence generation, allocation concealment, implementation, blinding any, par-
ticipant flow, numbers analysed, adverse events
Included number of RCTs, Journals 67, 4
Checklist version used 2001
Field of Study Opthalmology
Notes
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Unclear RCTs published in top 4 journals in subspe-
cialty over 1-year period - 67 included
Blinding? Unclear Not reported
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Lai 2007 (Continued)
Confounding by journal quality? Yes Top 4 impact factor journals in subspecialty -
no potential for clustering
Outcome Reporting? Yes No difference between planned and reported
outcomes/analyses
Multiple raters? Yes Quote: “Each of the eligible RCTs was evalu-
ated by two of the authors independently ac-
cording to the revised CONSORT statement.
”
Rater agreement? Unclear Not reported
Blinding, quality assessment? Yes Not applicable
Llorca 2004
Methods To study the quality of controlled clinical trials on glaucoma using 11 key methodological
items
Data 37 RCTs published in endorsing journals
Comparisons CONSORT endorsers versus non-endorsers, CONSORT endorsers before and after CON-
SORT publication
Outcomes CONSORT endorsers versus non-endorsers: sequence generation, allocation concealment,
blinding any, statistical methods, participant flow, recruitment, numbers analysed
CONSORT endorsers before and after CONSORT endorsement: sequence generation, al-
location concealment, blinding of participants, blinding any, statistical methods, participant
flow, recruitment, numbers analysed
Included number of RCTs, Journals 226, 7
Checklist version used Modification
Field of Study Glaucoma and intraocular high pressure
Notes Author provided data. This study also includes control comparison data, namely:
Pre-post CONSORT non-endorsers: blinding of participants, statistical methods, participant
flow, recruitment, numbers analysed
Pre-CONSORT endorsers versus non-endorsers: sequence generation, allocation concealment,
blinding any description and blinding of outcome assessor, statistical methods, participant
flow, recruitment, numbers analysed
Risk of bias
Item Authors’ judgement Description
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Llorca 2004 (Continued)
Large Cohort ? Yes Large sample of trials from 7 journals over 2
decades
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Yes No evidence of selective outcome reporting
Multiple raters? Yes Quote: “Each paper was revised by 2 of 4 re-
searchers with epidemiological skills. Discrep-
ancies between reviewers were solved by con-
sensus”
Rater agreement? Unclear Not reported
Blinding, quality assessment? Unclear Not reported
Moher 2001
Methods Aims to determine whether or not the CONSORT Statement is associated with improvement
in the quality of reports of RCTs
RCTs published in 1994 and 1998, with non-endorsing journal acting as a control
Data 71 endorsing RCTs in 1994 from 3 journals and 26 non-endorsing from 1 journal, 77 endorsing
RCTs from 3 journals in 1998 and 37 non-endorsing RCTs from one journal; the 3 journals
include BMJ, JAMA and The Lancet compared to the NEJM
Comparisons CONSORT endorsers versus non-endorsers, CONSORT-endorsing journals before and after
endorsement
Outcomes Allocation concealment, total sum score based on 40 items
Included number of RCTs, Journals 211, 4
Checklist version used 1996
Field of Study None specified
Notes This study was included in the original review
Author provided data
Jadad scale was also used to assess quality
This study also includes control comparison data: allocation concealment for both pre-CON-




Item Authors’ judgement Description
Large Cohort ? Yes 4 journals from 2 years, samples 4 years apart
in large number of trials
Blinding? No Quote: “Hard copies of relevant articles were
obtained but were not masked because evi-
dence concerning the effect of masking on as-
sessments of trial quality is inconsistent”
Confounding by journal quality? Yes Study included control group comparison to
assess clustering by quality
Outcome Reporting? Yes No evidence of selective outcome reporting
Multiple raters? Yes Quote: “Two reviewers (A.J., L.L.) completed
all of these evaluations.”
Rater agreement? Yes Quote: “A k statistic was calculated for each
item based on a randomly selected set of 10
RCTs, from 1994 and 1998, and these were
not included in this study”
Blinding, quality assessment? Yes Not applicable
Montané 2010
Methods Aimed to examine the quality of reporting RCTs on analgesics for postoperative pain after
traumatic or orthopaedic surgery
The quality of reports was assessed using the CONSORT checklist (scoring range from 0 to
22)
Data 92 included RCTs
Comparisons Qualitative description
Outcomes Insufficient data to include in quantitative synthesis
Included number of RCTs, Journals 92, 46
Checklist version used 2001





Item Authors’ judgement Description
Large Cohort ? Yes Multiple databases; 40 years, 92 included
studies
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Yes No difference between planned and reported
outcomes
Multiple raters? Yes Quote: “The quality of reporting of each in-
cluded study in the reports was assessed inde-
pendently by 3 evaluators (EM, AV, CA) with
CONSORT checklist [6]”
Rater agreement? No The agreement (ICC) between the 3 evalua-
tors for the overall scores of the CONSORT
checklist assessed was 0.77 (95% CI 0.70 to
0.84)
Blinding, quality assessment? Yes Not applicable
Montori 2002
Methods Assessed the quality of reporting in RCTs
4 endorsing and one non-endorsing journal
Data 40 RCTs per journal were sampled, hence, 40 non-endorsing RCTs compared with 160 en-
dorsing RCTs
Comparisons CONSORT endorsers versus non-endorsers
Outcomes Blinding: participant, outcome assessor, data analyst, intervention
Included number of RCTs, Journals 200, 5
Checklist version used Modification
Field of Study None specified
Notes This study was included in the original review




Item Authors’ judgement Description
Large Cohort ? Yes Wide range of journals searched
Blinding? Unclear Not reported
Confounding by journal quality? Yes Quote: “We only evaluated very recent RCTs
published in five leading general medicine
journals. Thus, our findings may not repre-
sent reporting in journals with less editorial
resources.”
Outcome Reporting? Unclear No evidence to suggest selective reporting of
outcomes
Multiple raters? Yes 2 authors assessed all criteria
Rater agreement? Yes Quote: “Kappa, a measure of interobserver
agreement, was between 0.8 and 1.0 for each
of the
variables assessed.”
Blinding, quality assessment? Yes Not applicable
Pagoto 2009
Methods Study aimed to determine whether reporting and correct use of ITT in behavioural medicine
randomised clinical trials (RCTs) published in behavioural journals has improved in recent
years and since the endorsement of CONSORT
Data Includes 50 RCTs pre-CONSORT from 3 journals 2000-2003 and 37 post CONSORT RCTs
from the same 3 journals 2006-2007
Comparisons CONSORT-endorsing journals before and after CONSORT endorsement
Outcomes Outcomes, sample size, baseline data, numbers analysed
Included number of RCTs, Journals 87, 3
Checklist version used 2001
Field of Study Behavioural medicine
Notes CONSORT endorsement dates confirmed with journals




Item Authors’ judgement Description
Large Cohort ? Unclear 3 journals, over 6 years
Blinding? No Quote: “As in other reviews of quality report-
ing, it was not deemed necessary to mask the
articles.”
Confounding by journal quality? Yes Not applicable
Outcome Reporting? Yes No evidence of selective reporting
Multiple raters? Yes Quote: “Each article was reviewed indepen-
dently by two assessors”
Rater agreement? No Average of 82% reported
Blinding, quality assessment? Yes Not applicable
Partsinevelou 2009
Methods Purpose of study to assess the reporting quality of RCTs involving patients with polycystic
ovary syndrome using a standardised tool based on CONSORT
Quality of reporting was assessed using a 24-item questionnaire based on the revised CON-
SORT checklist
Reporting was evaluated overall and for pre- and post CONSORT periods (1990-1995 and
1996-2008)
Data 27 pre-CONSORT RCTs and 237 post CONSORT RCTs
Comparisons Cross-sectional sample before and after publication
Outcomes Title and abstract, background, participants, interventions, objectives, outcomes, sample size,
sequence generation, allocation concealment, implementation, blinding any, statistical meth-
ods, participant flow, recruitment, baseline data, numbers analysed, outcomes and estimation,
ancillary analyses, adverse events, interpretation, generalisability, overall evidence
Included number of RCTs, Journals 264, 57
Checklist version used 2001
Field of Study Polycystic ovary syndrome
Notes Endorsers listed as those on the CONSORT website
45 journals did not endorse the CONSORT Statement when included in this study, hence,




Item Authors’ judgement Description
Large Cohort ? Yes Wide search of PubMed over 18 years
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Yes No evidence of selective outcome reporting
Multiple raters? Yes 2 authors assessed
Rater agreement? Yes Kappa reported 0.92
Blinding, quality assessment? Yes Not applicable
Parés 2008
Methods This study was designed to analyse the characteristics and the quality of reporting of RCTs
published during the last 10 years on fecal incontinence
Quality was assessed by characteristics of reporting, methodology quality assessment using the
Jadad scale, and a validated methodology quality score (MINCIR score), evaluation of the
items published in the CONSORT Statement, and the journal impact factor
Reports were divided into 2 groups: 1996 to 2000 (Group 1) and from 2001 to 2005 (Group
2)
Data 15 RCTs were assessed in group 1 and 27 RCTs in group 2
Comparisons Cross-sectional sample before and after CONSORT publication
Outcomes Title and abstract, introduction, interventions, sample size, sequence generation, allocation
concealment, statistical methods, participant flow, numbers analysed, outcomes and estima-
tion, adverse events, interpretation
Included number of RCTs, Journals 42, 22
Checklist version used 2001
Field of Study Fecal Incontinence
Notes Also considers Jadad score and MINCIR score
Risk of bias
Item Authors’ judgement Description
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Parés 2008 (Continued)
Large Cohort ? Yes RCTs in PubMed from 1996 to 2005
Blinding? Unclear Not clearly reported
Confounding by journal quality? Unclear Unsure if clustering by CONSORT
Outcome Reporting? Yes No difference between planned and reported
outcomes
Multiple raters? Unclear Not reported
Rater agreement? Yes Not applicable
Blinding, quality assessment? Yes Not applicable
Pat 2008
Methods Aims to analyse to what extent the different RCTs with information on PROs adhere to the
CONSORT Statement
Compliance with the (revised) CONSORT Statement was checked by 2 independent reviewers
by making for each study the simple sum of the 22 CONSORT items, or a weighted score
with a maximum rating of 31 points
Data 4 CONSORT-endorsing RCTs and 34 non-endorsing
Comparisons CONSORT endorsers versus non-endorsers
Outcomes Total sum score
Included number of RCTs, Journals 38, 7
Checklist version used 2001
Field of Study Chemotherapy for non-small cell lung cancer
Notes Author provided data of simple score by RCT
One journal was not included in analysis as endorsement could not be confirmed for the dates
of publication for the included RCTs
Complient with our endorser definition
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Yes Pubmed between 1980 and 2005
Blinding? Unclear Not reported
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Pat 2008 (Continued)
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Yes No difference between planned and reported
outcomes/analyses
Multiple raters? Yes 2 raters assessed CONSORT score
Rater agreement? Unclear Not reported
Blinding, quality assessment? Yes Not applicable
Peckitt 2007
Methods A systematic review comparing early breast cancer (EBC) RCTs pre- and post introduction of
CONSORT in systemic treatment was undertaken in part to assess the association between
the introduction of CONSORT and the publication quality
Data 0.5 scores given to partially reported items; these frequencies were not included in our analysis
Comparisons Cross-sectional sample before and after CONSORT publication
Outcomes Introduction, objectives, sample size, outcomes and estimation
Included number of RCTs, Journals 85, not reported
Checklist version used 1996
Field of Study Breast cancer
Notes Data published in abstract, unable to make contact with author
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Yes Wide database search for RCTs over multiple
years
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Unclear No evidence of selective reporting, informa-
tion limited as abstract for poster presentation
Multiple raters? Unclear Not reported
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Peckitt 2007 (Continued)
Rater agreement? Unclear Not reported
Blinding, quality assessment? Unclear Not reported
Prady 2008
Methods Conducted a before-and-after study, comparing ratings for quality of reporting following the
publication of both STRICTA and CONSORT recommendations
90 peer-reviewed journal articles reporting the results of acupuncture trials were selected at
random from a wider sample frame of 266 papers
Papers published in 3 distinct time periods (1994-1995, 1999-2000, and 2004-2005) were
compared
Data Pre 2001 groups were collapsed
Comparisons Cross-sectional sample before and after CONSORT publication
Outcomes Sequence generation, allocation concealment, blinding: outcome assessor, intervention, par-
ticipant, baseline data, number analysed
Included number of RCTs, Journals 90, 52
Checklist version used 2001
Field of Study Acupuncture
Notes Author provided data
Score by journal available, unable to determine endorsement for all journals
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Yes Multiple databases, 3 1-year cross-sections
Blinding? Unclear Quote: “Efforts were made to guard against
the possible introduction of systematic bias. In
order to assess whether knowledge of publica-
tion period, journal type or authorship might
affect scoring, all papers given to SJR had this
information removed. This was achieved by
censoring all pertinent material with a black
marker pen or blank paper prior to photo-
copying. SJR also remained unaware of the
three date ranges from which papers were
drawn. Blinding of the other assessor (SLP)
was not possible due to practical reasons, and
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she was already familiar with the research lit-
erature relating to acupuncture.”
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Yes No difference between planned and reported
outcomes/analyses
Multiple raters? Yes 2 reviewers assessed or 1 extractor and verifi-
cation
Rater agreement? Yes Quote: “There was a high degree of con-
cordance (kappa 0.8) between assessors in
terms of their scoring for the majority of
STRICTA (17/31) and CONSORT (6/8)
checklist items.”
Blinding, quality assessment? Yes Not applicable
Sanchez-Thorin 2001
Methods Assesses if structured abstract use is associated with improved reporting of RCTs
Data 56 items derived from the CONSORT checklist, comparison of 51 1991-1993 RCTs and 24
RCTs published in 1999
Comparisons CONSORT endorsers before and after endorsement
Outcomes Title and abstract, participants, interventions, objectives, outcomes, sample size, sequence gen-
eration, allocation concealment, implementation, blinding: interventions, outcome assessor,
participants, data analyst, statistical methods, participant flow, numbers analysed, outcomes
and estimation, overall evidence
Included number of RCTs, Journals 75, 1
Checklist version used 1996
Field of Study Opthalmology
Notes This study was included in the original review
Risk of bias
Item Authors’ judgement Description
Large Cohort ? No 1 volume of 1 journal sampled
Blinding? Unclear Not reported
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Sanchez-Thorin 2001 (Continued)
Confounding by journal quality? Yes Not applicable
Outcome Reporting? Unclear No evidence of selective reporting of outcomes
Multiple raters? Yes Quote: “Each study was evaluated by two in-
dependent observers”
Rater agreement? Unclear Not reported
Blinding, quality assessment? Yes Not applicable
Scales 2007
Methods Reports a systematic assessment of RCT quality in the urology literature by compliance with
CONSORT
Data 87 pre-CONSORT RCTs and 65 post CONSORT RCTs were included
Comparisons Cross-sectional sample before and after CONSORT publication
Outcomes Sample size, allocation concealment, implementation, blinding: intervention, participant, out-
come assessor, participant flow, number analysed
Included number of RCTs, Journals 152, 4
Checklist version used 2001
Field of Study Urology
Notes Endorsement status could not be confirmed for the 4 journals
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Yes Cross-section of 2 years on MEDLINE
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Yes No difference in planned and reported out-
comes/analyses
Multiple raters? Yes Quote: “As determined by the 2 reviewers, the
assessment of each criterion was entered into
a dedicated study database.”
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Rater agreement? Unclear Not reported
Blinding, quality assessment? Yes Not applicable
Selman 2008
Methods Assess if there has been progress made in establishing the evidence base for surgical interventions
in gynaecology
Quality was assessed for pre- and post CONSORT
Pre-CONSORT 1974-1996 publication intervention, 1998-2005 post CONSORT
Data 39 pre-CONSORT RCTs compared with 35 post CONSORT RCTs
Comparisons Cross-sectional sample before and after CONSORT publication
Outcomes Allocation concealment
Included number of RCTs, Journals 74, not reported
Checklist version used 1996
Field of Study Gynaecologic surgery
Notes This study was excluded prior to the inclusion of the cross-sectional sample comparison group
and re-included
RCTs obtained from 23 reviews published in The Cochrane Library
Risk of bias
Item Authors’ judgement Description
Large Cohort ? No RCTs included in Cochrane systematic re-
views 2006(Issue 3); only relevant reviews se-
lected, but no selection criteria given
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Yes No differences in planned and reported out-
comes/analyses
Multiple raters? Unclear Not reported
Rater agreement? Unclear Not applicable
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Blinding, quality assessment? Unclear Not applicable
Sinha 2009
Methods Assesses the quality of reporting of trial methodology and adverse events in a sample of general
surgical RCTs published in high-quality surgical journals using the criteria specified in the
CONSORT Statements
Data Not reported in needed format
Comparisons Qualitative comparison of CONSORT endorsers versus non-endorsers using the Jadad score
detailed in study
Outcomes Included for qualitative analysis
Included number of RCTs, Journals 42, 3
Checklist version used 2001
Field of Study Surgery
Notes Also considered Jadad score to assess quality
Risk of bias
Item Authors’ judgement Description
Large Cohort ? No Relatively few assessed studies from journals
selected by impact factor
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Yes No evidence of selective reporting of outcomes
Multiple raters? Yes 2 authors independently reviewed method-
ological items
Rater agreement? No Quote: “Agreement between the pair of ob-
servers who independently assessed the RCTs
was good (median K 0.795; range 0.4 to 1)”
Blinding, quality assessment? Unclear Not reported
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Spring 2007
Methods Compared analytic quality features of all behavioural health RCTs (n = 73) published in 3
leading behavioural journals and 2 leading medical journals between January 2000 and July
2003
Data 15 endorsing RCTs and 58 non-endorsing RCTs
Comparisons CONSORT endorsers versus non-endorsers
Outcomes Outcomes, sample size, participant flow, numbers analysed
Included number of RCTs, Journals 73, 5
Checklist version used Modification of 2001 version
Field of Study Behavioural health
Notes This is the companion study to Pagoto 2009
Provides supplementary outcomes data, included in a different comparison
Endorsement of journals confirmed
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Unclear 5 journals over 3 years, judgement based on
number of RCTs in endorsing group
Blinding? Unclear Quote: “It was not deemed necessary to mask
the articles.”
Confounding by journal quality? No Quote: “Perhaps if mental health had been
the outcome, the analytic quality of RCTs re-
ported in psychology journals might have been
superior because of the longer history of study-
ing that content area in psychology”
Outcome Reporting? Yes No evidence of selective outcome reporting
Multiple raters? Yes Quote: “Each article was reviewed and coded
by two people, using all possible combinations
of pairs of rater”
Rater agreement? No Quote: “Average intercoder agreement across
the 73 articles was 85% prior to resolving dis-
crepant rating”
Blinding, quality assessment? Unclear Not reported
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Thabane 2007
Methods Assesses the quality of reporting of RCTs of weight loss interventions and to identify predictors
of reporting quality
The RCTs assessed were derived from a published systematic review of trials investigating the
efficacy of weight loss interventions
Quality based on CONSORT items; 44-item score was detailed
Data 50 pre-CONSORT RCTs from 23 journals and 13 post CONSORT RCTs from 10 journals
Comparisons Cross-sectional sample before and after CONSORT publication in 1996
Outcomes Title and abstract, introduction, participants, interventions, objectives, outcomes, sample size,
sequence generation, allocation concealment, implementation, blinding of participants, statis-
tical methods, participant flow, recruitment, baseline data, outcomes and estimation, adverse
events, interpretation, generalisability, overall evidence
Included number of RCTs, Journals 63, 28
Checklist version used 1996
Field of Study Weight loss
Notes Author provided data for this study
RCTs published in 2001 were included as pre-CONSORT as a conservative estimate
This is the primary study of the companion Thoma 2006
Risk of bias
Item Authors’ judgement Description
Large Cohort ? No All RCTs identified from a single systematic
review
Blinding? Unclear Not reported
Confounding by journal quality? Yes Quote: “GEEs were chosen to account for the
possible intrajournal correlation and an ex-
changeable correlation structure was assumed
for these analyses”
Outcome Reporting? Yes No difference between planned and reported
outcomes/analyses
Multiple raters? Yes Quote: “An independent double review of in-
cluded trials was done by two authors (RC,
KC) to assess agreement regarding CON-
SORT criteria that were satisfied.”
Rater agreement? Unclear Not reported
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Blinding, quality assessment? Yes Not applicable
Tharyan 2008
Methods Examines the extent to which CONSORT has been adopted by Indian medical journals
RCTs published during 2004 and 2005 were assessed against selected CONSORT items and
ICMJE requirements, and scored on the Jadad scale
Data 31 endorsing RCTs and 120 non-endorsing RCTs
Comparisons CONSORT endorsers versus non-endorsers
Outcomes Total sum score on an unweighted score out of 13
Included number of RCTs, Journals 151, 37
Checklist version used 2001
Field of Study Indian medical journals
Notes With additional data, this could have been included by item
Instructions to authors were searched by study authors, but we were unable to confirm due to
insufficient information This study also reports Jadad scores
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Yes RCT reports published between 2004-5 in In-
dian medical journals; 151 included studies
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Yes No differences between planned and reported
outcomes/analyses
Multiple raters? Yes Single extraction with verification
Rater agreement? Unclear Not reported
Blinding, quality assessment? Unclear Not applicable
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Methods Assesses the reporting quality of published RCTs that compare endoscopic carpal tunnel release
(ECTR) with open carpal tunnel release (OCTR) using the CONSORT Statement
Data Studies published between 1989 and 2004
Before and after 1996 comparison with 11 RCTs published before 1997 and 7 after 1996
Comparisons Cross-sectional sample before and after CONSORT publication
Outcomes Total sum score
Included number of RCTs, Journals 18, not reported
Checklist version used 2001
Field of Study ECTR and OCTR
Notes This is the companion study of Thabane 2007
No journal information provided
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Yes Wide database search over 15 years
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Yes No evidence of outcome reporting bias
Multiple raters? Yes Quote: “Two investigators (RTC and KV) in-
dependently reviewed each articles”
Rater agreement? Yes Quote: “...kappa value of 0.90”
Blinding, quality assessment? Yes Not applicable
Tiruvoipati 2005
Methods Evaluates the quality of reporting of RCTs in cardiothoracic surgery, to identify factors asso-
ciated with good reporting quality, and assesses the awareness of CONSORT and ascertains
the views of authors reporting RCTs on the difficulties in conducting RCTs and the possible
ways to further improve the reporting quality of randomised controlled trials in cardiothoracic
surgery
Data 2 endorsing RCTs and 62 non-endorsing RCTs from 4 journals published in 2003
78
Tiruvoipati 2005 (Continued)
Comparisons CONSORT endorsers versus non-endorsers
Outcomes Total sum score
Included number of RCTs, Journals 64, 4
Checklist version used 2001
Field of Study Cardiothoracic surgery
Notes Potential for overlap of 2 RCTs from NEJM with Balasubramanian 2006. As this is not
confirmed, we have not listed these studies as companions.
This study has not been confirmed to be compliant with our endorser definition
Median score out of 90 reported; Jadad scores were also reported
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Unclear RCTs in cardiology published in 4 top journals
over 1 year period, n = 64
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Yes No difference between planned and reported
outcomes/analyses
Multiple raters? Yes Quote: “Each article included in the study was
then assessed for every item on the checklist
and scored independently by 2 observers (R.T.
and S.P.B.) to arrive at a consensus-modified
CONSORT score.”
Rater agreement? Yes Quote: “The agreement of the pair of ob-
servers who independently assessed the RCTs
by using the CONSORT checklist was good
(intra-class correlation coefficient, 0.85; 95%
confidence interval, 0.76-0.90; P .001).”
Blinding, quality assessment? Unclear Not reported
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Methods Assesses the quality of Japanese RCT reports by conducting a cross-sectional study to examine
the extent to which they adhere to the CONSORT Statement
Sample of 98 RCTs published in 2004
Data 11 endorsing RCTs and 87 non-endorsing RCTs
Comparisons CONSORT endorsers versus non-endorsers
Outcomes Title and abstract, background, participants, interventions, objectives, outcomes, sample size,
sequence generation, allocation concealment, implementation, blinding any, statistical meth-
ods, participant flow, recruitment, baseline data, numbers analysed, outcomes and estimation,
ancillary analyses, adverse events, interpretation, generalisability, overall evidence
Included number of RCTs, Journals 98, not reported
Checklist version used 2001
Field of Study Japanesse trials
Notes Journal endorsement determined from CONSORT website, however these have not been
checked against RCT publication dates to ensure that our definition of CONSORT endorser
coincides
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Unclear Sample of journals not reported
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Yes No evidence of selective reporting
Multiple raters? Yes Quote: “We adopted the “checked by a sec-
ond” method, which is recognized as a system-
atic review methodology”
Rater agreement? Unclear Not reported
Blinding, quality assessment? Yes Not applicable
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Methods Evaluates the quality of reporting of RCTs in TCM journals published in 1999 and 2004
Data Reported by years 1999 to 2004 and CONSORT item in the paper
This has been sorted into pre-CONSORT (1999-2001) and post CONSORT (2002-2004),
with 2930 and 4492 RCTs respectively
Comparisons Cross-sectional sample of RCTs before and after CONSORT publication
Outcomes Title and abstract, background, participants, interventions, objectives, outcomes, sample size,
sequence generation, allocation concealment, blinding of participants, statistical methods, par-
ticipant flow, recruitment, baseline data, outcomes and estimation, ancillary analyses, adverse
events, interpretation, generalisability, overall evidence
Included number of RCTs, Journals 7422, 13
Checklist version used Modification of the 2001 checklist
Field of Study Traditional Chinese Medicine
Notes This study also assesses quality based on the Jadad score
This study was found externally to the search
Score out of 30 items
It should be noted that this study was conducted on behalf of the CONSORT group for TCM
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Yes RCTs published in 13 journals over 5 years
(1999-2004)
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not explicitly discussed
Outcome Reporting? Yes No differences between planned and reported
outcomes and analyses
Multiple raters? Yes Quote: “Data extraction and the evaluation
of methodologic quality were performed in-
dependently by 2 reviewers”
Rater agreement? No Agreement was high (> 0.70), indicating low
interobserver and intraobserver variability
Blinding, quality assessment? Unclear Not reported
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Methods Evaluates the reporting quality of RCTs on papers published in 5 leading Chinese medical
journals by assessing adherence to CONSORT
Data 35 endorsing RCTs from 1 journal and 188 non-endorsing RCTs from 4 journals
Comparisons CONSORT endorsers versus non-endorsers
Outcomes Title and abstract, background, participants, interventions, objectives, outcomes, sample size,
sequence generation, allocation concealment, implementation, blinding any, statistical meth-
ods, participant flow, recruitment, baseline data, numbers analysed, outcomes and estimation,
ancillary analyses, adverse events, interpretation, generalisability
Included number of RCTs, Journals 123, 5
Checklist version used 2001
Field of Study Chinese medical journals
Notes Author provided data for post 2004 data from which a comparison group compliant with our
definition could be formed
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Unclear Only one journal in endorsing arm
Blinding? Yes Assessors were blinded
Confounding by journal quality? Unclear Potential clustering based on study design; this
was not discussed by the author
Outcome Reporting? Yes No evidence of selective outcome reporting
Multiple raters? Yes 2 independently assessed items
Rater agreement? No 0.61 reported interobserver agreement
Blinding, quality assessment? Yes Not applicable
Yu 2010
Methods Evaluates the use and reporting of adjusted analysis in randomised controlled trials (RCTs) and




Data Journal articles sampled from 2000 and 2006
355 RCTs pre-CONSORT and 422 RCTs post CONSORT
113 RCTs described as endorsing journals and 48 described as non-endorsing
Comparisons CONSORT endorsers versus non-endorsers, cross-sectional sample before and after publica-
tion
Outcomes Ancillary analyses
Included number of RCTs, Journals 777, not reported
Checklist version used 2001
Field of Study None specified
Notes This is a companion study to Hopewell 2010
Journal endorsement was not confirmed 6 months prior to the publication of each RCT, hence,
this does not strictly comply with our definition of CONSORT-endorsing journal
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Yes Large number of included trials from wide
sample
Blinding? Unclear Not reported
Confounding by journal quality? No Quote: “We identified slightly better reporting
of key methodological items in CONSORT
endorsing as opposed to non CONSORT en-
dorsing journals. However, because there was a
time-lag between article publication (Decem-
ber 2006) and when the journal ’Instructions
to Authors’ were assessed (June 2008) these
results should be viewed with some caution.”
Outcome Reporting? Yes No evidence of selective reporting of outcomes
Multiple raters? No Quote: “Data regarding trial characteristics
were extracted by two reviewers (LY and SH)
, while outcome and adjusted analysis infor-
mation were extracted by a single reviewer”
Rater agreement? Yes Not applicable
Blinding, quality assessment? Yes Not applicable
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Zhong 2010
Methods Assessed the reporting quality, scientific rigour, and ethics of randomised placebo-controlled
trials of TCM compound formulations and compared these differences between Chinese and
non-Chinese trials
Data 52 pre-CONSORT RCTs and 227 post CONSORT RCTs published before 1999 and from
2005-2009 respectively
Comparisons Cross-sectional sample before and after CONSORT publication
Outcomes Total sum score
Included number of RCTs, Journals 279, not reported
Checklist version used 2001
Field of Study Traditional Chinese Medicine articles
Notes Author provided additional data but no journal information
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Yes Large databases searched over many years
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Not reported
Outcome Reporting? Yes No evidence of selective reporting
Multiple raters? Yes Quote: “Two authors assessed each included
trial independently.”
Rater agreement? No Quote: “Interrater reliability was used to test
values from each reviewer and Cohen’s K was
0.721”
Blinding, quality assessment? Yes Not applicable
Ziogas 2009
Methods Evaluates the reporting quality of published RCTs concerning myeloid haematologic malig-
nancies according to the CONSORT Statement
Data 74 pre-CONSORT RCTs compared with 187 post CONSORT RCTs
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Comparisons Title and abstract, background, participants, interventions, objectives, outcomes, sample size,
sequence generation, allocation concealment, implementation, blinding any, statistical meth-
ods, participant flow, recruitment, baseline data, numbers analysed, outcomes and estimation,
ancillary analyses, adverse events, interpretation, generalisability, overall evidence
Outcomes Cross-sectional sample before and after CONSORT publication
Included number of RCTs, Journals 261, not reported
Checklist version used 1996
Field of Study Myeloid leukaemia and myelodysplastic syndromes
Notes
Risk of bias
Item Authors’ judgement Description
Large Cohort ? Yes Over 2 decades, large number of studies, wide
database search
Blinding? Unclear Not reported
Confounding by journal quality? Unclear Quote: “The RCTs of major IF journals have
adhered better to the CONSORT statement.
”
Outcome Reporting? Yes No evidence of outcome reporting
Multiple raters? Yes Quote: “No pilot training of the data extrac-
tion was performed.”
Rater agreement? Yes Not reported
Blinding, quality assessment? Yes Not applicable
BMJ: British Medical Journal
CI: confidence interval
CONSORT: Consolidated Standards of Reporting Trials
COPD: chronic obstructive pulmonary disease
ECTR: endoscopic carpal tunnel release
ITT: intention-to-treat
ICC: Intra-Class Correlation Coefficient
ICJME: Iternational Commitee of Medical Journal Editors
JAMA: Journal of the American Medical Association
ME: Managing Editor
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NEJM: New England Journal of Medicine
NPT: Non-pharmocological Trials
OCTR: open carpal tunnel release
PRO: Patient reported outcomes
RCT: randomised controlled trial
STRICTA: Standards for Reporting Interventions in Controlled Trials of Acupuncture
TCM: Traditional Chinese Medicine
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Albavera-Hernández 2009 No information available to form before and after or endorsers versus non-endorsers comparison groups
Berwanger 2009 Adherence limited to abstracts. This study reports data for 4 journals in 2006 all of which are endorsers
of CONSORT, which would prevent inclusion based on establishing reporting by comparison group
Chowers 2009 Unable to form comparison group
Ellis 2005 Author provided data to enable our team to determine if BJS could potentially be included in a before
and after comparison; given the BJS endorsement was in August 2006 and the study period runs through
2003, no comparison could be formed
Li 2009 Information was not available by journal, hence no comparison could be formed. It should be noted
that although this report was e-published in advance in 2009, it was not formally published until 2011
Mills 2005 Author investigated but was unable to find data file, as journal information was categorised by study we
were unable to determine endorsement status and form a comparison
Norton-Mabus 2008 Investigated, but unable to form an endorser comparison group
Smith 2008 Partial information reported in tables 1 and 2 of the text; as author was unable to provide additional
information we did not have sufficient information to include
Taghinia 2008 No information was obtained from author, hence no comparison group could be established
Xu 2008 Emailed authors in attempt to obtain data by journal; we did not receive a response, so unable to form
a comparison group
Yu 2009 Unable to determine comparison group
BJS: British Journal of Surgery
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D A T A A N D A N A L Y S E S
Comparison 1. CONSORT-endorsing journals versus CONSORT non-endorsing journals




participants Statistical method Effect size
1 Title and abstract 7 1233 Risk Ratio (IV, Random, 99% CI) 1.13 [0.96, 1.33]
1.1 Studies considering 1996
checklist
1 77 Risk Ratio (IV, Random, 99% CI) 0.93 [0.65, 1.32]
1.2 Studies considering 2001
checklist
6 1156 Risk Ratio (IV, Random, 99% CI) 1.16 [0.97, 1.39]
2 Introduction 5 513 Risk Ratio (IV, Random, 99% CI) 1.07 [1.01, 1.14]
3 Participants 6 683 Risk Ratio (IV, Random, 99% CI) 0.95 [0.56, 1.62]
4 Interventions 6 638 Risk Ratio (IV, Random, 99% CI) 1.00 [0.95, 1.05]
5 Objectives 5 540 Risk Ratio (IV, Random, 99% CI) 1.01 [0.96, 1.06]
6 Outcomes 8 1302 Risk Ratio (IV, Random, 99% CI) 1.17 [0.95, 1.43]
6.1 Studies considering 1996
checklist
1 73 Risk Ratio (IV, Random, 99% CI) 1.02 [0.58, 1.78]
6.2 Studies considering 2001
checklist
7 1229 Risk Ratio (IV, Random, 99% CI) 1.18 [0.94, 1.48]
7 Sample Size 11 1843 Risk Ratio (IV, Random, 99% CI) 1.61 [1.13, 2.29]
7.1 1996 checklist 3 547 Risk Ratio (IV, Random, 99% CI) 1.25 [1.08, 1.46]
7.2 2001 checklist 8 1296 Risk Ratio (IV, Random, 99% CI) 1.81 [1.10, 2.99]
8 Sequence generation 14 2231 Risk Ratio (IV, Random, 99% CI) 1.59 [1.38, 1.84]
9 Allocation concealment 16 2396 Risk Ratio (IV, Random, 99% CI) 1.81 [1.25, 2.61]
10 Implementation 5 498 Risk Ratio (IV, Random, 99% CI) 2.90 [0.54, 15.54]
11 Blinding 13 Risk Ratio (IV, Random, 99% CI) Subtotals only
11.1 Blinding (participants) 5 711 Risk Ratio (IV, Random, 99% CI) 1.39 [0.87, 2.21]
11.2 Blinding (intervenor) 5 710 Risk Ratio (IV, Random, 99% CI) 1.25 [0.74, 2.12]
11.3 Blinding (outcome
assessor)
5 719 Risk Ratio (IV, Random, 99% CI) 1.72 [0.69, 4.31]
11.4 Blinding (data analyst) 3 497 Risk Ratio (IV, Random, 99% CI) 3.56 [0.40, 31.99]
11.5 Blinding (any
description)
8 1851 Risk Ratio (IV, Random, 99% CI) 1.23 [0.93, 1.62]
12 Statistical methods 9 894 Risk Ratio (IV, Random, 99% CI) 1.03 [0.90, 1.18]
13 Participant flow 16 2461 Risk Ratio (IV, Random, 99% CI) 1.23 [0.98, 1.53]
13.1 1996 checklist 6 825 Risk Ratio (IV, Random, 99% CI) 1.01 [0.99, 1.02]
13.2 2001 checklist 10 1636 Risk Ratio (IV, Random, 99% CI) 1.35 [1.00, 1.82]
14 Recruitment 6 959 Risk Ratio (IV, Random, 99% CI) 1.03 [0.75, 1.40]
15 Baseline data 5 529 Risk Ratio (IV, Random, 99% CI) 1.07 [0.94, 1.22]
16 Numbers analysed 13 2145 Risk Ratio (IV, Random, 99% CI) 1.23 [0.98, 1.55]
16.1 Studies considering the
1996 checklist
3 665 Risk Ratio (IV, Random, 99% CI) 0.99 [0.83, 1.19]
16.2 Studies considering 2001
checklist
10 1480 Risk Ratio (IV, Random, 99% CI) 1.29 [0.99, 1.68]
17 Outcomes and estimation 6 617 Risk Ratio (IV, Random, 99% CI) 1.00 [0.96, 1.05]
18 Ancillary analyses 4 378 Risk Ratio (IV, Random, 99% CI) 1.31 [0.48, 3.58]
19 Adverse events 8 911 Risk Ratio (IV, Random, 99% CI) 1.14 [0.85, 1.51]
20 Interpretation 5 540 Risk Ratio (IV, Random, 99% CI) 1.01 [0.96, 1.06]
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21 Generalisability 5 540 Risk Ratio (IV, Random, 99% CI) 1.22 [0.87, 1.69]
22 Overall evidence 4 317 Risk Ratio (IV, Random, 99% CI) 1.03 [0.91, 1.17]
23 Total sum score 7 560 Std. Mean Difference (IV, Random, 99% CI) 0.68 [0.38, 0.98]
Comparison 2. CONSORT-endorsing journals before and after CONSORT endorsement




participants Statistical method Effect size
1 Title and abstract 3 532 Risk Ratio (IV, Random, 99% CI) 1.41 [0.63, 3.16]
1.1 Studies considering 1996
checklist
2 90 Risk Ratio (IV, Random, 99% CI) 1.75 [0.30, 10.17]
1.2 Studies considering 2001
checklist
1 442 Risk Ratio (IV, Random, 99% CI) 1.01 [0.97, 1.05]
2 Introduction 2 457 Risk Ratio (IV, Random, 99% CI) 1.04 [1.00, 1.08]
3 Participants 4 622 Risk Ratio (IV, Random, 99% CI) 0.98 [0.88, 1.09]
4 Interventions 4 630 Risk Ratio (IV, Random, 99% CI) 1.02 [0.97, 1.07]
5 Objectives 2 517 Risk Ratio (IV, Random, 99% CI) 1.04 [0.91, 1.17]
6 Outcomes 5 716 Risk Ratio (IV, Random, 99% CI) 1.68 [0.96, 2.96]
6.1 Studies considering 1996
checklist
2 89 Risk Ratio (IV, Random, 99% CI) 2.23 [0.20, 25.38]
6.2 Studies considering 2001
checklist
3 627 Risk Ratio (IV, Random, 99% CI) 1.61 [0.95, 2.72]
7 Sample size 6 983 Risk Ratio (IV, Random, 99% CI) 1.30 [0.71, 2.36]
7.1 studies considering 1996
checklist
3 356 Risk Ratio (IV, Random, 99% CI) 1.19 [0.62, 2.29]
7.2 Studies considering 2001
checklist
3 627 Risk Ratio (IV, Random, 99% CI) 1.50 [0.44, 5.13]
8 Sequence generation 8 1085 Risk Ratio (IV, Random, 99% CI) 1.46 [0.88, 2.45]
9 Allocation concealment 6 855 Risk Ratio (IV, Random, 99% CI) 1.23 [0.55, 2.74]
10 Implementation 2 517 Risk Ratio (IV, Random, 99% CI) 1.94 [0.15, 24.36]
11 Blinding 5 Risk Ratio (IV, Random, 99% CI) Subtotals only
11.1 Blinding (participants) 1 75 Risk Ratio (IV, Random, 99% CI) 0.77 [0.45, 1.31]
11.2 Blinding (interventions) 1 75 Risk Ratio (IV, Random, 99% CI) 0.26 [0.09, 0.73]
11.3 Blinding (outcome
assessors)
1 75 Risk Ratio (IV, Random, 99% CI) 0.66 [0.34, 1.31]
11.4 Blinding (data analyst) 1 75 Risk Ratio (IV, Random, 99% CI) 0.27 [0.02, 3.78]
11.5 Blinding (any
description)
4 926 Risk Ratio (IV, Random, 99% CI) 0.96 [0.61, 1.50]
12 Statistical methods 5 1111 Risk Ratio (IV, Random, 99% CI) 0.86 [0.62, 1.19]
13 Participant flow 8 992 Risk Ratio (IV, Random, 99% CI) 1.33 [0.95, 1.87]
13.1 Studies considering 1996
checklist
6 430 Risk Ratio (IV, Random, 99% CI) 1.44 [0.73, 2.87]
13.2 Studies considering 2001
checklist
2 562 Risk Ratio (IV, Random, 99% CI) 1.30 [1.08, 1.57]
14 Recruitment 3 828 Risk Ratio (IV, Random, 99% CI) 1.77 [0.48, 6.46]
15 Baseline data 2 529 Risk Ratio (IV, Random, 99% CI) 1.42 [1.24, 1.62]
16 Numbers analysed 6 1005 Risk Ratio (IV, Random, 99% CI) 1.72 [1.18, 2.49]
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16.1 Studies considering 1996
checklist
3 356 Risk Ratio (IV, Random, 99% CI) 1.50 [0.86, 2.62]
16.2 Studies considering 2001
checklist
3 649 Risk Ratio (IV, Random, 99% CI) 1.95 [1.60, 2.37]
17 Outcomes and estimation 3 532 Risk Ratio (IV, Random, 99% CI) 1.35 [0.73, 2.51]
18 Ancillary analyses 1 442 Risk Ratio (IV, Random, 99% CI) 3.46 [2.47, 4.84]
19 Adverse events 3 507 Risk Ratio (IV, Random, 99% CI) 1.39 [1.12, 1.73]
20 Interpretation 1 442 Risk Ratio (IV, Random, 99% CI) 1.01 [0.99, 1.04]
21 Generalisability 1 442 Risk Ratio (IV, Random, 99% CI) 1.77 [1.47, 2.11]
22 Overall evidence 2 517 Risk Ratio (IV, Random, 99% CI) 1.31 [0.99, 1.73]
23 Total sum score 1 148 Std. Mean Difference (IV, Random, 99% CI) 0.74 [0.30, 1.18]
Comparison 3. Sample of RCTs before and after CONSORT publication




participants Statistical method Effect size
1 Title and abstract 7 8225 Risk Ratio (IV, Random, 99% CI) 1.18 [0.98, 1.42]
1.1 Studies considering 1996
checklist
4 602 Risk Ratio (IV, Random, 99% CI) 1.13 [0.96, 1.33]
1.2 Studies considering 2001
checklist
3 7623 Risk Ratio (IV, Random, 99% CI) 1.18 [0.88, 1.59]
2 Introduction 8 8293 Risk Ratio (IV, Random, 99% CI) 1.10 [0.94, 1.30]
3 Participants 6 8368 Risk Ratio (IV, Random, 99% CI) 1.15 [0.99, 1.33]
4 Interventions 7 8224 Risk Ratio (IV, Random, 99% CI) 1.00 [0.97, 1.04]
5 Objectives 5 8028 Risk Ratio (IV, Random, 99% CI) 1.02 [0.97, 1.07]
6 Outcomes 7 9315 Risk Ratio (IV, Random, 99% CI) 1.24 [0.98, 1.58]
6.1 Studies considering 1996
checklist
4 602 Risk Ratio (IV, Random, 99% CI) 1.47 [0.87, 2.48]
6.2 Studies considering 2001
checklist
3 8713 Risk Ratio (IV, Random, 99% CI) 1.15 [0.85, 1.54]
7 Sample size 10 9568 Risk Ratio (IV, Random, 99% CI) 2.45 [1.37, 4.39]
7.1 Studies considering 1996
checklist
5 663 Risk Ratio (IV, Random, 99% CI) 2.49 [0.78, 7.95]
7.2 Studies considering 2001
checklist
5 8905 Risk Ratio (IV, Random, 99% CI) 2.68 [1.00, 7.16]
8 Sequence generation 11 9934 Risk Ratio (IV, Random, 99% CI) 1.67 [1.14, 2.45]
9 Allocation concealment 11 9772 Risk Ratio (IV, Random, 99% CI) 1.61 [1.23, 2.10]
10 Implementation 4 490 Risk Ratio (IV, Random, 99% CI) 1.25 [0.41, 3.79]
11 Blinding 10 Risk Ratio (IV, Random, 99% CI) Subtotals only
11.1 Blinding (participants) 6 8108 Risk Ratio (IV, Random, 99% CI) 1.21 [0.93, 1.58]
11.2 Blinding (intervenor) 3 586 Risk Ratio (IV, Random, 99% CI) 1.11 [0.88, 1.42]
11.3 Blinding (outcome
assessor)
4 600 Risk Ratio (IV, Random, 99% CI) 1.42 [0.99, 2.04]
11.4 Blinding (data analyst) 1 14 Risk Ratio (IV, Random, 99% CI) 1.2 [0.58, 2.50]
11.5 Blinding (any
description)
3 1660 Risk Ratio (IV, Random, 99% CI) 0.95 [0.76, 1.19]
12 Statistical methods 7 8223 Risk Ratio (IV, Random, 99% CI) 1.13 [1.01, 1.25]
13 Participant flow 8 8373 Risk Ratio (IV, Random, 99% CI) 1.36 [1.01, 1.83]
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13.1 Studies considering 1996
checklist
4 602 Risk Ratio (IV, Random, 99% CI) 1.16 [0.87, 1.53]
13.2 Studies considering 2001
checklist
4 7771 Risk Ratio (IV, Random, 99% CI) 2.14 [0.90, 5.09]
14 Recruitment 5 8024 Risk Ratio (IV, Random, 99% CI) 1.03 [0.89, 1.18]
15 Baseline data 6 8114 Risk Ratio (IV, Random, 99% CI) 1.20 [1.01, 1.43]
16 Numbers analysed 8 1307 Risk Ratio (IV, Random, 99% CI) 1.57 [0.91, 2.70]
16.1 Studies considering 1996
checklist
3 539 Risk Ratio (IV, Random, 99% CI) 2.32 [0.50, 10.87]
16.2 Studies considering 2001
checklist
5 768 Risk Ratio (IV, Random, 99% CI) 1.37 [0.80, 2.36]
17 Outcomes and estimation 9 8613 Risk Ratio (IV, Random, 99% CI) 1.06 [0.98, 1.15]
18 Ancillary analysis 5 8738 Risk Ratio (IV, Random, 99% CI) 1.06 [0.47, 2.39]
19 Adverse events 6 8186 Risk Ratio (IV, Random, 99% CI) 1.06 [0.91, 1.24]
20 Interpretation 4 7989 Risk Ratio (IV, Random, 99% CI) 0.99 [0.98, 1.01]
21 Generalisability 4 8010 Risk Ratio (IV, Random, 99% CI) 1.06 [0.99, 1.15]
22 Overall evidence 4 8010 Risk Ratio (IV, Random, 99% CI) 1.08 [0.97, 1.21]
23 Total sum score 5 528 Std. Mean Difference (IV, Random, 99% CI) 0.51 [-0.28, 1.30]
Analysis 1.1. Comparison 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals,
Outcome 1 Title and abstract.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals
Outcome: 1 Title and abstract
Study or subgroup Endorsers Non-Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
1 Studies considering 1996 checklist
Kober 2006 7/8 65/69 11.7 % 0.93 [ 0.65, 1.32 ]
Subtotal (99% CI) 8 69 11.7 % 0.93 [ 0.65, 1.32 ]
Total events: 7 (Endorsers), 65 (Non-Endorsers)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
2 Studies considering 2001 checklist
Halpern 2004 6/6 91/94 14.9 % 0.96 [ 0.73, 1.27 ]
Wei 2009 35/35 179/188 24.8 % 1.04 [ 0.97, 1.11 ]
Uetani 2009 10/11 69/87 14.5 % 1.15 [ 0.86, 1.52 ]
Ladd 2010 18/19 70/90 18.6 % 1.22 [ 1.00, 1.49 ]
Areia 2010 2/2 3/8 1.6 % 2.14 [ 0.60, 7.59 ]
Hopewell 2010 113/274 92/342 14.0 % 1.53 [ 1.14, 2.06 ]
0.01 0.1 1 10 100
Does not favour CONSORT Favours CONSORT
(Continued . . . )
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(. . . Continued)
Study or subgroup Endorsers Non-Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Subtotal (99% CI) 347 809 88.3 % 1.16 [ 0.97, 1.39 ]
Total events: 184 (Endorsers), 504 (Non-Endorsers)
Heterogeneity: Tau2 = 0.02; Chi2 = 17.28, df = 5 (P = 0.004); I2 =71%
Test for overall effect: Z = 2.16 (P = 0.030)
Total (99% CI) 355 878 100.0 % 1.13 [ 0.96, 1.33 ]
Total events: 191 (Endorsers), 569 (Non-Endorsers)
Heterogeneity: Tau2 = 0.02; Chi2 = 18.34, df = 6 (P = 0.01); I2 =67%
Test for overall effect: Z = 1.95 (P = 0.051)
Test for subgroup differences: Chi2 = 2.14, df = 1 (P = 0.14), I2 =53%
0.01 0.1 1 10 100
Does not favour CONSORT Favours CONSORT
Analysis 1.2. Comparison 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals,
Outcome 2 Introduction.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals
Outcome: 2 Introduction
Study or subgroup Endorsers Non-Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Areia 2010 2/2 8/8 0.8 % 1.00 [ 0.50, 2.01 ]
Kober 2006 7/8 64/65 3.3 % 0.89 [ 0.63, 1.26 ]
Ladd 2010 19/19 79/90 21.0 % 1.12 [ 0.97, 1.28 ]
Uetani 2009 9/11 60/87 2.4 % 1.19 [ 0.79, 1.79 ]
Wei 2009 35/35 174/188 72.5 % 1.07 [ 0.99, 1.15 ]
Total (99% CI) 75 438 100.0 % 1.07 [ 1.01, 1.14 ]
Total events: 72 (Endorsers), 385 (Non-Endorsers)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.99, df = 4 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 2.89 (P = 0.0039)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Does not favour CONSORT Favours CONSORT
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Analysis 1.3. Comparison 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals,
Outcome 3 Participants.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals
Outcome: 3 Participants
Study or subgroup Endorsers Non-Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Faunce 2003 2/2 0/4 2.1 % 8.33 [ 0.25, 281.33 ]
Halpern 2004 1/6 7/94 3.8 % 2.24 [ 0.18, 28.13 ]
Folkes 2008 42/163 55/83 23.4 % 0.39 [ 0.26, 0.58 ]
Uetani 2009 11/11 59/87 25.5 % 1.42 [ 1.11, 1.81 ]
Wei 2009 35/35 181/188 26.8 % 1.03 [ 0.96, 1.09 ]
Areia 2010 2/2 8/8 18.4 % 1.00 [ 0.50, 2.01 ]
Total (99% CI) 219 464 100.0 % 0.95 [ 0.56, 1.62 ]
Total events: 93 (Endorsers), 310 (Non-Endorsers)
Heterogeneity: Tau2 = 0.16; Chi2 = 54.04, df = 5 (P<0.00001); I2 =91%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Does not favour CONSORT Favours CONSORT
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Analysis 1.4. Comparison 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals,
Outcome 4 Interventions.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals
Outcome: 4 Interventions
Study or subgroup Endorsers Non-Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Halpern 2004 5/6 92/94 1.1 % 0.85 [ 0.53, 1.36 ]
Kober 2006 6/8 66/67 0.9 % 0.76 [ 0.45, 1.29 ]
Wei 2009 35/35 186/188 77.9 % 1.00 [ 0.95, 1.06 ]
Ethgen 2009 17/17 108/115 16.5 % 1.04 [ 0.92, 1.17 ]
Uetani 2009 10/11 81/87 3.6 % 0.98 [ 0.76, 1.26 ]
Areia 2010 1/2 6/8 0.1 % 0.67 [ 0.10, 4.44 ]
Total (99% CI) 79 559 100.0 % 1.00 [ 0.95, 1.05 ]
Total events: 74 (Endorsers), 539 (Non-Endorsers)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.59, df = 5 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.97)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Does not favour CONSORT Favours CONSORT
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Analysis 1.5. Comparison 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals,
Outcome 5 Objectives.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals
Outcome: 5 Objectives
Study or subgroup Endorsers Non-Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Halpern 2004 6/6 85/94 2.9 % 1.03 [ 0.78, 1.37 ]
Uetani 2009 10/11 82/87 3.6 % 0.96 [ 0.75, 1.24 ]
Wei 2009 35/35 188/188 86.3 % 1.00 [ 0.95, 1.05 ]
Areia 2010 2/2 8/8 0.5 % 1.00 [ 0.50, 2.01 ]
Ladd 2010 18/19 75/90 6.8 % 1.14 [ 0.95, 1.37 ]
Total (99% CI) 73 467 100.0 % 1.01 [ 0.96, 1.06 ]
Total events: 71 (Endorsers), 438 (Non-Endorsers)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.21, df = 4 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.66)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Does not favour CONSORT Favours CONSORT
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Analysis 1.6. Comparison 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals,
Outcome 6 Outcomes.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals
Outcome: 6 Outcomes
Study or subgroup Endorsers Non-Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
1 Studies considering 1996 checklist
Kober 2006 6/8 48/65 8.5 % 1.02 [ 0.58, 1.78 ]
Subtotal (99% CI) 8 65 8.5 % 1.02 [ 0.58, 1.78 ]
Total events: 6 (Endorsers), 48 (Non-Endorsers)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
2 Studies considering 2001 checklist
Halpern 2004 6/6 86/94 15.6 % 1.02 [ 0.77, 1.35 ]
Spring 2007 14/15 37/58 14.7 % 1.46 [ 1.07, 2.00 ]
Uetani 2009 4/11 21/87 2.9 % 1.51 [ 0.48, 4.70 ]
Wei 2009 35/35 184/188 21.6 % 1.01 [ 0.95, 1.07 ]
Ladd 2010 17/19 79/90 17.4 % 1.02 [ 0.81, 1.28 ]
Hopewell 2010 176/274 148/342 18.3 % 1.48 [ 1.22, 1.81 ]
Areia 2010 1/2 3/8 0.9 % 1.33 [ 0.15, 11.65 ]
Subtotal (99% CI) 362 867 91.5 % 1.18 [ 0.94, 1.48 ]
Total events: 253 (Endorsers), 558 (Non-Endorsers)
Heterogeneity: Tau2 = 0.03; Chi2 = 31.80, df = 6 (P = 0.00002); I2 =81%
Test for overall effect: Z = 1.91 (P = 0.056)
Total (99% CI) 370 932 100.0 % 1.17 [ 0.95, 1.43 ]
Total events: 259 (Endorsers), 606 (Non-Endorsers)
Heterogeneity: Tau2 = 0.03; Chi2 = 31.82, df = 7 (P = 0.00004); I2 =78%
Test for overall effect: Z = 1.90 (P = 0.058)
Test for subgroup differences: Chi2 = 0.42, df = 1 (P = 0.52), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Does not favour CONSORT Favours CONSORT
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Analysis 1.7. Comparison 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals,
Outcome 7 Sample Size.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals
Outcome: 7 Sample Size
Study or subgroup Endorsers Non-Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
1 1996 checklist
Faunce 2003 0/2 0/4 Not estimable
Kober 2006 2/8 17/65 3.7 % 0.96 [ 0.18, 5.06 ]
Kane 2007 141/178 183/290 18.6 % 1.26 [ 1.08, 1.46 ]
Subtotal (99% CI) 188 359 22.2 % 1.25 [ 1.08, 1.46 ]
Total events: 143 (Endorsers), 200 (Non-Endorsers)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 3.83 (P = 0.00013)
2 2001 checklist
Halpern 2004 5/6 55/94 13.6 % 1.42 [ 0.85, 2.40 ]
Lai 2007 26/51 9/16 11.4 % 0.91 [ 0.46, 1.77 ]
Spring 2007 12/15 12/58 10.4 % 3.87 [ 1.84, 8.11 ]
Wei 2009 11/35 1/188 1.6 % 59.09 [ 4.18, 834.84 ]
Uetani 2009 5/11 18/87 7.5 % 2.20 [ 0.80, 6.02 ]
Areia 2010 2/2 6/8 9.1 % 1.15 [ 0.49, 2.70 ]
Hopewell 2010 158/274 121/342 17.8 % 1.63 [ 1.29, 2.05 ]
Ladd 2010 5/19 15/90 6.3 % 1.58 [ 0.49, 5.04 ]
Subtotal (99% CI) 413 883 77.8 % 1.81 [ 1.10, 2.99 ]
Total events: 224 (Endorsers), 237 (Non-Endorsers)
Heterogeneity: Tau2 = 0.19; Chi2 = 28.44, df = 7 (P = 0.00018); I2 =75%
Test for overall effect: Z = 3.07 (P = 0.0022)
Total (99% CI) 601 1242 100.0 % 1.61 [ 1.13, 2.29 ]
Total events: 367 (Endorsers), 437 (Non-Endorsers)
Heterogeneity: Tau2 = 0.10; Chi2 = 36.90, df = 9 (P = 0.00003); I2 =76%
Test for overall effect: Z = 3.44 (P = 0.00058)
Test for subgroup differences: Chi2 = 3.32, df = 1 (P = 0.07), I2 =70%
0.1 0.2 0.5 1 2 5 10
Does not favour CONSORT Favours CONSORT
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Analysis 1.8. Comparison 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals,
Outcome 8 Sequence generation.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals
Outcome: 8 Sequence generation
Study or subgroup Endorsers Non-Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Devereaux 2002 38/49 22/49 7.7 % 1.73 [ 1.10, 2.72 ]
Hill 2002 2/8 23/113 0.7 % 1.23 [ 0.24, 6.39 ]
Llorca 2004 14/37 6/23 1.7 % 1.45 [ 0.51, 4.16 ]
Halpern 2004 5/6 53/94 6.1 % 1.48 [ 0.87, 2.50 ]
Dias 2006 14/19 24/41 6.8 % 1.26 [ 0.77, 2.05 ]
Kober 2006 0/8 13/61 0.2 % 0.26 [ 0.01, 9.28 ]
Lai 2007 27/51 6/16 2.3 % 1.41 [ 0.58, 3.47 ]
Kane 2007 126/178 148/290 21.1 % 1.39 [ 1.14, 1.68 ]
Ethgen 2009 16/17 61/115 15.1 % 1.77 [ 1.35, 2.34 ]
Uetani 2009 6/11 32/87 2.9 % 1.48 [ 0.67, 3.29 ]
Wei 2009 31/35 77/188 15.1 % 2.16 [ 1.64, 2.85 ]
Ladd 2010 12/19 39/90 5.7 % 1.46 [ 0.84, 2.52 ]
Areia 2010 1/2 4/8 0.5 % 1.00 [ 0.13, 7.66 ]
Hopewell 2010 117/274 92/342 14.1 % 1.59 [ 1.19, 2.13 ]
Total (99% CI) 714 1517 100.0 % 1.59 [ 1.38, 1.84 ]
Total events: 409 (Endorsers), 600 (Non-Endorsers)
Heterogeneity: Tau2 = 0.01; Chi2 = 17.18, df = 13 (P = 0.19); I2 =24%
Test for overall effect: Z = 8.41 (P < 0.00001)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
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Analysis 1.9. Comparison 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals,
Outcome 9 Allocation concealment.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals
Outcome: 9 Allocation concealment
Study or subgroup Endorsers Non-Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Moher 2001 47/77 14/37 7.8 % 1.61 [ 0.89, 2.91 ]
Devereaux 2002 28/49 17/49 7.8 % 1.65 [ 0.91, 2.99 ]
Hill 2002 4/8 19/113 5.4 % 2.97 [ 1.03, 8.57 ]
Halpern 2004 4/6 51/94 6.8 % 1.23 [ 0.56, 2.69 ]
Llorca 2004 5/37 11/23 4.8 % 0.28 [ 0.08, 0.95 ]
Greenfield 2005 5/98 7/182 3.8 % 1.33 [ 0.30, 5.79 ]
Hewitt 2005 138/166 35/68 9.1 % 1.62 [ 1.18, 2.22 ]
Kober 2006 7/7 12/67 7.2 % 5.10 [ 2.54, 10.26 ]
Dias 2006 9/19 13/41 6.4 % 1.49 [ 0.63, 3.52 ]
Lai 2007 17/51 7/16 6.2 % 0.76 [ 0.31, 1.86 ]
Ethgen 2009 12/17 34/115 8.0 % 2.39 [ 1.38, 4.13 ]
Wei 2009 13/35 8/188 5.4 % 8.73 [ 3.04, 25.09 ]
Uetani 2009 4/11 13/87 4.7 % 2.43 [ 0.72, 8.25 ]
Ladd 2010 9/19 19/90 6.6 % 2.24 [ 0.99, 5.07 ]
Areia 2010 0/2 4/8 1.0 % 0.33 [ 0.01, 10.34 ]
Hopewell 2010 91/274 65/342 8.9 % 1.75 [ 1.22, 2.51 ]
Total (99% CI) 876 1520 100.0 % 1.81 [ 1.25, 2.61 ]
Total events: 393 (Endorsers), 329 (Non-Endorsers)
Heterogeneity: Tau2 = 0.21; Chi2 = 60.42, df = 15 (P<0.00001); I2 =75%
Test for overall effect: Z = 4.14 (P = 0.000035)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals,
Outcome 10 Implementation.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals
Outcome: 10 Implementation
Study or subgroup Endorsers Non-Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Halpern 2004 1/6 8/94 21.1 % 1.96 [ 0.16, 24.04 ]
Lai 2007 19/51 5/16 34.4 % 1.19 [ 0.41, 3.45 ]
Wei 2009 11/35 0/188 13.6 % 120.75 [ 3.01, 4842.78 ]
Uetani 2009 3/11 12/87 30.8 % 1.98 [ 0.47, 8.38 ]
Areia 2010 0/2 0/8 Not estimable
Total (99% CI) 105 393 100.0 % 2.90 [ 0.54, 15.54 ]
Total events: 34 (Endorsers), 25 (Non-Endorsers)
Heterogeneity: Tau2 = 1.06; Chi2 = 9.64, df = 3 (P = 0.02); I2 =69%
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals,
Outcome 11 Blinding.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals
Outcome: 11 Blinding
Study or subgroup Endorsers Non-Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
1 Blinding (participants)
Devereaux 2002 36/49 36/49 28.7 % 1.00 [ 0.73, 1.37 ]
Ethgen 2009 6/17 17/115 12.8 % 2.39 [ 0.86, 6.65 ]
Haahr 2006 13/14 99/185 29.9 % 1.74 [ 1.34, 2.25 ]
Halpern 2004 2/2 65/80 19.4 % 1.03 [ 0.52, 2.03 ]
Montori 2002 26/160 4/40 9.2 % 1.63 [ 0.44, 6.00 ]
Subtotal (99% CI) 242 469 100.0 % 1.39 [ 0.87, 2.21 ]
Total events: 83 (Endorsers), 221 (Non-Endorsers)
Heterogeneity: Tau2 = 0.10; Chi2 = 15.42, df = 4 (P = 0.004); I2 =74%
Test for overall effect: Z = 1.80 (P = 0.072)
2 Blinding (intervenor)
Devereaux 2002 17/49 20/49 21.4 % 0.85 [ 0.43, 1.66 ]
Ethgen 2009 4/17 12/115 10.6 % 2.25 [ 0.60, 8.51 ]
Haahr 2006 12/15 91/185 27.9 % 1.63 [ 1.11, 2.39 ]
Halpern 2004 2/2 38/78 20.1 % 1.71 [ 0.83, 3.54 ]
Montori 2002 34/160 12/40 20.0 % 0.71 [ 0.34, 1.48 ]
Subtotal (99% CI) 243 467 100.0 % 1.25 [ 0.74, 2.12 ]
Total events: 69 (Endorsers), 173 (Non-Endorsers)
Heterogeneity: Tau2 = 0.13; Chi2 = 11.47, df = 4 (P = 0.02); I2 =65%
Test for overall effect: Z = 1.11 (P = 0.27)
3 Blinding (outcome assessor)
Devereaux 2002 22/49 11/49 24.0 % 2.00 [ 0.90, 4.43 ]
Ethgen 2009 11/17 28/115 25.8 % 2.66 [ 1.42, 4.97 ]
Haahr 2006 4/14 9/185 17.7 % 5.87 [ 1.49, 23.19 ]
Halpern 2004 2/4 70/86 18.5 % 0.61 [ 0.17, 2.24 ]
Montori 2002 6/160 3/40 14.1 % 0.50 [ 0.09, 2.92 ]
Subtotal (99% CI) 244 475 100.0 % 1.72 [ 0.69, 4.31 ]
Total events: 45 (Endorsers), 121 (Non-Endorsers)
Heterogeneity: Tau2 = 0.43; Chi2 = 15.04, df = 4 (P = 0.005); I2 =73%
0.1 0.2 0.5 1 2 5 10
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Study or subgroup Endorsers Non-Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Test for overall effect: Z = 1.52 (P = 0.13)
4 Blinding (data analyst)
Devereaux 2002 4/49 0/49 33.3 % 9.00 [ 0.20, 404.37 ]
Haahr 2006 0/14 3/185 32.9 % 1.77 [ 0.04, 81.79 ]
Montori 2002 5/160 0/40 33.8 % 2.80 [ 0.06, 122.49 ]
Subtotal (99% CI) 223 274 100.0 % 3.56 [ 0.40, 31.99 ]
Total events: 9 (Endorsers), 3 (Non-Endorsers)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.64, df = 2 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.49 (P = 0.14)
5 Blinding (any description)
Greenfield 2005 75/98 148/182 16.2 % 0.94 [ 0.79, 1.12 ]
Hopewell 2010 88/274 72/342 13.5 % 1.53 [ 1.07, 2.17 ]
Kane 2007 165/178 219/220 17.1 % 0.93 [ 0.88, 0.98 ]
Ladd 2010 1/19 13/90 1.1 % 0.36 [ 0.03, 4.87 ]
Lai 2007 44/51 13/16 13.7 % 1.06 [ 0.75, 1.49 ]
Llorca 2004 37/37 22/23 16.5 % 1.05 [ 0.91, 1.22 ]
Uetani 2009 6/11 22/87 6.6 % 2.16 [ 0.92, 5.06 ]
Wei 2009 33/35 84/188 15.4 % 2.11 [ 1.67, 2.67 ]
Subtotal (99% CI) 703 1148 100.0 % 1.23 [ 0.93, 1.62 ]
Total events: 449 (Endorsers), 593 (Non-Endorsers)
Heterogeneity: Tau2 = 0.07; Chi2 = 95.55, df = 7 (P<0.00001); I2 =93%
Test for overall effect: Z = 1.91 (P = 0.057)
Test for subgroup differences: Chi2 = 2.44, df = 4 (P = 0.66), I2 =0.0%
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Analysis 1.12. Comparison 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals,
Outcome 12 Statistical methods.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals
Outcome: 12 Statistical methods
Study or subgroup Endorsers Non-Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Hill 2002 6/8 36/113 3.8 % 2.35 [ 1.25, 4.44 ]
Devereaux 2002 31/49 32/49 8.2 % 0.97 [ 0.66, 1.43 ]
Llorca 2004 27/37 19/23 9.2 % 0.88 [ 0.62, 1.26 ]
Halpern 2004 6/6 91/94 12.4 % 0.96 [ 0.73, 1.27 ]
Kober 2006 5/8 64/67 3.2 % 0.65 [ 0.32, 1.33 ]
Wei 2009 35/35 185/188 24.2 % 1.00 [ 0.95, 1.06 ]
Uetani 2009 11/11 87/87 18.9 % 1.00 [ 0.86, 1.17 ]
Ladd 2010 19/19 79/90 20.0 % 1.12 [ 0.97, 1.28 ]
Areia 2010 2/2 0/8 0.1 % 15.00 [ 0.41, 550.11 ]
Total (99% CI) 175 719 100.0 % 1.03 [ 0.90, 1.18 ]
Total events: 142 (Endorsers), 593 (Non-Endorsers)
Heterogeneity: Tau2 = 0.01; Chi2 = 22.67, df = 8 (P = 0.004); I2 =65%
Test for overall effect: Z = 0.53 (P = 0.59)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals,
Outcome 13 Participant flow.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals
Outcome: 13 Participant flow
Study or subgroup Endorsers Non-Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
1 1996 checklist
Devereaux 2002 36/49 31/49 9.9 % 1.16 [ 0.81, 1.66 ]
Hill 2002 5/8 66/113 5.4 % 1.07 [ 0.51, 2.23 ]
Faunce 2003 2/2 1/4 1.3 % 2.78 [ 0.42, 18.22 ]
Kober 2006 3/7 46/65 2.9 % 0.61 [ 0.19, 1.90 ]
Dias 2006 10/19 21/41 5.9 % 1.03 [ 0.52, 2.04 ]
Kane 2007 178/178 288/290 13.3 % 1.01 [ 0.99, 1.02 ]
Subtotal (99% CI) 263 562 38.7 % 1.01 [ 0.99, 1.02 ]
Total events: 234 (Endorsers), 453 (Non-Endorsers)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.37, df = 5 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
2 2001 checklist
Llorca 2004 21/37 12/23 6.4 % 1.09 [ 0.58, 2.05 ]
Halpern 2004 6/6 84/94 10.9 % 1.04 [ 0.78, 1.39 ]
Greenfield 2005 5/98 12/182 2.3 % 0.77 [ 0.20, 2.93 ]
Lai 2007 13/51 4/16 2.5 % 1.02 [ 0.29, 3.65 ]
Spring 2007 9/15 24/58 6.0 % 1.45 [ 0.74, 2.85 ]
Wei 2009 25/35 75/188 9.9 % 1.79 [ 1.25, 2.56 ]
Uetani 2009 5/11 24/87 3.8 % 1.65 [ 0.63, 4.31 ]
Hopewell 2010 107/274 65/342 10.0 % 2.05 [ 1.45, 2.91 ]
Areia 2010 0/2 3/8 0.4 % 0.43 [ 0.01, 14.12 ]
Ladd 2010 14/19 57/90 9.2 % 1.16 [ 0.77, 1.75 ]
Subtotal (99% CI) 548 1088 61.3 % 1.35 [ 1.00, 1.82 ]
Total events: 205 (Endorsers), 360 (Non-Endorsers)
Heterogeneity: Tau2 = 0.06; Chi2 = 23.27, df = 9 (P = 0.01); I2 =61%
Test for overall effect: Z = 2.61 (P = 0.0090)
Total (99% CI) 811 1650 100.0 % 1.23 [ 0.98, 1.53 ]
Total events: 439 (Endorsers), 813 (Non-Endorsers)
Heterogeneity: Tau2 = 0.06; Chi2 = 54.57, df = 15 (P<0.00001); I2 =73%
Test for overall effect: Z = 2.38 (P = 0.017)
Test for subgroup differences: Chi2 = 6.52, df = 1 (P = 0.01), I2 =85%
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Analysis 1.14. Comparison 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals,
Outcome 14 Recruitment.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals
Outcome: 14 Recruitment
Study or subgroup Endorsers Non-Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Halpern 2004 3/6 12/94 5.4 % 3.92 [ 1.11, 13.81 ]
Llorca 2004 3/37 2/23 1.9 % 0.93 [ 0.10, 8.84 ]
Kane 2007 147/178 285/290 44.5 % 0.84 [ 0.77, 0.92 ]
Uetani 2009 2/11 6/87 2.5 % 2.64 [ 0.38, 18.25 ]
Wei 2009 33/35 171/188 43.2 % 1.04 [ 0.92, 1.17 ]
Areia 2010 1/2 6/8 2.6 % 0.67 [ 0.10, 4.44 ]
Total (99% CI) 269 690 100.0 % 1.03 [ 0.75, 1.40 ]
Total events: 189 (Endorsers), 482 (Non-Endorsers)
Heterogeneity: Tau2 = 0.03; Chi2 = 23.68, df = 5 (P = 0.00025); I2 =79%
Test for overall effect: Z = 0.20 (P = 0.84)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals,
Outcome 15 Baseline data.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals
Outcome: 15 Baseline data
Study or subgroup Endorsers Non-Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Devereaux 2002 45/49 46/49 28.1 % 0.98 [ 0.85, 1.13 ]
Halpern 2004 6/6 86/94 14.0 % 1.02 [ 0.77, 1.35 ]
Wei 2009 34/35 153/188 32.1 % 1.19 [ 1.06, 1.34 ]
Uetani 2009 11/11 78/87 23.2 % 1.07 [ 0.90, 1.29 ]
Areia 2010 2/2 7/8 2.6 % 1.00 [ 0.46, 2.16 ]
Total (99% CI) 103 426 100.0 % 1.07 [ 0.94, 1.22 ]
Total events: 98 (Endorsers), 370 (Non-Endorsers)
Heterogeneity: Tau2 = 0.01; Chi2 = 8.22, df = 4 (P = 0.08); I2 =51%
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals,
Outcome 16 Numbers analysed.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals
Outcome: 16 Numbers analysed
Study or subgroup Endorsers Non-Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
1 Studies considering the 1996 checklist
Hill 2002 2/8 34/113 1.8 % 0.83 [ 0.16, 4.20 ]
Kober 2006 1/8 19/68 0.8 % 0.45 [ 0.04, 5.24 ]
Kane 2007 116/178 189/290 13.5 % 1.00 [ 0.84, 1.20 ]
Subtotal (99% CI) 194 471 16.1 % 0.99 [ 0.83, 1.19 ]
Total events: 119 (Endorsers), 242 (Non-Endorsers)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.79, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
2 Studies considering 2001 checklist
Llorca 2004 2/37 4/23 1.1 % 0.31 [ 0.04, 2.60 ]
Halpern 2004 5/6 79/94 8.9 % 0.99 [ 0.61, 1.61 ]
Spring 2007 11/15 22/50 7.7 % 1.67 [ 0.94, 2.96 ]
Lai 2007 37/51 11/16 8.9 % 1.06 [ 0.65, 1.72 ]
Ethgen 2009 15/17 90/115 12.4 % 1.13 [ 0.87, 1.46 ]
Uetani 2009 6/11 46/87 5.7 % 1.03 [ 0.48, 2.20 ]
Wei 2009 22/35 35/188 8.5 % 3.38 [ 2.02, 5.66 ]
Areia 2010 2/2 8/8 6.3 % 1.00 [ 0.50, 2.01 ]
Ladd 2010 15/19 53/90 10.5 % 1.34 [ 0.92, 1.96 ]
Hopewell 2010 215/274 207/342 14.0 % 1.30 [ 1.13, 1.49 ]
Subtotal (99% CI) 467 1013 83.9 % 1.29 [ 0.99, 1.68 ]
Total events: 330 (Endorsers), 555 (Non-Endorsers)
Heterogeneity: Tau2 = 0.06; Chi2 = 33.76, df = 9 (P = 0.00010); I2 =73%
Test for overall effect: Z = 2.53 (P = 0.012)
Total (99% CI) 661 1484 100.0 % 1.23 [ 0.98, 1.55 ]
Total events: 449 (Endorsers), 797 (Non-Endorsers)
Heterogeneity: Tau2 = 0.05; Chi2 = 44.99, df = 12 (P = 0.00001); I2 =73%
Test for overall effect: Z = 2.33 (P = 0.020)
Test for subgroup differences: Chi2 = 4.60, df = 1 (P = 0.03), I2 =78%
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Analysis 1.17. Comparison 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals,
Outcome 17 Outcomes and estimation.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals
Outcome: 17 Outcomes and estimation
Study or subgroup Endorsers Non-Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Halpern 2004 6/6 94/94 3.3 % 1.00 [ 0.76, 1.31 ]
Kober 2006 8/8 69/69 5.5 % 1.00 [ 0.81, 1.23 ]
Uetani 2009 2/11 6/87 0.1 % 2.64 [ 0.38, 18.25 ]
Wei 2009 35/35 188/188 89.7 % 1.00 [ 0.95, 1.05 ]
Ladd 2010 13/19 48/90 1.1 % 1.28 [ 0.80, 2.06 ]
Areia 2010 2/2 7/8 0.4 % 1.00 [ 0.46, 2.16 ]
Total (99% CI) 81 536 100.0 % 1.00 [ 0.96, 1.05 ]
Total events: 66 (Endorsers), 412 (Non-Endorsers)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.46, df = 5 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.86)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals,
Outcome 18 Ancillary analyses.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals
Outcome: 18 Ancillary analyses
Study or subgroup Endorsers Non-Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Uetani 2009 0/11 3/87 6.1 % 1.05 [ 0.02, 47.43 ]
Ladd 2010 1/19 12/90 11.5 % 0.39 [ 0.03, 5.32 ]
Yu 2010 65/113 11/48 41.0 % 2.51 [ 1.23, 5.12 ]
Areia 2010 2/2 8/8 41.4 % 1.00 [ 0.50, 2.01 ]
Total (99% CI) 145 233 100.0 % 1.31 [ 0.48, 3.58 ]
Total events: 68 (Endorsers), 34 (Non-Endorsers)
Heterogeneity: Tau2 = 0.29; Chi2 = 7.51, df = 3 (P = 0.06); I2 =60%
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals,
Outcome 19 Adverse events.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals
Outcome: 19 Adverse events
Study or subgroup Endorsers Non-Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Halpern 2004 6/6 89/94 18.9 % 0.99 [ 0.75, 1.30 ]
Greenfield 2005 68/98 120/182 20.2 % 1.05 [ 0.84, 1.31 ]
Dias 2006 3/19 6/41 2.6 % 1.08 [ 0.20, 5.76 ]
Kober 2006 6/8 54/65 12.5 % 0.90 [ 0.52, 1.56 ]
Lai 2007 39/51 10/16 12.7 % 1.22 [ 0.71, 2.09 ]
Wei 2009 30/35 93/188 19.3 % 1.73 [ 1.34, 2.25 ]
Uetani 2009 7/11 46/87 10.6 % 1.20 [ 0.63, 2.29 ]
Areia 2010 1/2 8/8 3.1 % 0.53 [ 0.12, 2.38 ]
Total (99% CI) 230 681 100.0 % 1.14 [ 0.85, 1.51 ]
Total events: 160 (Endorsers), 426 (Non-Endorsers)
Heterogeneity: Tau2 = 0.05; Chi2 = 22.59, df = 7 (P = 0.002); I2 =69%
Test for overall effect: Z = 1.16 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 1.20. Comparison 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals,
Outcome 20 Interpretation.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals
Outcome: 20 Interpretation
Study or subgroup Endorsers Non-Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Halpern 2004 4/6 67/94 0.4 % 0.94 [ 0.44, 2.00 ]
Wei 2009 35/35 188/188 85.9 % 1.00 [ 0.95, 1.05 ]
Uetani 2009 6/11 45/87 0.4 % 1.05 [ 0.49, 2.25 ]
Areia 2010 2/2 8/8 0.5 % 1.00 [ 0.50, 2.01 ]
Ladd 2010 19/19 80/90 12.8 % 1.10 [ 0.96, 1.26 ]
Total (99% CI) 73 467 100.0 % 1.01 [ 0.96, 1.06 ]
Total events: 66 (Endorsers), 388 (Non-Endorsers)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.13, df = 4 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 1.21. Comparison 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals,
Outcome 21 Generalisability.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals
Outcome: 21 Generalisability
Study or subgroup Endorsers Non-Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Halpern 2004 4/6 24/94 10.2 % 2.61 [ 1.09, 6.24 ]
Wei 2009 26/35 149/188 27.9 % 0.94 [ 0.71, 1.23 ]
Uetani 2009 9/11 51/87 21.7 % 1.40 [ 0.90, 2.15 ]
Ladd 2010 16/19 64/90 26.6 % 1.18 [ 0.87, 1.61 ]
Areia 2010 2/2 8/8 13.6 % 1.00 [ 0.50, 2.01 ]
Total (99% CI) 73 467 100.0 % 1.22 [ 0.87, 1.69 ]
Total events: 57 (Endorsers), 296 (Non-Endorsers)
Heterogeneity: Tau2 = 0.05; Chi2 = 11.16, df = 4 (P = 0.02); I2 =64%
Test for overall effect: Z = 1.53 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 1.22. Comparison 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals,
Outcome 22 Overall evidence.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals
Outcome: 22 Overall evidence
Study or subgroup Endorsers Non-Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Halpern 2004 6/6 94/94 21.5 % 1.00 [ 0.76, 1.31 ]
Uetani 2009 10/11 86/87 25.8 % 0.92 [ 0.72, 1.18 ]
Ladd 2010 18/19 77/90 49.5 % 1.11 [ 0.93, 1.32 ]
Areia 2010 2/2 8/8 3.2 % 1.00 [ 0.50, 2.01 ]
Total (99% CI) 38 279 100.0 % 1.03 [ 0.91, 1.17 ]
Total events: 36 (Endorsers), 265 (Non-Endorsers)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.57, df = 3 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 1.23. Comparison 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals,
Outcome 23 Total sum score.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 1 CONSORT-endorsing journals versus CONSORT non-endorsing journals
Outcome: 23 Total sum score







N Mean(SD) N Mean(SD) IV,Random,99% CI IV,Random,99% CI
Moher 2001 (1) 77 27.1 (4.81) 37 22.8 (4.68) 30.6 % 0.90 [ 0.36, 1.43 ]
Kidwell 2001 (2) 9 88.3 (13.45) 25 71.2 (20.82) 8.2 % 0.87 [ -0.17, 1.91 ]
Tiruvoipati 2005 2 74.9 (2.37) 62 65.75 (7.67) 2.5 % 1.19 [ -0.68, 3.06 ]
Balasubramanian 2006 (3) 11 77.28 (5.87) 58 68.88 (10.02) 11.7 % 0.87 [ 0.00, 1.74 ]
Agha 2007 8 12.25 (1.49) 82 11.03 (1.76) 9.6 % 0.70 [ -0.27, 1.66 ]
Pat 2008 (4) 4 19.25 (0.96) 34 16.94 (2.71) 4.6 % 0.87 [ -0.52, 2.25 ]
Tharyan 2008 (5) 31 5.55 (2.51) 120 4.93 (2.04) 32.7 % 0.29 [ -0.23, 0.81 ]
Total (99% CI) 142 418 100.0 % 0.68 [ 0.38, 0.98 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.98, df = 6 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 5.87 (P < 0.00001)
Test for subgroup differences: Not applicable
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(2) Scale is out of 100. SD imputed based on other included studies.
(3) Score is out of 90. Medians reported.
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Analysis 2.1. Comparison 2 CONSORT-endorsing journals before and after CONSORT endorsement,
Outcome 1 Title and abstract.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 2 CONSORT-endorsing journals before and after CONSORT endorsement
Outcome: 1 Title and abstract
Study or subgroup Post Endorsers Pre Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
1 Studies considering 1996 checklist
Sanchez-Thorin 2001 23/24 14/51 30.5 % 3.49 [ 1.92, 6.34 ]
Kober 2006 7/8 7/7 32.9 % 0.89 [ 0.57, 1.39 ]
Subtotal (99% CI) 32 58 63.4 % 1.75 [ 0.30, 10.17 ]
Total events: 30 (Post Endorsers), 21 (Pre Endorsers)
Heterogeneity: Tau2 = 0.89; Chi2 = 22.23, df = 1 (P<0.00001); I2 =96%
Test for overall effect: Z = 0.82 (P = 0.41)
2 Studies considering 2001 checklist
Han 2008 272/276 162/166 36.6 % 1.01 [ 0.97, 1.05 ]
Subtotal (99% CI) 276 166 36.6 % 1.01 [ 0.97, 1.05 ]
Total events: 272 (Post Endorsers), 162 (Pre Endorsers)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Total (99% CI) 308 224 100.0 % 1.41 [ 0.63, 3.16 ]
Total events: 302 (Post Endorsers), 183 (Pre Endorsers)
Heterogeneity: Tau2 = 0.27; Chi2 = 29.15, df = 2 (P<0.00001); I2 =93%
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Chi2 = 0.64, df = 1 (P = 0.42), I2 =0.0%
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Analysis 2.2. Comparison 2 CONSORT-endorsing journals before and after CONSORT endorsement,
Outcome 2 Introduction.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 2 CONSORT-endorsing journals before and after CONSORT endorsement
Outcome: 2 Introduction
Study or subgroup Post Endorsers Pre Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Han 2008 276/276 160/166 99.4 % 1.04 [ 1.00, 1.08 ]
Kober 2006 7/8 6/7 0.6 % 1.02 [ 0.60, 1.73 ]
Total (99% CI) 284 173 100.0 % 1.04 [ 1.00, 1.08 ]
Total events: 283 (Post Endorsers), 166 (Pre Endorsers)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 2.40 (P = 0.016)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 CONSORT-endorsing journals before and after CONSORT endorsement,
Outcome 3 Participants.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 2 CONSORT-endorsing journals before and after CONSORT endorsement
Outcome: 3 Participants
Study or subgroup Post Endorsers Pre Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Sanchez-Thorin 2001 (1) 22/24 48/51 24.8 % 0.97 [ 0.81, 1.17 ]
Faunce 2003 2/2 5/5 2.2 % 1.00 [ 0.48, 2.09 ]
Han 2008 272/276 163/166 68.9 % 1.00 [ 0.97, 1.04 ]
Alvarez 2009 21/53 27/45 4.1 % 0.66 [ 0.39, 1.13 ]
Total (99% CI) 355 267 100.0 % 0.98 [ 0.88, 1.09 ]
Total events: 317 (Post Endorsers), 243 (Pre Endorsers)
Heterogeneity: Tau2 = 0.00; Chi2 = 4.16, df = 3 (P = 0.24); I2 =28%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
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(1) Alvarez- this is multicentre versus single centre may not be applicable
Analysis 2.4. Comparison 2 CONSORT-endorsing journals before and after CONSORT endorsement,
Outcome 4 Interventions.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 2 CONSORT-endorsing journals before and after CONSORT endorsement
Outcome: 4 Interventions
Study or subgroup Post Endorsers Pre Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Sanchez-Thorin 2001 23/24 50/51 14.6 % 0.98 [ 0.87, 1.10 ]
Kober 2006 6/8 7/7 0.6 % 0.77 [ 0.43, 1.38 ]
Han 2008 270/276 158/166 83.6 % 1.03 [ 0.98, 1.08 ]
Alvarez 2009 33/53 26/45 1.2 % 1.08 [ 0.70, 1.65 ]
Total (99% CI) 361 269 100.0 % 1.02 [ 0.97, 1.07 ]
Total events: 332 (Post Endorsers), 241 (Pre Endorsers)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.62, df = 3 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 CONSORT-endorsing journals before and after CONSORT endorsement,
Outcome 5 Objectives.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 2 CONSORT-endorsing journals before and after CONSORT endorsement
Outcome: 5 Objectives
Study or subgroup Post Endorsers Pre Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Han 2008 276/276 154/166 58.8 % 1.08 [ 1.02, 1.14 ]
Sanchez-Thorin 2001 23/24 50/51 41.2 % 0.98 [ 0.87, 1.10 ]
Total (99% CI) 300 217 100.0 % 1.04 [ 0.91, 1.17 ]
Total events: 299 (Post Endorsers), 204 (Pre Endorsers)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.62, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 CONSORT-endorsing journals before and after CONSORT endorsement,
Outcome 6 Outcomes.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 2 CONSORT-endorsing journals before and after CONSORT endorsement
Outcome: 6 Outcomes
Study or subgroup Post Endorsers Pre Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
1 Studies considering 1996 checklist
Sanchez-Thorin 2001 14/24 5/51 12.2 % 5.95 [ 1.83, 19.38 ]
Kober 2006 6/8 5/6 18.7 % 0.90 [ 0.44, 1.82 ]
Subtotal (99% CI) 32 57 30.9 % 2.23 [ 0.20, 25.38 ]
Total events: 20 (Post Endorsers), 10 (Pre Endorsers)
Heterogeneity: Tau2 = 1.64; Chi2 = 12.51, df = 1 (P = 0.00040); I2 =92%
Test for overall effect: Z = 0.85 (P = 0.39)
2 Studies considering 2001 checklist
Han 2008 206/276 56/166 24.6 % 2.21 [ 1.65, 2.97 ]
Alvarez 2009 33/53 19/45 21.4 % 1.47 [ 0.87, 2.50 ]
Pagoto 2009 26/37 29/50 23.1 % 1.21 [ 0.80, 1.83 ]
Subtotal (99% CI) 366 261 69.1 % 1.61 [ 0.95, 2.72 ]
Total events: 265 (Post Endorsers), 104 (Pre Endorsers)
Heterogeneity: Tau2 = 0.10; Chi2 = 10.13, df = 2 (P = 0.01); I2 =80%
Test for overall effect: Z = 2.32 (P = 0.020)
Total (99% CI) 398 318 100.0 % 1.68 [ 0.96, 2.96 ]
Total events: 285 (Post Endorsers), 114 (Pre Endorsers)
Heterogeneity: Tau2 = 0.18; Chi2 = 23.08, df = 4 (P = 0.00012); I2 =83%
Test for overall effect: Z = 2.38 (P = 0.017)
Test for subgroup differences: Chi2 = 0.12, df = 1 (P = 0.73), I2 =0.0%
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Analysis 2.7. Comparison 2 CONSORT-endorsing journals before and after CONSORT endorsement,
Outcome 7 Sample size.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 2 CONSORT-endorsing journals before and after CONSORT endorsement
Outcome: 7 Sample size
Study or subgroup Post Endorsers Pre Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
1 studies considering 1996 checklist
Sanchez-Thorin 2001 8/24 22/51 17.1 % 0.77 [ 0.33, 1.81 ]
Kober 2006 2/8 0/7 2.3 % 4.44 [ 0.10, 196.52 ]
Kane 2007 141/178 50/88 24.8 % 1.39 [ 1.08, 1.81 ]
Subtotal (99% CI) 210 146 44.1 % 1.19 [ 0.62, 2.29 ]
Total events: 151 (Post Endorsers), 72 (Pre Endorsers)
Heterogeneity: Tau2 = 0.09; Chi2 = 3.59, df = 2 (P = 0.17); I2 =44%
Test for overall effect: Z = 0.68 (P = 0.50)
2 Studies considering 2001 checklist
Han 2008 77/276 66/166 23.9 % 0.70 [ 0.49, 1.00 ]
Pagoto 2009 15/37 7/50 14.6 % 2.90 [ 1.03, 8.18 ]
Alvarez 2009 23/53 10/45 17.4 % 1.95 [ 0.86, 4.45 ]
Subtotal (99% CI) 366 261 55.9 % 1.50 [ 0.44, 5.13 ]
Total events: 115 (Post Endorsers), 83 (Pre Endorsers)
Heterogeneity: Tau2 = 0.59; Chi2 = 17.59, df = 2 (P = 0.00015); I2 =89%
Test for overall effect: Z = 0.85 (P = 0.39)
Total (99% CI) 576 407 100.0 % 1.30 [ 0.71, 2.36 ]
Total events: 266 (Post Endorsers), 155 (Pre Endorsers)
Heterogeneity: Tau2 = 0.21; Chi2 = 27.14, df = 5 (P = 0.00005); I2 =82%
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Chi2 = 0.19, df = 1 (P = 0.67), I2 =0.0%
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Analysis 2.8. Comparison 2 CONSORT-endorsing journals before and after CONSORT endorsement,
Outcome 8 Sequence generation.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 2 CONSORT-endorsing journals before and after CONSORT endorsement
Outcome: 8 Sequence generation
Study or subgroup Post Endorsers Pre Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Sanchez-Thorin 2001 21/24 15/51 13.9 % 2.98 [ 1.64, 5.38 ]
Hill 2002 1/5 2/12 2.7 % 1.20 [ 0.07, 20.56 ]
Llorca 2004 5/37 31/83 9.3 % 0.36 [ 0.12, 1.12 ]
Dias 2006 14/19 17/34 14.2 % 1.47 [ 0.84, 2.59 ]
Kober 2006 7/7 7/7 16.0 % 1.00 [ 0.72, 1.39 ]
Kane 2007 126/178 56/88 16.5 % 1.11 [ 0.87, 1.42 ]
Han 2008 183/276 42/166 15.8 % 2.62 [ 1.83, 3.76 ]
Alvarez 2009 24/53 9/45 11.6 % 2.26 [ 0.96, 5.36 ]
Total (99% CI) 599 486 100.0 % 1.46 [ 0.88, 2.45 ]
Total events: 381 (Post Endorsers), 179 (Pre Endorsers)
Heterogeneity: Tau2 = 0.23; Chi2 = 55.15, df = 7 (P<0.00001); I2 =87%
Test for overall effect: Z = 1.91 (P = 0.056)
Test for subgroup differences: Not applicable
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Analysis 2.9. Comparison 2 CONSORT-endorsing journals before and after CONSORT endorsement,
Outcome 9 Allocation concealment.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 2 CONSORT-endorsing journals before and after CONSORT endorsement
Outcome: 9 Allocation concealment
Study or subgroup Post Endorsers Pre Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Sanchez-Thorin 2001 6/24 17/51 16.8 % 0.75 [ 0.26, 2.13 ]
Moher 2001 47/77 28/71 21.9 % 1.55 [ 0.99, 2.42 ]
Hill 2002 1/5 4/12 7.0 % 0.60 [ 0.05, 7.55 ]
Llorca 2004 5/37 31/83 16.0 % 0.36 [ 0.12, 1.12 ]
Dias 2006 9/19 8/34 17.1 % 2.01 [ 0.73, 5.53 ]
Han 2008 123/276 24/166 21.4 % 3.08 [ 1.84, 5.16 ]
Total (99% CI) 438 417 100.0 % 1.23 [ 0.55, 2.74 ]
Total events: 191 (Post Endorsers), 112 (Pre Endorsers)
Heterogeneity: Tau2 = 0.41; Chi2 = 26.87, df = 5 (P = 0.00006); I2 =81%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 2.10. Comparison 2 CONSORT-endorsing journals before and after CONSORT endorsement,
Outcome 10 Implementation.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 2 CONSORT-endorsing journals before and after CONSORT endorsement
Outcome: 10 Implementation
Study or subgroup Post Endorsers Pre Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Han 2008 84/276 10/166 51.3 % 5.05 [ 2.22, 11.51 ]
Sanchez-Thorin 2001 5/24 15/51 48.7 % 0.71 [ 0.22, 2.28 ]
Total (99% CI) 300 217 100.0 % 1.94 [ 0.15, 24.36 ]
Total events: 89 (Post Endorsers), 25 (Pre Endorsers)
Heterogeneity: Tau2 = 1.78; Chi2 = 12.55, df = 1 (P = 0.00040); I2 =92%
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 2.11. Comparison 2 CONSORT-endorsing journals before and after CONSORT endorsement,
Outcome 11 Blinding.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 2 CONSORT-endorsing journals before and after CONSORT endorsement
Outcome: 11 Blinding
Study or subgroup Post Endorsers Pre Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
1 Blinding (participants)
Sanchez-Thorin 2001 13/24 36/51 100.0 % 0.77 [ 0.45, 1.31 ]
Subtotal (99% CI) 24 51 100.0 % 0.77 [ 0.45, 1.31 ]
Total events: 13 (Post Endorsers), 36 (Pre Endorsers)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
2 Blinding (interventions)
Sanchez-Thorin 2001 5/24 41/51 100.0 % 0.26 [ 0.09, 0.73 ]
Subtotal (99% CI) 24 51 100.0 % 0.26 [ 0.09, 0.73 ]
Total events: 5 (Post Endorsers), 41 (Pre Endorsers)
Heterogeneity: not applicable
Test for overall effect: Z = 3.34 (P = 0.00083)
3 Blinding (outcome assessors)
Sanchez-Thorin 2001 10/24 32/51 100.0 % 0.66 [ 0.34, 1.31 ]
Subtotal (99% CI) 24 51 100.0 % 0.66 [ 0.34, 1.31 ]
Total events: 10 (Post Endorsers), 32 (Pre Endorsers)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
4 Blinding (data analyst)
Sanchez-Thorin 2001 1/24 8/51 100.0 % 0.27 [ 0.02, 3.78 ]
Subtotal (99% CI) 24 51 100.0 % 0.27 [ 0.02, 3.78 ]
Total events: 1 (Post Endorsers), 8 (Pre Endorsers)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
5 Blinding (any description)
Llorca 2004 37/37 83/83 26.8 % 1.00 [ 0.95, 1.05 ]
Kane 2007 165/178 52/88 25.1 % 1.57 [ 1.24, 1.98 ]
Han 2008 98/276 108/166 24.8 % 0.55 [ 0.42, 0.70 ]
Alvarez 2009 37/53 32/45 23.4 % 0.98 [ 0.70, 1.38 ]
Subtotal (99% CI) 544 382 100.0 % 0.96 [ 0.61, 1.50 ]
Total events: 337 (Post Endorsers), 275 (Pre Endorsers)
Heterogeneity: Tau2 = 0.11; Chi2 = 61.75, df = 3 (P<0.00001); I2 =95%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Chi2 = 10.15, df = 4 (P = 0.04), I2 =61%
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Analysis 2.12. Comparison 2 CONSORT-endorsing journals before and after CONSORT endorsement,
Outcome 12 Statistical methods.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 2 CONSORT-endorsing journals before and after CONSORT endorsement
Outcome: 12 Statistical methods
Study or subgroup Post Endorsers Pre Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Sanchez-Thorin 2001 22/24 48/51 22.5 % 0.97 [ 0.81, 1.17 ]
Hill 2002 3/5 3/12 3.5 % 2.40 [ 0.49, 11.83 ]
Llorca 2004 27/37 77/83 20.8 % 0.79 [ 0.60, 1.03 ]
Kober 2006 5/8 5/7 8.0 % 0.88 [ 0.34, 2.23 ]
Han 2008 272/276 154/166 24.1 % 1.06 [ 1.00, 1.13 ]
Han 2008 98/276 108/166 21.1 % 0.55 [ 0.42, 0.70 ]
Total (99% CI) 626 485 100.0 % 0.86 [ 0.62, 1.19 ]
Total events: 427 (Post Endorsers), 395 (Pre Endorsers)
Heterogeneity: Tau2 = 0.07; Chi2 = 51.54, df = 5 (P<0.00001); I2 =90%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Does not favour CONSORT Favours CONSORT
124
Analysis 2.13. Comparison 2 CONSORT-endorsing journals before and after CONSORT endorsement,
Outcome 13 Participant flow.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 2 CONSORT-endorsing journals before and after CONSORT endorsement
Outcome: 13 Participant flow
Study or subgroup Post Endorsers Pre Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
1 Studies considering 1996 checklist
Sanchez-Thorin 2001 24/24 6/51 8.1 % 7.84 [ 3.04, 20.23 ]
Hill 2002 4/5 10/12 12.0 % 0.96 [ 0.49, 1.87 ]
Faunce 2003 2/2 3/5 6.6 % 1.43 [ 0.47, 4.33 ]
Dias 2006 10/19 15/34 10.7 % 1.19 [ 0.56, 2.52 ]
Kober 2006 3/7 3/5 4.3 % 0.71 [ 0.16, 3.09 ]
Kane 2007 178/178 86/88 22.2 % 1.03 [ 0.98, 1.08 ]
Subtotal (99% CI) 235 195 63.9 % 1.44 [ 0.73, 2.87 ]
Total events: 221 (Post Endorsers), 123 (Pre Endorsers)
Heterogeneity: Tau2 = 0.32; Chi2 = 31.77, df = 5 (P<0.00001); I2 =84%
Test for overall effect: Z = 1.38 (P = 0.17)
2 Studies considering 2001 checklist
Llorca 2004 21/37 38/83 15.4 % 1.24 [ 0.77, 2.01 ]
Han 2008 203/276 93/166 20.7 % 1.31 [ 1.07, 1.60 ]
Subtotal (99% CI) 313 249 36.1 % 1.30 [ 1.08, 1.57 ]
Total events: 224 (Post Endorsers), 131 (Pre Endorsers)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 3.68 (P = 0.00024)
Total (99% CI) 548 444 100.0 % 1.33 [ 0.95, 1.87 ]
Total events: 445 (Post Endorsers), 254 (Pre Endorsers)
Heterogeneity: Tau2 = 0.08; Chi2 = 41.72, df = 7 (P<0.00001); I2 =83%
Test for overall effect: Z = 2.17 (P = 0.030)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.71), I2 =0.0%
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Analysis 2.14. Comparison 2 CONSORT-endorsing journals before and after CONSORT endorsement,
Outcome 14 Recruitment.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 2 CONSORT-endorsing journals before and after CONSORT endorsement
Outcome: 14 Recruitment
Study or subgroup Post Endorsers Pre Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Llorca 2004 3/37 13/83 24.8 % 0.52 [ 0.11, 2.49 ]
Kane 2007 147/178 48/88 38.4 % 1.51 [ 1.16, 1.98 ]
Han 2008 182/276 23/166 36.8 % 4.76 [ 2.86, 7.93 ]
Total (99% CI) 491 337 100.0 % 1.77 [ 0.48, 6.46 ]
Total events: 332 (Post Endorsers), 84 (Pre Endorsers)
Heterogeneity: Tau2 = 0.65; Chi2 = 30.82, df = 2 (P<0.00001); I2 =94%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Does not favour CONSORT Favours CONSORT
Analysis 2.15. Comparison 2 CONSORT-endorsing journals before and after CONSORT endorsement,
Outcome 15 Baseline data.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 2 CONSORT-endorsing journals before and after CONSORT endorsement
Outcome: 15 Baseline data
Study or subgroup Post Endorsers Pre Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Han 2008 264/276 111/166 84.7 % 1.43 [ 1.24, 1.65 ]
Pagoto 2009 31/37 31/50 15.3 % 1.35 [ 0.96, 1.90 ]
Total (99% CI) 313 216 100.0 % 1.42 [ 1.24, 1.62 ]
Total events: 295 (Post Endorsers), 142 (Pre Endorsers)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 6.76 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.16. Comparison 2 CONSORT-endorsing journals before and after CONSORT endorsement,
Outcome 16 Numbers analysed.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 2 CONSORT-endorsing journals before and after CONSORT endorsement
Outcome: 16 Numbers analysed
Study or subgroup Post Endorsers Pre Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
1 Studies considering 1996 checklist
Sanchez-Thorin 2001 24/24 41/51 28.6 % 1.23 [ 1.01, 1.49 ]
Kober 2006 1/8 1/7 1.2 % 0.88 [ 0.03, 25.96 ]
Kane 2007 116/178 29/88 22.3 % 1.98 [ 1.30, 3.00 ]
Subtotal (99% CI) 210 146 52.1 % 1.50 [ 0.86, 2.62 ]
Total events: 141 (Post Endorsers), 71 (Pre Endorsers)
Heterogeneity: Tau2 = 0.08; Chi2 = 7.24, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 1.86 (P = 0.063)
2 Studies considering 2001 checklist
Llorca 2004 2/37 3/83 2.4 % 1.50 [ 0.15, 14.85 ]
Han 2008 259/276 81/166 28.3 % 1.92 [ 1.56, 2.37 ]
Pagoto 2009 26/37 16/50 17.2 % 2.20 [ 1.21, 3.99 ]
Subtotal (99% CI) 350 299 47.9 % 1.95 [ 1.60, 2.37 ]
Total events: 287 (Post Endorsers), 100 (Pre Endorsers)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.38, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 8.75 (P < 0.00001)
Total (99% CI) 560 445 100.0 % 1.72 [ 1.18, 2.49 ]
Total events: 428 (Post Endorsers), 171 (Pre Endorsers)
Heterogeneity: Tau2 = 0.07; Chi2 = 21.22, df = 5 (P = 0.00074); I2 =76%
Test for overall effect: Z = 3.74 (P = 0.00018)
Test for subgroup differences: Chi2 = 1.30, df = 1 (P = 0.26), I2 =23%
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Analysis 2.17. Comparison 2 CONSORT-endorsing journals before and after CONSORT endorsement,
Outcome 17 Outcomes and estimation.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 2 CONSORT-endorsing journals before and after CONSORT endorsement
Outcome: 17 Outcomes and estimation
Study or subgroup Post Endorsers Pre Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Sanchez-Thorin 2001 24/24 49/51 43.6 % 1.03 [ 0.92, 1.15 ]
Kober 2006 5/8 3/7 14.5 % 1.46 [ 0.39, 5.50 ]
Han 2008 233/276 80/166 41.9 % 1.75 [ 1.41, 2.18 ]
Total (99% CI) 308 224 100.0 % 1.35 [ 0.73, 2.51 ]
Total events: 262 (Post Endorsers), 132 (Pre Endorsers)
Heterogeneity: Tau2 = 0.13; Chi2 = 31.85, df = 2 (P<0.00001); I2 =94%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 2.18. Comparison 2 CONSORT-endorsing journals before and after CONSORT endorsement,
Outcome 18 Ancillary analyses.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 2 CONSORT-endorsing journals before and after CONSORT endorsement
Outcome: 18 Ancillary analyses
Study or subgroup Post Endorsers Pre Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Han 2008 253/276 44/166 100.0 % 3.46 [ 2.47, 4.84 ]
Total (99% CI) 276 166 100.0 % 3.46 [ 2.47, 4.84 ]
Total events: 253 (Post Endorsers), 44 (Pre Endorsers)
Heterogeneity: not applicable
Test for overall effect: Z = 9.51 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.19. Comparison 2 CONSORT-endorsing journals before and after CONSORT endorsement,
Outcome 19 Adverse events.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 2 CONSORT-endorsing journals before and after CONSORT endorsement
Outcome: 19 Adverse events
Study or subgroup Post Endorsers Pre Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Dias 2006 3/19 3/34 1.2 % 1.79 [ 0.25, 12.83 ]
Kober 2006 6/8 3/4 5.8 % 1.00 [ 0.40, 2.49 ]
Han 2008 193/276 82/166 93.0 % 1.42 [ 1.13, 1.78 ]
Total (99% CI) 303 204 100.0 % 1.39 [ 1.12, 1.73 ]
Total events: 202 (Post Endorsers), 88 (Pre Endorsers)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.02, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 3.90 (P = 0.000097)
Test for subgroup differences: Not applicable
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Analysis 2.20. Comparison 2 CONSORT-endorsing journals before and after CONSORT endorsement,
Outcome 20 Interpretation.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 2 CONSORT-endorsing journals before and after CONSORT endorsement
Outcome: 20 Interpretation
Study or subgroup Post Endorsers Pre Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Han 2008 276/276 164/166 100.0 % 1.01 [ 0.99, 1.04 ]
Total (99% CI) 276 166 100.0 % 1.01 [ 0.99, 1.04 ]
Total events: 276 (Post Endorsers), 164 (Pre Endorsers)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 2.21. Comparison 2 CONSORT-endorsing journals before and after CONSORT endorsement,
Outcome 21 Generalisability.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 2 CONSORT-endorsing journals before and after CONSORT endorsement
Outcome: 21 Generalisability
Study or subgroup Post Endorsers Pre Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Han 2008 270/276 92/166 100.0 % 1.77 [ 1.47, 2.11 ]
Total (99% CI) 276 166 100.0 % 1.77 [ 1.47, 2.11 ]
Total events: 270 (Post Endorsers), 92 (Pre Endorsers)
Heterogeneity: not applicable
Test for overall effect: Z = 8.10 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 2.22. Comparison 2 CONSORT-endorsing journals before and after CONSORT endorsement,
Outcome 22 Overall evidence.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 2 CONSORT-endorsing journals before and after CONSORT endorsement
Outcome: 22 Overall evidence
Study or subgroup Post Endorsers Pre Endorsers Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Sanchez-Thorin 2001 24/24 43/51 48.1 % 1.17 [ 0.98, 1.39 ]
Han 2008 276/276 114/166 51.9 % 1.46 [ 1.27, 1.67 ]
Total (99% CI) 300 217 100.0 % 1.31 [ 0.99, 1.73 ]
Total events: 300 (Post Endorsers), 157 (Pre Endorsers)
Heterogeneity: Tau2 = 0.02; Chi2 = 6.45, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 2.50 (P = 0.013)
Test for subgroup differences: Not applicable
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Analysis 2.23. Comparison 2 CONSORT-endorsing journals before and after CONSORT endorsement,
Outcome 23 Total sum score.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 2 CONSORT-endorsing journals before and after CONSORT endorsement
Outcome: 23 Total sum score







N Mean(SD) N Mean(SD) IV,Random,99% CI IV,Random,99% CI
Moher 2001 77 27.1 (4.81) 71 23.4 (5.1) 100.0 % 0.74 [ 0.30, 1.18 ]
Total (99% CI) 77 71 100.0 % 0.74 [ 0.30, 1.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.37 (P = 0.000013)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 3.1. Comparison 3 Sample of RCTs before and after CONSORT publication, Outcome 1 Title and
abstract.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 3 Sample of RCTs before and after CONSORT publication
Outcome: 1 Title and abstract
Study or subgroup Post-CONSORT Pre-CONSORT Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
1 Studies considering 1996 checklist
Anttila 2006 7/7 5/7 5.9 % 1.36 [ 0.71, 2.63 ]
Thabane 2007 8/13 17/50 4.7 % 1.81 [ 0.85, 3.87 ]
Ziogas 2009 168/187 61/74 21.4 % 1.09 [ 0.94, 1.27 ]
Partsinevelou 2009 201/237 21/27 16.0 % 1.09 [ 0.83, 1.43 ]
Subtotal (99% CI) 444 158 48.0 % 1.13 [ 0.96, 1.33 ]
Total events: 384 (Post-CONSORT), 104 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.52, df = 3 (P = 0.32); I2 =15%
Test for overall effect: Z = 1.93 (P = 0.053)
2 Studies considering 2001 checklist
Wang 2007 2774/4492 1353/2930 24.5 % 1.34 [ 1.26, 1.42 ]
Par s 2008 17/27 8/15 5.0 % 1.18 [ 0.57, 2.45 ]
Ladd 2010 83/89 63/70 22.5 % 1.04 [ 0.91, 1.18 ]
Subtotal (99% CI) 4608 3015 52.0 % 1.18 [ 0.88, 1.59 ]
Total events: 2874 (Post-CONSORT), 1424 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.03; Chi2 = 22.25, df = 2 (P = 0.00001); I2 =91%
Test for overall effect: Z = 1.45 (P = 0.15)
Total (99% CI) 5052 3173 100.0 % 1.18 [ 0.98, 1.42 ]
Total events: 3258 (Post-CONSORT), 1528 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.02; Chi2 = 31.95, df = 6 (P = 0.00002); I2 =81%
Test for overall effect: Z = 2.35 (P = 0.019)
Test for subgroup differences: Chi2 = 0.12, df = 1 (P = 0.73), I2 =0.0%
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132
Analysis 3.2. Comparison 3 Sample of RCTs before and after CONSORT publication, Outcome 2
Introduction.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 3 Sample of RCTs before and after CONSORT publication
Outcome: 2 Introduction
Study or subgroup Post-CONSORT Pre-CONSORT Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Anttila 2006 7/7 6/7 6.5 % 1.15 [ 0.70, 1.90 ]
Thabane 2007 13/13 50/50 14.3 % 1.00 [ 0.87, 1.15 ]
Peckitt 2007 43/45 21/26 11.4 % 1.18 [ 0.91, 1.53 ]
Wang 2007 2697/4492 1350/2930 15.5 % 1.30 [ 1.23, 1.38 ]
Par s 2008 27/27 14/15 12.4 % 1.08 [ 0.87, 1.35 ]
Partsinevelou 2009 210/237 24/27 13.2 % 1.00 [ 0.83, 1.20 ]
Ziogas 2009 142/187 45/74 11.3 % 1.25 [ 0.96, 1.62 ]
Ladd 2010 83/87 68/69 15.4 % 0.97 [ 0.90, 1.04 ]
Total (99% CI) 5095 3198 100.0 % 1.10 [ 0.94, 1.30 ]
Total events: 3222 (Post-CONSORT), 1578 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.03; Chi2 = 78.01, df = 7 (P<0.00001); I2 =91%
Test for overall effect: Z = 1.55 (P = 0.12)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Sample of RCTs before and after CONSORT publication, Outcome 3
Participants.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 3 Sample of RCTs before and after CONSORT publication
Outcome: 3 Participants
Study or subgroup Post-CONSORT Pre-CONSORT Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Anttila 2006 5/7 5/7 2.5 % 1.00 [ 0.42, 2.39 ]
Thabane 2007 13/13 37/50 15.7 % 1.31 [ 1.02, 1.69 ]
Wang 2007 2844/4492 1770/2930 29.3 % 1.05 [ 1.00, 1.10 ]
Bausch 2009 88/105 150/239 21.4 % 1.34 [ 1.13, 1.58 ]
Ziogas 2009 181/187 73/74 29.2 % 0.98 [ 0.93, 1.03 ]
Partsinevelou 2009 171/237 5/27 1.8 % 3.90 [ 1.37, 11.08 ]
Total (99% CI) 5041 3327 100.0 % 1.15 [ 0.99, 1.33 ]
Total events: 3302 (Post-CONSORT), 2040 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.01; Chi2 = 39.73, df = 5 (P<0.00001); I2 =87%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Sample of RCTs before and after CONSORT publication, Outcome 4
Interventions.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 3 Sample of RCTs before and after CONSORT publication
Outcome: 4 Interventions
Study or subgroup Post-CONSORT Pre-CONSORT Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Anttila 2006 6/7 5/7 0.2 % 1.20 [ 0.58, 2.50 ]
Thabane 2007 13/13 49/50 4.2 % 0.99 [ 0.86, 1.15 ]
Wang 2007 2904/4492 1826/2930 34.4 % 1.04 [ 0.99, 1.09 ]
Par s 2008 27/27 15/15 5.0 % 1.00 [ 0.88, 1.14 ]
Partsinevelou 2009 234/237 27/27 17.6 % 1.00 [ 0.94, 1.07 ]
Ziogas 2009 179/187 73/74 27.7 % 0.97 [ 0.92, 1.02 ]
Ladd 2010 84/88 67/70 11.0 % 1.00 [ 0.91, 1.09 ]
Total (99% CI) 5051 3173 100.0 % 1.00 [ 0.97, 1.04 ]
Total events: 3447 (Post-CONSORT), 2062 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.00; Chi2 = 6.46, df = 6 (P = 0.37); I2 =7%
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Sample of RCTs before and after CONSORT publication, Outcome 5
Objectives.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 3 Sample of RCTs before and after CONSORT publication
Outcome: 5 Objectives
Study or subgroup Post-CONSORT Pre-CONSORT Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Anttila 2006 6/7 5/7 0.5 % 1.20 [ 0.58, 2.50 ]
Peckitt 2007 44/47 15/20 2.0 % 1.25 [ 0.88, 1.77 ]
Wang 2007 3575/4492 2287/2930 50.4 % 1.02 [ 0.99, 1.05 ]
Partsinevelou 2009 231/237 23/27 5.2 % 1.14 [ 0.93, 1.41 ]
Ziogas 2009 183/187 73/74 41.9 % 0.99 [ 0.95, 1.04 ]
Total (99% CI) 4970 3058 100.0 % 1.02 [ 0.97, 1.07 ]
Total events: 4039 (Post-CONSORT), 2403 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.00; Chi2 = 6.75, df = 4 (P = 0.15); I2 =41%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 Sample of RCTs before and after CONSORT publication, Outcome 6
Outcomes.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 3 Sample of RCTs before and after CONSORT publication
Outcome: 6 Outcomes
Study or subgroup Post-CONSORT Pre-CONSORT Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
1 Studies considering 1996 checklist
Anttila 2006 4/7 4/7 3.5 % 1.00 [ 0.30, 3.29 ]
Thabane 2007 8/13 21/50 7.8 % 1.47 [ 0.72, 2.98 ]
Partsinevelou 2009 165/237 6/27 5.2 % 3.13 [ 1.23, 7.97 ]
Ziogas 2009 179/187 59/74 22.2 % 1.20 [ 1.03, 1.40 ]
Subtotal (99% CI) 444 158 38.6 % 1.47 [ 0.87, 2.48 ]
Total events: 356 (Post-CONSORT), 90 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.09; Chi2 = 7.40, df = 3 (P = 0.06); I2 =59%
Test for overall effect: Z = 1.89 (P = 0.058)
2 Studies considering 2001 checklist
Wang 2007 2600/4492 1789/2930 24.2 % 0.95 [ 0.90, 1.00 ]
Ladd 2010 61/87 32/69 15.2 % 1.51 [ 1.03, 2.21 ]
Hopewell 2010 324/616 232/519 22.1 % 1.18 [ 1.00, 1.38 ]
Subtotal (99% CI) 5195 3518 61.4 % 1.15 [ 0.85, 1.54 ]
Total events: 2985 (Post-CONSORT), 2053 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.03; Chi2 = 20.15, df = 2 (P = 0.00004); I2 =90%
Test for overall effect: Z = 1.20 (P = 0.23)
Total (99% CI) 5639 3676 100.0 % 1.24 [ 0.98, 1.58 ]
Total events: 3341 (Post-CONSORT), 2143 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.04; Chi2 = 43.15, df = 6 (P<0.00001); I2 =86%
Test for overall effect: Z = 2.31 (P = 0.021)
Test for subgroup differences: Chi2 = 1.13, df = 1 (P = 0.29), I2 =11%
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Analysis 3.7. Comparison 3 Sample of RCTs before and after CONSORT publication, Outcome 7 Sample
size.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 3 Sample of RCTs before and after CONSORT publication
Outcome: 7 Sample size
Study or subgroup Post-CONSORT Pre-CONSORT Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
1 Studies considering 1996 checklist
Anttila 2006 3/7 1/7 3.7 % 3.00 [ 0.21, 41.89 ]
Thabane 2007 13/13 50/50 15.5 % 1.00 [ 0.87, 1.15 ]
Peckitt 2007 14/27 0/34 2.2 % 36.25 [ 0.94, 1390.57 ]
Ziogas 2009 86/187 10/74 12.2 % 3.40 [ 1.55, 7.46 ]
Partsinevelou 2009 76/237 4/27 9.3 % 2.16 [ 0.64, 7.28 ]
Subtotal (99% CI) 471 192 42.8 % 2.49 [ 0.78, 7.95 ]
Total events: 192 (Post-CONSORT), 65 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.66; Chi2 = 25.41, df = 4 (P = 0.00004); I2 =84%
Test for overall effect: Z = 2.02 (P = 0.043)
2 Studies considering 2001 checklist
Scales 2007 41/87 12/65 12.5 % 2.55 [ 1.23, 5.31 ]
Wang 2007 156/4492 8/2930 11.1 % 12.72 [ 5.01, 32.29 ]
Par s 2008 16/27 3/15 8.2 % 2.96 [ 0.74, 11.92 ]
Hopewell 2010 279/616 142/519 15.3 % 1.66 [ 1.33, 2.06 ]
Ladd 2010 10/85 9/69 10.0 % 0.90 [ 0.30, 2.73 ]
Subtotal (99% CI) 5307 3598 57.2 % 2.68 [ 1.00, 7.16 ]
Total events: 502 (Post-CONSORT), 174 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.60; Chi2 = 34.98, df = 4 (P<0.00001); I2 =89%
Test for overall effect: Z = 2.58 (P = 0.010)
Total (99% CI) 5778 3790 100.0 % 2.45 [ 1.37, 4.39 ]
Total events: 694 (Post-CONSORT), 239 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.33; Chi2 = 97.77, df = 9 (P<0.00001); I2 =91%
Test for overall effect: Z = 3.97 (P = 0.000072)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.90), I2 =0.0%
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Analysis 3.8. Comparison 3 Sample of RCTs before and after CONSORT publication, Outcome 8 Sequence
generation.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 3 Sample of RCTs before and after CONSORT publication
Outcome: 8 Sequence generation
Study or subgroup Post-CONSORT Pre-CONSORT Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Anttila 2006 3/7 6/7 5.9 % 0.50 [ 0.15, 1.65 ]
Wang 2007 484/4492 97/2930 13.0 % 3.25 [ 2.46, 4.31 ]
Scales 2007 30/87 12/65 8.9 % 1.87 [ 0.86, 4.04 ]
Thabane 2007 2/13 12/50 3.4 % 0.64 [ 0.11, 3.86 ]
Par s 2008 20/27 9/15 10.2 % 1.23 [ 0.67, 2.29 ]
Prady 2008 19/39 7/51 7.1 % 3.55 [ 1.31, 9.63 ]
Ziogas 2009 80/187 22/74 11.2 % 1.44 [ 0.86, 2.39 ]
Bausch 2009 38/105 55/239 11.6 % 1.57 [ 1.00, 2.47 ]
Partsinevelou 2009 140/237 8/27 8.8 % 1.99 [ 0.92, 4.33 ]
Hopewell 2010 209/616 109/519 13.1 % 1.62 [ 1.24, 2.10 ]
Ladd 2010 16/81 8/66 6.9 % 1.63 [ 0.58, 4.57 ]
Total (99% CI) 5891 4043 100.0 % 1.67 [ 1.14, 2.45 ]
Total events: 1041 (Post-CONSORT), 345 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.16; Chi2 = 46.89, df = 10 (P<0.00001); I2 =79%
Test for overall effect: Z = 3.48 (P = 0.00050)
Test for subgroup differences: Not applicable
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Analysis 3.9. Comparison 3 Sample of RCTs before and after CONSORT publication, Outcome 9
Allocation concealment.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 3 Sample of RCTs before and after CONSORT publication
Outcome: 9 Allocation concealment
Study or subgroup Post-CONSORT Pre-CONSORT Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Dickinson 2002 0/6 1/31 0.4 % 1.52 [ 0.03, 88.93 ]
Wang 2007 14/4492 7/2930 4.7 % 1.30 [ 0.40, 4.29 ]
Thabane 2007 1/13 5/50 1.0 % 0.77 [ 0.05, 11.51 ]
Scales 2007 19/87 5/65 4.5 % 2.84 [ 0.83, 9.65 ]
Prady 2008 19/39 7/51 6.5 % 3.55 [ 1.31, 9.63 ]
Par s 2008 18/27 5/15 6.4 % 2.00 [ 0.73, 5.46 ]
Selman 2008 21/35 10/39 9.9 % 2.34 [ 1.06, 5.14 ]
Bausch 2009 16/105 24/239 10.2 % 1.52 [ 0.70, 3.29 ]
Ziogas 2009 50/187 14/74 12.2 % 1.41 [ 0.71, 2.83 ]
Ladd 2010 14/86 11/66 7.1 % 0.98 [ 0.38, 2.52 ]
Hopewell 2010 156/616 94/519 37.2 % 1.40 [ 1.04, 1.89 ]
Total (99% CI) 5693 4079 100.0 % 1.61 [ 1.23, 2.10 ]
Total events: 328 (Post-CONSORT), 183 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.02; Chi2 = 11.50, df = 10 (P = 0.32); I2 =13%
Test for overall effect: Z = 4.60 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.10. Comparison 3 Sample of RCTs before and after CONSORT publication, Outcome 10
Implementation.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 3 Sample of RCTs before and after CONSORT publication
Outcome: 10 Implementation
Study or subgroup Post-CONSORT Pre-CONSORT Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Anttila 2006 2/7 0/7 8.1 % 5.00 [ 0.11, 218.40 ]
Scales 2007 10/87 3/65 32.8 % 2.49 [ 0.48, 12.87 ]
Thabane 2007 0/13 3/50 7.9 % 0.52 [ 0.01, 23.64 ]
Ziogas 2009 13/187 7/74 51.2 % 0.73 [ 0.23, 2.33 ]
Total (99% CI) 294 196 100.0 % 1.25 [ 0.41, 3.79 ]
Total events: 25 (Post-CONSORT), 13 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.16; Chi2 = 3.76, df = 3 (P = 0.29); I2 =20%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 3.11. Comparison 3 Sample of RCTs before and after CONSORT publication, Outcome 11
Blinding.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 3 Sample of RCTs before and after CONSORT publication
Outcome: 11 Blinding
Study or subgroup Post-CONSORT Pre-CONSORT Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
1 Blinding (participants)
Dickinson 2002 3/6 11/31 4.2 % 1.41 [ 0.41, 4.79 ]
Wang 2007 232/4492 147/2930 26.5 % 1.03 [ 0.79, 1.34 ]
Scales 2007 42/87 25/65 16.0 % 1.26 [ 0.77, 2.06 ]
Thabane 2007 11/13 22/50 15.4 % 1.92 [ 1.15, 3.21 ]
Prady 2008 20/39 20/51 12.6 % 1.31 [ 0.72, 2.39 ]
Bausch 2009 55/105 127/239 25.3 % 0.99 [ 0.74, 1.31 ]
Subtotal (99% CI) 4742 3366 100.0 % 1.21 [ 0.93, 1.58 ]
Total events: 363 (Post-CONSORT), 352 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.03; Chi2 = 10.41, df = 5 (P = 0.06); I2 =52%
Test for overall effect: Z = 1.83 (P = 0.067)
2 Blinding (intervenor)
Scales 2007 35/87 18/65 15.3 % 1.45 [ 0.78, 2.69 ]
Prady 2008 19/39 20/51 15.3 % 1.24 [ 0.67, 2.30 ]
Bausch 2009 55/105 122/239 69.3 % 1.03 [ 0.77, 1.37 ]
Subtotal (99% CI) 231 355 100.0 % 1.11 [ 0.88, 1.42 ]
Total events: 109 (Post-CONSORT), 160 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.97, df = 2 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
3 Blinding (outcome assessor)
Anttila 2006 2/7 0/7 0.9 % 5.00 [ 0.11, 218.40 ]
Scales 2007 34/87 16/65 30.3 % 1.59 [ 0.82, 3.06 ]
Prady 2008 16/39 17/51 25.9 % 1.23 [ 0.60, 2.50 ]
Bausch 2009 27/105 44/239 42.8 % 1.40 [ 0.80, 2.43 ]
Subtotal (99% CI) 238 362 100.0 % 1.42 [ 0.99, 2.04 ]
Total events: 79 (Post-CONSORT), 77 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.20, df = 3 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 2.51 (P = 0.012)
4 Blinding (data analyst)
Anttila 2006 6/7 5/7 100.0 % 1.20 [ 0.58, 2.50 ]
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(. . . Continued)
Study or subgroup Post-CONSORT Pre-CONSORT Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Subtotal (99% CI) 7 7 100.0 % 1.20 [ 0.58, 2.50 ]
Total events: 6 (Post-CONSORT), 5 (Pre-CONSORT)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
5 Blinding (any description)
Ziogas 2009 26/187 10/74 6.5 % 1.03 [ 0.42, 2.51 ]
Partsinevelou 2009 110/237 10/27 11.4 % 1.25 [ 0.64, 2.45 ]
Hopewell 2010 160/616 148/519 82.1 % 0.91 [ 0.71, 1.17 ]
Subtotal (99% CI) 1040 620 100.0 % 0.95 [ 0.76, 1.19 ]
Total events: 296 (Post-CONSORT), 168 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.37, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Chi2 = 6.88, df = 4 (P = 0.14), I2 =42%
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Analysis 3.12. Comparison 3 Sample of RCTs before and after CONSORT publication, Outcome 12
Statistical methods.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 3 Sample of RCTs before and after CONSORT publication
Outcome: 12 Statistical methods
Study or subgroup Post-CONSORT Pre-CONSORT Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Anttila 2006 6/7 5/7 2.0 % 1.20 [ 0.58, 2.50 ]
Thabane 2007 13/13 47/50 15.6 % 1.04 [ 0.88, 1.22 ]
Wang 2007 2210/4492 1161/2930 22.2 % 1.24 [ 1.16, 1.33 ]
Par s 2008 26/27 15/15 15.7 % 0.98 [ 0.83, 1.15 ]
Partsinevelou 2009 228/237 24/27 14.7 % 1.08 [ 0.91, 1.29 ]
Ziogas 2009 174/187 57/74 15.1 % 1.21 [ 1.02, 1.43 ]
Ladd 2010 81/87 55/70 14.7 % 1.18 [ 0.99, 1.42 ]
Total (99% CI) 5050 3173 100.0 % 1.13 [ 1.01, 1.25 ]
Total events: 2738 (Post-CONSORT), 1364 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.01; Chi2 = 17.95, df = 6 (P = 0.01); I2 =67%
Test for overall effect: Z = 2.83 (P = 0.0047)
Test for subgroup differences: Not applicable
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Analysis 3.13. Comparison 3 Sample of RCTs before and after CONSORT publication, Outcome 13
Participant flow.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 3 Sample of RCTs before and after CONSORT publication
Outcome: 13 Participant flow
Study or subgroup Post-CONSORT Pre-CONSORT Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
1 Studies considering 1996 checklist
Anttila 2006 0/7 1/7 0.5 % 0.33 [ 0.01, 18.28 ]
Thabane 2007 13/13 47/50 26.5 % 1.04 [ 0.88, 1.22 ]
Ziogas 2009 172/187 61/74 26.9 % 1.12 [ 0.96, 1.30 ]
Partsinevelou 2009 159/237 6/27 7.6 % 3.02 [ 1.19, 7.69 ]
Subtotal (99% CI) 444 158 61.4 % 1.16 [ 0.87, 1.53 ]
Total events: 344 (Post-CONSORT), 115 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.02; Chi2 = 9.27, df = 3 (P = 0.03); I2 =68%
Test for overall effect: Z = 1.35 (P = 0.18)
2 Studies considering 2001 checklist
Wang 2007 63/4492 24/2930 13.0 % 1.71 [ 0.93, 3.17 ]
Scales 2007 17/87 2/65 2.3 % 6.35 [ 0.97, 41.56 ]
Par s 2008 22/27 2/15 2.8 % 6.11 [ 1.10, 33.86 ]
Ladd 2010 55/88 37/67 20.5 % 1.13 [ 0.79, 1.61 ]
Subtotal (99% CI) 4694 3077 38.6 % 2.14 [ 0.90, 5.09 ]
Total events: 157 (Post-CONSORT), 65 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.28; Chi2 = 12.29, df = 3 (P = 0.01); I2 =76%
Test for overall effect: Z = 2.27 (P = 0.023)
Total (99% CI) 5138 3235 100.0 % 1.36 [ 1.01, 1.83 ]
Total events: 501 (Post-CONSORT), 180 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.05; Chi2 = 24.93, df = 7 (P = 0.00078); I2 =72%
Test for overall effect: Z = 2.62 (P = 0.0088)
Test for subgroup differences: Chi2 = 3.04, df = 1 (P = 0.08), I2 =67%
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Analysis 3.14. Comparison 3 Sample of RCTs before and after CONSORT publication, Outcome 14
Recruitment.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 3 Sample of RCTs before and after CONSORT publication
Outcome: 14 Recruitment
Study or subgroup Post-CONSORT Pre-CONSORT Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Anttila 2006 3/7 5/7 1.2 % 0.60 [ 0.17, 2.16 ]
Thabane 2007 13/13 49/50 29.5 % 0.99 [ 0.86, 1.15 ]
Wang 2007 3158/4492 1909/2930 41.9 % 1.08 [ 1.03, 1.13 ]
Partsinevelou 2009 97/237 1/27 0.3 % 11.05 [ 0.88, 139.51 ]
Ziogas 2009 151/187 61/74 27.1 % 0.98 [ 0.83, 1.16 ]
Total (99% CI) 4936 3088 100.0 % 1.03 [ 0.89, 1.18 ]
Total events: 3422 (Post-CONSORT), 2025 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.01; Chi2 = 10.76, df = 4 (P = 0.03); I2 =63%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Does not favour CONSORT Favours CONSORT
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Analysis 3.15. Comparison 3 Sample of RCTs before and after CONSORT publication, Outcome 15
Baseline data.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 3 Sample of RCTs before and after CONSORT publication
Outcome: 15 Baseline data
Study or subgroup Post-CONSORT Pre-CONSORT Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Anttila 2006 6/7 5/7 5.0 % 1.20 [ 0.58, 2.50 ]
Thabane 2007 4/13 12/50 1.9 % 1.28 [ 0.37, 4.49 ]
Wang 2007 4034/4492 2413/2930 42.6 % 1.09 [ 1.06, 1.12 ]
Prady 2008 35/39 32/51 18.2 % 1.43 [ 1.05, 1.95 ]
Ziogas 2009 131/187 47/74 22.2 % 1.10 [ 0.85, 1.43 ]
Partsinevelou 2009 198/237 14/27 10.0 % 1.61 [ 0.99, 2.61 ]
Total (99% CI) 4975 3139 100.0 % 1.20 [ 1.01, 1.43 ]
Total events: 4408 (Post-CONSORT), 2523 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.01; Chi2 = 9.51, df = 5 (P = 0.09); I2 =47%
Test for overall effect: Z = 2.73 (P = 0.0063)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Does not favour CONSORT Favours CONSORT
147
Analysis 3.16. Comparison 3 Sample of RCTs before and after CONSORT publication, Outcome 16
Numbers analysed.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 3 Sample of RCTs before and after CONSORT publication
Outcome: 16 Numbers analysed
Study or subgroup Post-CONSORT Pre-CONSORT Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
1 Studies considering 1996 checklist
Anttila 2006 5/7 5/7 14.8 % 1.00 [ 0.42, 2.39 ]
Partsinevelou 2009 33/237 0/27 2.0 % 7.88 [ 0.21, 298.34 ]
Ziogas 2009 67/187 7/74 13.6 % 3.79 [ 1.45, 9.89 ]
Subtotal (99% CI) 431 108 30.4 % 2.32 [ 0.50, 10.87 ]
Total events: 105 (Post-CONSORT), 12 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.70; Chi2 = 8.05, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 1.41 (P = 0.16)
2 Studies considering 2001 checklist
Scales 2007 25/87 22/65 18.1 % 0.85 [ 0.46, 1.58 ]
Prady 2008 13/39 8/51 12.9 % 2.13 [ 0.77, 5.89 ]
Par s 2008 3/14 3/10 6.5 % 0.71 [ 0.12, 4.38 ]
Bausch 2009 29/105 46/239 19.4 % 1.43 [ 0.84, 2.44 ]
Ladd 2010 21/88 7/70 12.6 % 2.39 [ 0.84, 6.79 ]
Subtotal (99% CI) 333 435 69.6 % 1.37 [ 0.80, 2.36 ]
Total events: 91 (Post-CONSORT), 86 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.10; Chi2 = 7.82, df = 4 (P = 0.10); I2 =49%
Test for overall effect: Z = 1.50 (P = 0.13)
Total (99% CI) 764 543 100.0 % 1.57 [ 0.91, 2.70 ]
Total events: 196 (Post-CONSORT), 98 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.19; Chi2 = 17.62, df = 7 (P = 0.01); I2 =60%
Test for overall effect: Z = 2.13 (P = 0.033)
Test for subgroup differences: Chi2 = 0.69, df = 1 (P = 0.41), I2 =0.0%
0.01 0.1 1 10 100
Does not favour CONSORT Favours CONSORT
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Analysis 3.17. Comparison 3 Sample of RCTs before and after CONSORT publication, Outcome 17
Outcomes and estimation.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 3 Sample of RCTs before and after CONSORT publication
Outcome: 17 Outcomes and estimation
Study or subgroup Post-CONSORT Pre-CONSORT Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Anttila 2006 2/7 2/7 0.1 % 1.00 [ 0.11, 8.82 ]
Peckitt 2007 34/34 10/11 5.4 % 1.13 [ 0.85, 1.50 ]
Wang 2007 4352/4492 2756/2930 20.9 % 1.03 [ 1.02, 1.04 ]
Thabane 2007 13/13 48/50 11.3 % 1.01 [ 0.87, 1.18 ]
Par s 2008 26/27 13/15 5.6 % 1.11 [ 0.84, 1.47 ]
Ziogas 2009 179/187 69/74 16.4 % 1.03 [ 0.94, 1.12 ]
Partsinevelou 2009 235/237 27/27 18.1 % 1.01 [ 0.94, 1.08 ]
Bausch 2009 58/105 40/239 2.7 % 3.30 [ 2.14, 5.10 ]
Ladd 2010 89/89 68/69 19.4 % 1.02 [ 0.97, 1.07 ]
Total (99% CI) 5191 3422 100.0 % 1.06 [ 0.98, 1.15 ]
Total events: 4988 (Post-CONSORT), 3033 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.00; Chi2 = 49.92, df = 8 (P<0.00001); I2 =84%
Test for overall effect: Z = 2.06 (P = 0.040)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Does not favour CONSORT Favours CONSORT
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Analysis 3.18. Comparison 3 Sample of RCTs before and after CONSORT publication, Outcome 18
Ancillary analysis.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 3 Sample of RCTs before and after CONSORT publication
Outcome: 18 Ancillary analysis
Study or subgroup Post-CONSORT Pre-CONSORT Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Anttila 2006 1/7 2/7 6.3 % 0.50 [ 0.03, 8.54 ]
Wang 2007 130/4492 182/2930 25.8 % 0.47 [ 0.35, 0.62 ]
Partsinevelou 2009 99/237 4/27 16.8 % 2.82 [ 0.85, 9.41 ]
Ziogas 2009 131/187 36/74 25.5 % 1.44 [ 1.03, 2.01 ]
Yu 2010 113/422 84/355 25.6 % 1.13 [ 0.82, 1.56 ]
Total (99% CI) 5345 3393 100.0 % 1.06 [ 0.47, 2.39 ]
Total events: 474 (Post-CONSORT), 308 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.37; Chi2 = 57.21, df = 4 (P<0.00001); I2 =93%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Does not favour CONSORT Favours CONSORT
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Analysis 3.19. Comparison 3 Sample of RCTs before and after CONSORT publication, Outcome 19
Adverse events.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 3 Sample of RCTs before and after CONSORT publication
Outcome: 19 Adverse events
Study or subgroup Post-CONSORT Pre-CONSORT Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Thabane 2007 9/13 23/50 5.6 % 1.51 [ 0.81, 2.79 ]
Wang 2007 869/4492 563/2930 37.4 % 1.01 [ 0.89, 1.14 ]
Par s 2008 12/17 10/11 8.8 % 0.78 [ 0.48, 1.25 ]
Partsinevelou 2009 123/237 9/27 4.2 % 1.56 [ 0.76, 3.20 ]
Ziogas 2009 121/187 42/74 17.6 % 1.14 [ 0.85, 1.53 ]
Ladd 2010 70/84 51/64 26.4 % 1.05 [ 0.85, 1.28 ]
Total (99% CI) 5030 3156 100.0 % 1.06 [ 0.91, 1.24 ]
Total events: 1204 (Post-CONSORT), 698 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.01; Chi2 = 8.07, df = 5 (P = 0.15); I2 =38%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Does not favour CONSORT Favours CONSORT
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Analysis 3.20. Comparison 3 Sample of RCTs before and after CONSORT publication, Outcome 20
Interpretation.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 3 Sample of RCTs before and after CONSORT publication
Outcome: 20 Interpretation
Study or subgroup Post-CONSORT Pre-CONSORT Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Wang 2007 4228/4492 2776/2930 91.0 % 0.99 [ 0.98, 1.01 ]
Par s 2008 27/27 15/15 1.1 % 1.00 [ 0.88, 1.14 ]
Partsinevelou 2009 233/237 27/27 4.1 % 1.00 [ 0.93, 1.07 ]
Ziogas 2009 180/187 71/74 3.8 % 1.00 [ 0.93, 1.08 ]
Total (99% CI) 4943 3046 100.0 % 0.99 [ 0.98, 1.01 ]
Total events: 4668 (Post-CONSORT), 2889 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.17, df = 3 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Does not favour CONSORT Favours CONSORT
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Analysis 3.21. Comparison 3 Sample of RCTs before and after CONSORT publication, Outcome 21
Generalisability.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 3 Sample of RCTs before and after CONSORT publication
Outcome: 21 Generalisability
Study or subgroup Post-CONSORT Pre-CONSORT Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Thabane 2007 1/13 9/50 0.1 % 0.43 [ 0.03, 5.72 ]
Wang 2007 1218/4492 752/2930 54.5 % 1.06 [ 0.95, 1.17 ]
Ziogas 2009 172/187 62/74 28.1 % 1.10 [ 0.95, 1.27 ]
Partsinevelou 2009 219/237 24/27 17.4 % 1.04 [ 0.87, 1.25 ]
Total (99% CI) 4929 3081 100.0 % 1.06 [ 0.99, 1.15 ]
Total events: 1610 (Post-CONSORT), 847 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.28, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 2.11 (P = 0.035)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Does not favour CONSORT Favours CONSORT
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Analysis 3.22. Comparison 3 Sample of RCTs before and after CONSORT publication, Outcome 22 Overall
evidence.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 3 Sample of RCTs before and after CONSORT publication
Outcome: 22 Overall evidence
Study or subgroup Post-CONSORT Pre-CONSORT Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,99% CI IV,Random,99% CI
Wang 2007 2841/4492 1791/2930 59.4 % 1.03 [ 0.99, 1.09 ]
Thabane 2007 0/13 5/50 0.1 % 0.33 [ 0.01, 13.73 ]
Partsinevelou 2009 215/237 22/27 16.2 % 1.11 [ 0.87, 1.42 ]
Ziogas 2009 168/187 56/74 24.3 % 1.19 [ 0.99, 1.42 ]
Total (99% CI) 4929 3081 100.0 % 1.08 [ 0.97, 1.21 ]
Total events: 3224 (Post-CONSORT), 1874 (Pre-CONSORT)
Heterogeneity: Tau2 = 0.00; Chi2 = 4.65, df = 3 (P = 0.20); I2 =36%
Test for overall effect: Z = 1.80 (P = 0.072)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Does not favour CONSORT Favours CONSORT
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Analysis 3.23. Comparison 3 Sample of RCTs before and after CONSORT publication, Outcome 23 Total
sum score.
Review: Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals
Comparison: 3 Sample of RCTs before and after CONSORT publication
Outcome: 23 Total sum score







N Mean(SD) N Mean(SD) IV,Random,99% CI IV,Random,99% CI
Bian 2006 24 19.78 (3.85) 43 20.81 (4.21) 20.7 % -0.25 [ -0.91, 0.41 ]
Thoma 2006 7 12.14 (3.8) 11 8.36 (3.11) 14.2 % 1.06 [ -0.28, 2.41 ]
Lai 2006 (1) 43 10 (2.22) 31 7 (3.7) 20.8 % 1.01 [ 0.37, 1.66 ]
Agha 2007 42 10.91 (2.49) 48 11.18 (2.43) 21.7 % -0.11 [ -0.65, 0.44 ]
Zhong 2010 227 14.6 (3.85) 52 10.88 (3.33) 22.7 % 0.99 [ 0.58, 1.40 ]
Total (99% CI) 343 185 100.0 % 0.51 [ -0.28, 1.30 ]
Heterogeneity: Tau2 = 0.39; Chi2 = 31.36, df = 4 (P<0.00001); I2 =87%
Test for overall effect: Z = 1.66 (P = 0.096)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Does not favour CONSORT Favours CONSORT
(1) Score out of 15; Reported as median (IQR).
A D D I T I O N A L T A B L E S




TITLE and ABSTRACT 1 How participants were allocated to interventions (e.g. ’random allocation’, ’ran-
domised’, or ’randomly assigned’)
INTRODUCTION
Background
2 Scientific background and explanation of rationale
METHODS
Participants
3 Eligibility criteria for participants and the settings and locations where the data
were collected
Interventions 4 Precise details of the interventions intended for each group and how and when
they were actually administered
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Table 1. 2001 CONSORT checklist of items to include when reporting a randomised controlled trial (Continued)
Objectives 5 Specific objectives and hypotheses
Outcomes 6 Clearly defined primary and secondary outcome measures and, when applicable,
any methods used to enhance the quality of measurements (e.g. multiple obser-
vations, training of assessors)
Sample size 7 How sample size was determined and, when applicable, explanation of any interim
analyses and stopping rules
Randomisation
Sequence generation
8 Method used to generate the random allocation sequence, including details of any
restriction (e.g. blocking, stratification)
Randomisation
Allocation concealment
9 Method used to implement the random allocation sequence (e.g. numbered con-




10 Who generated the allocation sequence, who enrolled participants, and who as-
signed participants to their groups
Blinding (masking) 11 Whether or not participants, those administering the interventions, and those
assessing the outcomes were blinded to group assignment. When relevant, how
the success of blinding was evaluated
Statistical methods 12 Statistical methods used to compare groups for primary outcome(s); methods for
additional analyses, such as subgroup analyses and adjusted analyses
RESULTS
Participant flow
13 Flow of participants through each stage (a diagram is strongly recommended).
Specifically, for each group report the numbers of participants randomly assigned,
receiving intended treatment, completing the study protocol, and analysed for the
primary outcome. Describe protocol deviations from study as planned, together
with reasons
Recruitment 14 Dates defining the periods of recruitment and follow-up
Baseline data 15 Baseline demographic and clinical characteristics of each group
Numbers analysed 16 Number of participants (denominator) in each group included in each analysis
and whether the analysis was by ’intention-to-treat’. State the results in absolute
numbers when feasible (e.g. 10/20, not 50%)
Outcomes and estimation 17 For each primary and secondary outcome, a summary of results for each group,
and the estimated effect size and its precision (e.g. 95% confidence interval)
Ancillary analyses 18 Address multiplicity by reporting any other analyses performed, including sub-
group analyses and adjusted analyses, indicating those pre-specified and those ex-
ploratory
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Table 1. 2001 CONSORT checklist of items to include when reporting a randomised controlled trial (Continued)
Adverse events 19 All important adverse events or side effects in each intervention group
DISCUSSION
Interpretation
20 Interpretation of the results, taking into account study hypotheses, sources of
potential bias or imprecision, and the dangers associated with multiplicity of
analyses and outcomes
Generalisability 21 Generalisability (external validity) of the trial findings
Overall evidence 22 General interpretation of the results in the context of current evidence
A P P E N D I C E S
Appendix 1. Search strategy
Ovid MEDLINE(R) <2005 to March Week 1 2010>
















17 (consort or consolidat$ standard$).tw.
18 9 and 16
19 18 not randomized controlled trial.pt.
20 limit 19 to abstracts
21 19 not 20
22 17 or 21
23 limit 22 to (comment or editorial or guideline or letter)
24 22 not 23
EMBASE <1980 to 2010 Week 16>
1 (consort or consolidat$ standard$).tw.















16 9 and 15
17 limit 16 to abstracts
18 16 not 17
19 1 or 18
20 limit 19 to “reviews (2 or more terms high specificity)”
21 limit 19 to (editorial or letter)
22 19 not (20 or 21)
ISI Web of Knowledge: 27 March 2010
TS=(consort AND (checklist* OR quality))
DocType=All document types; Language=All languages; Database=SCI-EXPANDED, SSCI;
Cochrane Methodology Register and Cochrane Database of Systematic Reviews, The Cochrane Library, 2010, Issue 2 (Wiley
interface)
Cochrane [all fields]
PubMed ’Related Items’ search (27 May 2010)
Using two PMIDS: PMID: 12161081 or PMID: 11308436.
Appendix 2. Validity assessment tool
Assessment of risk of bias (validity assessment) in included studies:
Question Possible Responses
The RCTs included in the study represent a large cohort (i.e. an




The reviewer(s) who assessed CONSORT criteria was blinded to




Was consideration of potential clustering reported? (If potential










More than one reviewer assessed CONSORT criteria Yes (low)
No (high)
Can’t tell (medium)
If applicable (i.e. more than one reviewer assessed CONSORT
criteria), whether inter-reviewer agreement was greater than or





If quality of included RCTs was assessed, the reviewer(s) con-
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C O N T R I B U T I O N S O F A U T H O R S
DM, AP, LT, LS, and LW identified relevant evaluations to include in the review. JP identified endorsement status of RCTs and dates of
endorsement for journals. LT and LS extracted data from the included evaluations. TK and SD provided own data and commented on
various drafts. LT carried out the analysis. LT drafted the review with input from all authors. DM, DGA, and KFS provided conceptual
and methodological supervision of the review.
D E C L A R A T I O N S O F I N T E R E S T
Three review team members (DM, DGA, and KFS) comprise the executive of the CONSORT Group and have led the development
of the CONSORT Statement since its inception in 1996. DM, KFS, and DGA are also members of the EQUATOR executive. One
team member (LS) is CONSORT research staff, for which salary support is provided, in part, by the Medical Research Council, United
Kingdom. Salary support for LT is provided under the Cochrane Bias Methods Group, funded by Canadian Institutes of Health
Research.
159
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Internal sources
• Cochrane Bias Methods Group, Canada.
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External sources
• Medical Research Council (MRC), UK.
The CONSORT group is currently funded through a grant from the MRC. Grant no: MR/J004871/1
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
This was a complex review to complete. The review included evaluations with varied objectives, populations, and study methods.
Although this was an updated review, and the protocol guidance extensive, based mainly on the quantity of included evaluations, some
developments were not foreseen at the protocol stage and as such amendments were made as the evaluation progressed and documented
here.
We encountered evaluations which did not report (or provide) data on CONSORT endorsement status for RCTs published in journals
before and after publication of the CONSORT Statement (1996 or 2001). Due to the vast quantity of associated trials examined in
included evaluations, resource limitations precluded us from obtaining the necessary data (from evaluation authors or, subsequently,
included journals) in a timely and efficient manner. As such, we developed an additional comparison group (comparison 3) that allowed
for these evaluations to be included subject in relation to their choice of evaluation design. Excluding comparison 3 would have omitted
a substantial body of evidence and may have led to potentially misleading results. The robustness of comparison 3 is addressed in the
Results and Discussion of this review.
In addition to comparison 3, we encountered data in included evaluations which could be used to form comparisons of potential
’control’ groups, as described in the Objectives. Data for these comparisons were sparse and not included in this review; however they
are available upon request.
During the review process, the search strategy for relevant literature as laid out in the protocol was broadened to remove the limitation
of identifying literature published in only ’core clinical journals’.
During the review process, the secondary outcomes as specified in the protocol, were amended to reflect that only data on ’methodological
quality’ of included evaluations would be assessed. We did not collect data on overall quality since it was felt that there were no good
or different measures for this outcome than those used to assess methodological quality. Validity assessment, while still carried out, was
erroneously listed as a secondary outcome in the protocol and is not listed as one in this review. Validity assessment was nonetheless
carried out, as described in Assessment of risk of bias in included studies.
In the protocol it was suggested that sensitivity analyses considering RCTs for which endorsement could not be strictly defined would
be conducted. The protocol describes that RCTs would be excluded at the evaluation level (within evaluation). As a more efficient, and
potentially more suitable, alternative we omitted the evaluations for which endorsement was not strictly compliant.
The protocol provides details of an analysis plan for assessing potential reporting biases across evaluations. Upon further consideration
and consultation with statistical experts, given the type of data included in this review, standard means of assessing reporting bias were
not suitable. Hence, we have not formally assessed reporting bias across the included evaluations.
Evaluations typically did not adjust for potential confounders in their analysis, and given the lack of information it was not possible
for the research team to adjust for them. Due to methodological heterogeneity across evaluations, it was also not feasible to arbitrarily
formulate an aggregate adjustment. As a result, we have included all results but used wider, more conservative, 99% confidence intervals,
which is different from the standard 95% as detailed in the protocol.
160
N O T E S
We were able to abstract additional data from four included evaluations which provided information on potential confounding. This
included the improvement of reporting over time, or the difference in completeness of reporting in endorsing and non-endorsing
journals. This information was very sparse and led to many empty forest plots; we did not feel this evidence contributed substantially
to the results of the review so it is not reported here, but fully available upon request.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Checklist [∗standards]; Periodicals as Topic [∗standards]; Publishing [∗standards]; Randomized Controlled Trials as Topic [∗standards];
Reference Standards
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